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Abstract
Theranostic nanoparticles (NP) have the potential to revolutionize cancer
diagnosis and therapy. We aimed to develop dual paclitaxel/SPIO-loaded PLGA-
based NP for cancer therapy and magnetic resonnance imaging. In the first
part we prepared and characterized these mutfifunctionnal nanoparticles. We
demonstrated their in vitro efficacy as T2 contrast agent, their significant cellular
uptake by CT26 cells and in vivo anti-tumor efficacy. In the second part, we
compared different targeting strategies in vivo: passive, active targeting (AT) of
αvβ3 integrin, magnetic targeting (MT) and the combination of the two latest.
Using Electron Spin Resonance spectroscopy and Magnetic Resonance Imaging
(MRI), we demonstrated that the combination of AT and MT drastically enhanced
nanoparticle accumulation into the tumor tissue, contrast in MRI and anti-cancer
efficacy. Double targeting of nanoparticles to tumors could be a promising
approach for therapeutic treatment and personalized therapy.
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I. TUMOR MICROENVIRONMENT 
Tumor microenvironment is one of many areas, which are studied to design new anti-cancer 
therapies. Indeed, many efforts have been made in research field to develop different 
therapeutic strategies based on the numerous differences between tumor and normal tissue 
including vascular abnormalities, oxygenation, perfusion, pH and metabolic states. Therefore, 
the knowledge and the understanding of tumor microenvironment are crucial. Here, the 
differences in terms of morphology of tumor vasculature and the pH will be particularly 
described, as they are the more relevant characteristics for the design of nanocarriers as tumor 
targeted drug delivery systems.  
I.1. ANGIOGENESIS 
Angiogenesis refers to the process by which new blood vessels arise from the existing-ones. 
This process plays a critical role in organ growth in the embryo as well as in wound repair 
and ovulation in adulthood. Angiogenesis is a highly regulated process by a multitude of 
stimulators and inhibitors but an imbalance in these regulators contributes to the pathogenesis 
of various disorders including tumor malignancy. Indeed, even in adulthood, endothelial cells 
retain their ability of dividing rapidly in response to a physiological stimulus such as hypoxia 
[Carmeliet, 2005; Distler et al., 2003].  
Thus, when tumors reach approximately 2 mm3, the increased interstitial pressure within the 
tumor inhibits the diffusion of metabolites and nutrients necessary for tumor growth. A state 
of cellular hypoxia begins, inducing the sprouting of new blood vessels from the established 
vasculature. Consequently, oxygen and nutrients are carried to tumor cells, which need them 
to survive and proliferate [Folkman, 1971; Jain, 1987]. This ability of tumors to progress from 
a non-angiogenic to angiogenic phenotype (called the “angiogenic switch”) is central to 
progression of cancer [Carmeliet, 2000; Naumov et al., 2006]. 
Angiogenesis is a five-step process (Figure 1) in which:  
(i) endothelial cells are activated by pro-angiogenic signals 
(ii) vessels are destabilized and basement membrane is degraded 
(iii) the proliferating endothelial cells migrate through the disintegrated basement 
membrane 
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(iv) endothelial cells arrange to form a tube-like structure (lumen formation) 
(v) angiogenic remodeling occurs: the vascular tube is stabilized by mural cells 
(pericytes) 
 
Figure 1. Schematic representation of the 5-step angiogenesis process (adapted from [Danhier et al., 2012b]). 
When hypoxia is sensed by the endothelial cells oxygen sensors (e.g. prolyl hydroxylase 
domain 2 – PHD2), cellular hypoxia inducible factor (HIF) transcription increases, leading to 
upregulation of pro-angiogenic proteins such as vascular endothelial growth factor (VEGF), 
platelet derived growth factor (PDGF) or tumor necrosis factor-α (TNF-α) [Carmeliet, 2000; 
Carmeliet et al., 2011]. Activated endothelial cells express the dimeric transmembrane 
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integrin αvβ3, which interacts with extracellular matrix proteins (e.g., vibronectin, fibronectin) 
and regulates the migration of the endothelial cell through the extracellular matrix during 
vessel formation [Avraamides et al., 2008]. The activated endothelial cells synthesize 
proteolytic enzymes, such as matrix metalloproteinases, used to degrade the basement 
membrane and the extracellular matrix. The inner layer of endothelial cells undergoes 
apoptosis leading to formation of the vessel lumen. Immature vasculature undergoes 
extensive remodeling during which pericytes and smooth-muscle cells stabilize the vessels. 
This step is often incomplete resulting in irregular shaped, dilated and tortuous tumor blood 
vessels [Stollman et al., 2009].  
I.2. PH 
Consistent with the characteristic hypoxia found in tumor tissue, most tumor cells energy 
production relies on glycolysis. Interestingly, tumor cells have been shown to use this 
metabolic pathway even when there is enough O2 to support mitochondrial oxidative 
phosphorylation. This phenomenon was first reported by Warburg in the 1920s, giving this 
phenomenon the name of “Warburg effect”. This observation led to the hypothesis that cancer 
cells suffer from impaired mitochondrial metabolism. Such aerobic glycolysis leads to the 
accumulation of lactate and H+ into tumor cells [Barar et al., 2013; Feron, 2009; Justus et al., 
2013]. Consequently, the export of protons and lactic acid from tumor cells into the 
extracellular space by transporters including Na+/H+ exchangers and monocarboxylate 
transporters (a lactate/H+ co-transporter), may lead to acidosis in the tumor microenvironment 
[Justus et al., 2013]. Indeed, tumor extracellular pH is generally more acidic (pH 6.5) 
compared to physiological pH (7.3) [Gullotti et al., 2009]. To support high rate proliferation 
as needed for tumor tissue growing, high glycolytic flux maintenance is needed. Nicotinamide 
adenine dinucleotide (NAD+) is involved in redox reactions that are essential for conversion 
of pyruvate to lactic acid produced by cancer cells. Interestingly, the conversion of pyruvate 
into lactate generates NAD+. This metabolic conversion makes glycolysis self-sufficient as 
long as elevated glucose uptake is possible [Barar et al., 2013; Feron, 2009]. Therefore, tumor 
cells implement an abnormally high rate of glucose uptake through an enhanced expression of 
HIF-1α-dependent glucose transporters (GLUT) [Peppicelli et al., 2014].   
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I.3. EPR EFFECT 
Since solid tumors are rapidly growing tissue, it is of crucial importance for them to facilitate 
adequate supply of nutrients and oxygen to meet the great demands for growth [Fang et al., 
2003]. Therefore, blood vessels in most solid tumors possess unique characteristics that are 
not usually observed in normal blood vessels (Figure 2): 
(i) Extensive angiogenesis and hence, high vascular density [Folkman, 1971] 
(ii) Defective vascular architecture. Indeed, tumor vasculature exhibits large gaps in 
endothelial cell-cell junctions (fenestrations) that lead to an enhanced diffusion of 
macromolecules to the interstitium space. These fenestrations present a diameter 
ranging from 10 to 1000 nm. However, it is notworthy that pore cutoff size of 
porous blood vessels in majority tumors is known to be 380–780 nm [Bae et al., 
2011]. Moreover, neoangiogenic vessels are characterized by a lack of smooth 
muscle layer cells, pericytes and by a tortuous architecture [Greish, 2007; 
Torchilin, 2000] 
(iii) Extensive production of vascular mediators that facilitates extravasation (e.g. 
matrix metalloproteinases or MMP, Bradykinin, etc…) [Fang et al., 2011; Maeda 
et al., 2013] 
(iv) Irregular blood flow 
(v) Impaired lymphatic system leading to an inefficient drainage, thus, affecting the 
clearance of macromolecules from interstitial tissue [Fang et al., 2003] 
(vi) Slow venous return that leads to accumulation in the interstitium of tumor [Jain, 
1988; Maeda et al., 2009] 
Due to the defective vascular architecture macromolecules can diffuse easily to the 
interstitium. This phenomenon is referred as the enhanced permeability effect. Moreover, due 
to the lack of an efficient lymphatic system, the so-entered macromolecules are then retained 
in the tumor tissue (retention effect). This passive phenomenon has been called the “enhanced 
permeability and retention (EPR) effect” and was first described by Matsumara and Maeda in 
1986 [Matsumura et al., 1986]. According to this concept, it is possible to take advantage of 
this particular microenvironment to passively target tumor tissue with macromolecular drug 
or nanocarriers. To benefit from the EPR effect, nanomedicines should be larger than 40 kDa 
or for macromolecules and 10 nm for nanocarriers, respectively and have long-circulating 
time to provide a sufficient level of target accumulation [Fang et al., 2011; Torchilin, 2000].  
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Figure 2. Differences between normal and tumor tissues that explain the passive targeting of nanocarriers via the 
enhanced permeability and retention effect. (A) Normal tissues is highly structured with pericytes covering the 
endothelium cells. Fibroblasts, collagen fibers, macrophages and muscular fibers surround them constituting the 
extracellular matrix. Lymphatic vessels ensure lymphatic drainage. (B) Tumor tissue contains defective blood 
vessels with many sac-like formations and fenestrations. There is a lack of lymphatic system. (Adapted from 
[Heldin et al., 2004]) 
Interestingly, vascular permeability due to fenestration was first observed in inflammation 
process and in hypoxic areas of infracted myocardium. Although it is still controverted, the 
essential difference between inflamed and tumor tissue lies in the presence of an efficient 
lymphatic system in inflamed tissue leading to an enhanced permeability without any 
retention effect [Maeda et al., 2009; Maeda et al., 2013]. 
I.4. DRUG TARGETING 
A major issue in current cancer therapies is the lack of selectivity, which leads to insufficient 
drug concentration at the target site and damages in healthy tissues. Consequently, patients 
frequently suffer from harmful side effects.  Hence, researchers have studied over the years 
innovative targeting strategies to address this problem. The goal of such targeted drug 
delivery is to be as selective as possible to avoid or minimize accumulation in the healthy 
tissues [Cukierman et al., 2010; Dandamudi et al., 2007]. Nanoparticles are highly attractive 
materials to address such a challenge since they allow multiple targeting strategies [Danhier et 
al., 2010]. Various different concepts have been studied for nanomedicine drug targeting to 
tumors over the years including passive targeting, active targeting and triggered drug delivery.  
I.4.1. Passive targeting 
Passive targeting relies on the presence of fenestration in the tumor vascular endothelium that 
allows the extravasation of nanocarriers to the interstitium by EPR effect [Arias et al., 2011]. 
Movement of molecules through the vasculature is governed by both vascular morphology 
(vascular gap size, number…) and blood flow rate. Transport of molecules from the vascular 
	   A	   B	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compartment to the interstitium is mediated by convection, passive diffusion depending on 
the particle size and, to some extent, by transcytosis [Jain, 1987; Jain, 1990]. While diffusion, 
defined as a process by which small molecules are transported across the cell membrane 
according to their gradient of concentration, is the main route for low-molecular weight 
molecules, convection must be the predominant route for large particles. Convection is based 
on the movement of molecules within fluids. Since nanoparticles are relatively large, the most 
predominant transport mode for them should be convection [Florence, 2012; Frenkel, 2008]. 
However, since convection is governed by the rate of fluid leakage, it will depend on the 
difference between the vascular and interstitial osmotic pressure. Due to the high interstitial 
pressure in tumor, convection is maintained at a minimal rate and the major mode of drug 
transport is even though diffusion [Jain, 1990]. Once nanoparticles enter the interstitium in 
the absence of anatomically well-defined functioning lymphatic vessels, their accumulation 
occurs by the EPR effect  [Haley et al., 2008] (Figure 3).  
To benefit from this EPR effect, nanocarriers have to present several characteristics:  
(i) Particles size should be compromised between 50 and 200 nm. Indeed, to 
ensure an efficient extravasation from the fenestrations in the leaky vasculature 
nanaoparticles should present a size of less than 700 nm. However, particles of 
more than 200 nm are often taken up by macrophages resulting in liver and 
spleen accumulation. On the other hand, nanoparticles of 50-100 nm have a 
high probability of getting trapped into the hepatic parenchyma [Reddy et al., 
2012]. Moreover, particles presenting a size <10 nm will undergo rapid renal 
clearance [Kwon et al., 2012]. 
(ii) Nanocarriers should present a long circulation time to optimize accumulation 
at the target site. Indeed, it takes about 6 hours or longer for drugs in 
circulation to benefit from the EPR effect [Fang et al., 2003]. Therefore, 
nanoparticles need to be hidden from the reticulo-endothelial system, which is 
responsible for the destruction of foreign material through opsonization 
followed by phagocytosis [Reddy et al., 2012].  
(iii) Particles should be neutral to avoid renal elimination and minimize the 
interaction with plasma protein and thus, prolongs the circulation time by 
avoiding phagocytosis process [Reddy et al., 2012]. 
CHAPTER I - INTRODUCTION 
11 
Nevertheless, despite all efforts made to obtain the « perfect candidate », EPR effect have 
been shown to exhibit some limitations contributing to poor localization of nanomedicines in 
tumors:  
(i) Heterogenous blood supply depending on the tumor type, grade etc. Indeed, 
the average vascular surface area decreases with tumor growth. Hence, large 
tumors are less expected to show a good accumulation of drug by EPR than 
smaller tumors  
(ii) Elevated interstitial fluid pressure. As aforementioned, tumors contain region 
of high interstitial pressure which lowers fluid extravasation  
(iii) Large transport distances in the tumor interstitium, which are rendered difficult 
by the presence of a dense extracellular matrix [Jain, 1990; Nichols et al., 
2014] 
  
Figure 3. Passive targeting. Nanocarriers reach tumor passively through the leaky vasculature of neoangiogenic 
vessels (adapted from [Danhier et al., 2012b]). 
 
I.4.2. Active targeting 
The principle of this strategy is to target a specific site based on molecular recognition 
process. Hence, a ligand is coupled to the surface of nanoparticles, which can interact with its 
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receptor at the target cell site (Figure 4) [Danhier et al., 2009b]. Indeed, since nanoparticles 
have high surface area-to-volume ratios, they may be surface functionalized with targeting 
ligands [Kelkar et al., 2011]. Potential methods for active targeting have been extensively 
investigated. These methods include particles coupled to specific monoclonal antibodies (or 
antibody fragments) as well as ligand-coated particles targeting proteins overexpressed on 
endothelial cells of tumor neoangiogenic vessels (e.g., integrin surface receptor) or on cancer 
cell membranes themselves (e.g., folate receptor) [Arias, 2011]. Ideally, the targeted receptor 
should be overexpressed by tumor cells or tumor vessels and not expressed by normal cells to 
ensure a good selectivity of the treatment. This may help to increase both the target-to-
background contrast in imaging for diagnostic purpose and the therapeutic concentration at 
the target of interest, limiting systemic toxicity [Kelkar et al., 2011].  
In cancer chemotherapy, two strategies can be used: targeting tumor endothelium or targeting 
tumor cells. The former aims to kill tumor cells by the lack of oxygen and nutrients. This 
concept has been first suggested in 1971 by Folkman [Folkman, 1971]. Such tumor 
endothelium targeting presents some undeniable advantages: (i) nanocarriers can directly 
reach the target without any need for extravasation; (ii) they can bind to their receptor directly 
after i.v. injection; (iii) most of endothelial cells markers are expressed by numerous tumor 
type [Gosk et al., 2008].  
While targeting tumor cells, a particular attention is paid to the internalization of 
nanoparticles for drug delivery inside cancer cells. For this purpose, ligand coupled 
nanoparticles are useful to facilitate internalization since this approach typically leads to 
receptor-mediated cell endocytosis [Arias et al., 2011; Cole et al., 2011]. However, since 
nanoparticles have no means of self-propulsion, reaching the target only depends on the 
movement of blood passing through the target, wherever it may be. The presence of ligand on 
the surface does not change anything [Kwon et al., 2012]. Hence, in tumor cells targeting, the 
chance of targeted-nanoparticles to reach the target only relies on the EPR effect. Ligand-
targeted therapeutics are divided into different classes depending on the approach of drug 
delivery [Allen, 2002]. Main classes to mediate targeting are peptide, monoclonal antibodies 
or small molecules. These classes can target different receptors among which the most studied 
are: (i) Integrin, (ii) Folate receptor, (iii) Transferrin receptor and (iv) Human/Epidermal 
epidermal growth factor receptor 2 [Arias et al., 2011; Kelkar et al., 2011]. 
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Figure 4. Schematic representation of active targeting modalities of nanocarriers. Targeted nanocarriers 
presenting targeted ligands on his surface. The ligand can be either a monoclonal antibody or a non-antibody 
ligand that specifically recognizes an over-expressed receptor at the surface of (A) tumor cells and (B) 
neoangiogenic endothelial cells (adapted from [Danhier et al., 2012b]). 
 
I.4.2.1. Monoclonal antibodies-mediated targeting 
The aim of this strategy is to direct monoclonal antibodies against specific antigen or 
receptors presented by tumor cells. This could be achieved by using (i) monoclonal 
antibodies, (ii) antibody fragments, (iii) antibody-drug conjugates and (iv) antibody-
conjugated nanocarriers. In this last case, antibodies are coupled to the particle surface of 
nanocarriers loaded with a cytotoxic drug. Those monoclonal antibody-conjugated 
nanocarriers are called immunonanocarriers and aim to target specific receptors presented by 
tumor cells and recognized by the targeting ligand (monoclonal antibody or fragments) 
[Arias, 2011; Lammers et al., 2012a]. For instance, doxorubicin (DOX)-loaded prostate cell-
specific Mab (Mab5D4) conjugated with liposomes enhanced cytotoxicity towards prostate 
cancer cell lines compared with the non-targeted DOX liposome in vitro [Sawant et al., 2008]. 
Recently, Talelli et al. obtained promising results using nanobody-modified polymeric 
micelles for tumor targeted combination therapy [Talelli et al., 2013]. However, to date and in 
spite of significant advances made at the pre-clinical level with regard to active targeting, no 
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actively targeted-nanocarriers have been approved for clinical use. Nevertheless, several 
antibody-based therapeutic agents are clinically approved (see Table 1). In this case, 
antibodies (monoclonal antibodies or fragments) target a specific receptor, interfering with 
signal transduction pathways regulating proto-oncogenes involved in tumor cells 
proliferation. For instance, bevacizumab (Avastin®), a tumor angiogenesis inhibitor that 
binds to VEGF and was approved for treating colorectal cancer in 2004 [Lu et al., 2008] and 
trastuzumab (anti-ERBB2, Herceptin®) for specific binding to breast cancer cells. Another 
strategy involves the association of an antibody with a therapeutic agent (e.g., toxin and 
radioisotope) [Lammers et al., 2012a]. For instance, 90yttrium-ibritumomab tiuxtan 
(Zevalin®) is the first radioimmunotherapeutic directed against CD-20 an activated-
glycosylated phosphoprotein expressed on the surface of B-lymphocytes and is currently 
approved for the treatment of Rituximab-failed non-Hodgkin’s lymphoma [Das et al., 2009; 
Wiseman et al., 1999]. Denileukin diftitox (Ontak®), a chimeric immunotoxin composed of 
the modified cytotoxic domain of diphtheria toxin and human interleukin-2 (IL-2) protein, 
targets cells expressing CD25 [Ansell et al., 2012; Dang et al., 2004]. Gemtuzumab 
ozogamicin (Mylotarg®), a immunoconjugate between an anti-CD33 antibody (hP67.6) and a 
toxic calicheamicin-γ1 derivative also received clinical approval [Jurcic, 2001; Sharkey et al., 
2006]. Finally, a radiolabeled monoclonal antibody directed against CD-20 (iodine-131 
tositumomab, Bexxar®) has been recently approved [Lammers et al., 2012a].  
Table 1. Examples of clinically used tumor-targeted antibodies. 
Type Name Formulation Indication Status 
Monoclonal 
Antibody 
Herceptin Anti-ERBB2 Breast cancer Approved 
Avastin Anti-VEGF Colorectal cancer Approved 
Rituxan Anti-CD20 NHL Approved 
Antibodies 
coupled with 
therapeutics 
Ontak CD25-targeted diphtheria toxin-IL2 fusion 
protein 
T-cell lymphoma Approved 
Mylotarg CD33-targeted gemtuzumab ozogamicin Leukemia Approved 
Zevalin CD20-targeted 90yttrium-ibritumomab 
tiuxtan 
NHL Approved 
 Bexxar CD20-targeted iodine-131-tositumomab NHL Approved 
I.4.2.2. Integrin targeting 
A large number of receptors are overexpressed at the surface of certain tumor cell or tumor 
neoangiogenic endothelial cells such as receptors for somatostatin analog, VEGF analog, 
vasoactive intestinal peptide, gastrin-related peptide and RGD peptide. Peptide analog can 
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easily be conjugated to a drug carrier system to allow tumor-specific targeting of cytotoxic 
agents by interaction with its receptors [Das et al., 2009]. Peptides are becoming the 
alternative to other targeting moieties because of their small size, lower immuno-genicity and 
ease to manufacture.  
Integrins are cell surface receptors involved in cell adhesion via interactions with the 
extracellular matrix (ECM) or counter-receptors on other cells. These cell adhesion molecules 
are heterodymeric transmembrane glycoproteins consisting of a α and a β subunit. To date, 24 
different subtypes of integrins have been discovered arising from different arrangements of 
the 18 α and 8 β existing subunits [Huveneers et al., 2007; Marelli et al., 2013]. Each subunit 
is composed of three regions: (i) an intracellular domain, which is connected to the 
cytoskeleton via associated multi-protein complex, (ii) a single transmembrane region and 
(iii) an extracellular domain responsible for binding to components of the ECM [Danhier et 
al., 2012b; Huveneers et al., 2007]. Multiple ligands are known to bind these integrins 
including ECM molecules (fibronectin, vitronectin, collagen), cell surface proteins such as 
intracellular adhesion molecule-1 (ICAM-1), vascular adhesion molecules-1 (VCAM-1), 
growth factors, cytokines and matrix-degrading proteinases. Despite the abundance of integrin 
ligands, minimal integrin recognition sequences were shown to be shared by most of the 
ligands. Among those, the tripeptide Arg-Gly-Asp (RGD, see Figure 4A) has been 
extensively studied since it is recognized by almost half of the integrins [Barczyk et al., 2010; 
Marelli et al., 2013]. Ligand binding to integrin promotes the so-called “outside-in” signaling, 
an intracellular signal transduction cascade including the activation of Ras, MAP kinase, focal 
adhesion kinase (FAK), Src, Rac/Rho/cdc42 GTPases, PKC and PI3K (phosphatidylinositol 
3-kinase) resulting in promoting cell survival, proliferation and differentiation [Eliceiri et al., 
2001; Huveneers et al., 2007]. Moreover, in cancer, integrins play an important role in 
angiogenesis by promoting vascular endothelial cell proliferation, migration, invasion and 
metastasis [Liu, 2006; Marelli et al., 2013]. Noteworthy, given that integrin are devoid of 
enzymatic activity, this signaling cascade seems to be mediated, at least partly, through 
growth factor receptor transactivation (VEGFR, EGFR, etc.). This phenomenon is known as 
“Integrin and growth factor receptor cross-talk” [Huveneers et al., 2007]. 
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Figure 4. (A) Integrin recognition motif RGD; (B) schematic representation of cyclic RGD (cRGD); (C) 
Cilengitide – c(RGDf-NMeVal) (adapted from [Marelli et al., 2013]). 
Since we worked with RGD peptide, this thesis will focus on this strategy. 
 
αvβ3 Integrin 
Numerous integrin sub-types including αvβ3, αvβ5, αvβ6, α2β1, α5β1, α6β1 and α6β4 were shown 
to be overexpressed at the surface of many cancer cells, showing the important role of 
integrins in cancer progression [Weis et al., 2011]. Among these integrins, αvβ3 is the most 
extensively studied given its strong implication in the regulation of angiogenesis. 
Interestingly, whereas many integrins are constitutively expressed in adult tissues, integrin 
αvβ3 was shown to be overexpressed on neoangiogenic endothelial cells [Brooks et al., 1994]. 
Beside its expression on endothelial cells, αvβ3 integrin was shown to be expressed by a 
multitude of tumor cells including breast cancer cells [Zitzmann et al., 2002]. Therefore, 
many efforts have been made by researchers to specifically target this integrin in order to 
make the most of this possible “double sword” [Danhier et al., 2009b; Liu et al., 2013].  
Moreover, the presence of αvβ3 was correlated with tumor progression and invasiveness in 
numerous cancer types including ovarian cancer, melanomas, glioblastomas as well as breast, 
stomach, pancreas and cervix cancers [Baum et al., 2007]. Numerous angiogenic growth 
factors upregulated in tumor tissue including VEGF, basic fibroblast growth factor (bFGF) 
interleukin-8, and TNF-α have been shown to promote its expression [Danhier et al., 2009b; 
Eliceiri et al., 2001].  The angiogenic promoting activity of αvβ3 can be partially explained by 
its functionally active complex with binding to matrix metalloproteinase (MMP-2). Indeed, 
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after ligand binding, αvβ3 induce an intracellular transduction leading to a higher transcription 
rate of MMP-2 and, hence, to an enhanced matrix degradation activity [Baum et al., 2007]. 
Finally, αvβ3 was shown to play a role in survival by inducing NFκB activation and, hence, 
inhibition of apoptosis (mediated by the expression of inhibitor of apoptosis proteins, IAP) 
[von Wnuck et al., 2006]. 
Numerous studies have shown that the tripeptide arginine–glycine–aspartic acid (RGD) was 
able to bind preferentially to αvβ3 integrin [Danhier et al., 2009b; Garanger et al., 2006; 
Murphy et al., 2008; Son et al., 2013]. Cilengitide® is a cyclic (RGD) peptide that binds to the 
integrins and is currently in Phase II clinical trials for the treatment of non-small cell lung 
cancer and pancreatic cancer.  
RGD-based strategies for cancer therapy and diagnosis 
Since the discovery of the tripeptide RGD as the cell recognition sequence in fibronectin back 
in 1984 by Ruoslahti et al. and subsequent discovery of the integrins, many efforts have been 
made to develop RGD-based strategies as both novel cancer therapeutic agents and targeted 
diagnostic agents [Pierschbacher et al., 1984; Temming et al., 2005]. 
The arginine-glycine-aspartic (RGD) tripetide sequence originally found in fibronectin turned 
out to be the cell attachment site of many other adhesive proteins including vitronectin, 
fibronectin, fibrinogen, lamin, collagen and osteoponin [Liu, 2006; Ruoslahti, 1996]. The 
expression of αvβ3 on both endothelial cells and tumors cells have led researchers to develop 
RGD-based double targeting, namely anti-angiogenic and anti-tumor strategies [Liu, 2006]. 
This tripeptide sequence is currently the basic module in almost all the strategies aiming to 
preferentially bind to αvβ3 integrin and other αv–related integrin [Temming et al., 2005]. The 
different integrin targeting strategies include: (i) monoclonal antibodies, (ii) RGD-based 
strategies, (iii) non-RGD antagonists. In this thesis, we will focus on the RGD-based 
strategies.  
Because of its small structure, the RGD sequence can be easily reproduced with synthetic 
peptides. Indeed, short peptides containing the RGD sequence can mimic cell adhesion 
proteins [Ruoslahti, 1996]. Furthermore, RGD-affinity and specificity for its integrin as well 
as metabolic stability and biodistibution can be modulated resulting in optimized smart-
engineered RGD peptides analogs. For instance, introduction of some amino-acids flanking 
the RGD sequence has been shown to improve integrin affinity and selectivity.  Similarly, 
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cyclization (Figure 4 B) is a currently used method to provide conformational restraint and, 
hence, improve selectivity and specificity [Marelli et al., 2013; Ruoslahti, 1996].   
Based on this strategy, Cilengitide®, a very potent RGD-based αvβ3 antagonist, was developed 
by using cyclization and has been clinically tested by Merck for treatment of glioblastoma 
multiforme (Figure 4 C). However, despite promising preliminary data, failure in phase-III 
clinical trials has led to its discontinued use as anticancer therapeutic [Marelli et al., 2013]. 
More recently, N-methylation has been reported as an important element in modulating 
peptides [Chatterjee et al., 2008]. 
Beside Cilengitide®, other RGD peptides have been developed among which cRGDfV, 
cRGDfK and RGD4C, cRGDfX, etc. [Marelli et al., 2013]. These RGD based peptide have 
been shown to inhibit angiogenesis through αvβ3 antagonism via regulation of the VEGF 
receptor, production of VEGF and stimulation of p53 tumor suppressor gene [Hsu et al., 
2007]. In this case, RGD-based strategies were used as anti-cancer treatment using its anti-
angiogenic effect.  
 
Beside this anti-angiogenic purpose, RGD can be used as targeting ligand when grafted to the 
surface of a nanocarrier. The use of nanocarriers such as liposomes, nanoparticles, micelles 
etc. for RGD-based strategies for cancer therapy offers numerous advantages: (i) carriers have 
the capacity to be grafted with multiple ligands on their surface exploiting the concept of 
multivalency [Marelli et al., 2013]; (ii) nanocarriers can incorporate various pharmacological 
agents e.g. anti-cancer drug [Folkman, 1971]; (iii) due to their large size, these carriers system 
are not subjected to renal filtration [Kwon et al., 2012]; (iv) the size of these nanocarriers 
allow passive accumulation trough the leaky vasculature of tumor angiogenic vessels, the so-
called EPR effect [Reddy et al., 2012]; (v) grafting of a ligand on their surface promotes 
receptor-mediated endocytosis of the particles [Prokop et al., 2008].   
 
One of the rationales for using nanocarriers is the delivery of cytostatic agent in the targeted 
endothelial cells expressing αvβ3. Indeed, once internalized through endocytosis, the 
nanocarrier can release its cytotoxic drug leading to angiogenic endothelial cell death. Thus, 
subsequent tumor cells death occurs by lack of oxygen and nutrients [Folkman, 1971]. 
Moreover, since integrin is also expressed on many tumor cells, RGD-grafted nanocarriers 
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can also kill tumor cells directly, making this RGD-based anti-cancer strategy a double sword 
[Danhier et al., 2010].  
 
Some examples of developed RGD-targeted nanocarriers are given in Table 2. 
The first results to show the inhibition of metastases with this kind of strategy were obtained 
with targeted nanoparticles loaded with doxorubicin (DOX) [Murphy et al., 2008]. Danhier et 
al. developed PLGA-based nanoparticles grafted with GRGDS. They showed a high cellular 
uptake in vitro leading to an improved anticancer efficacy and survival rate in TLT-bearing 
mice and A-431-bearing mice [Danhier et al., 2012c]. The demonstration of the targeting of 
the tumor endothelium was performed both in vitro and in vivo using fluorescence 
microscopy (Figure 5). Recently, Li et al., developed RGD-fatty alcohol-modified docetaxel 
liposomes and showed a better anti-tumor activity in S-180 sarcoma-bearing mice than the 
non-modified liposomal form [Li et al., 2014]. Meng et al. developed cRGD-based liposomes 
loaded with paclitaxel and showed a lower tumor microvessel density than for taxol-treated 
group [Meng et al., 2011]. In si-RNA-based therapy, Yonenaga et al. developed RGD-based 
polycation liposomes bearing siRNA for cancer treatment in B16F10-luc2-bearing mice 
[Yonenaga et al., 2012]. An elegant study conducted by Han et al. showed very interesting in 
vivo results in 3 different ovarian carcinoma models. Their developed RGD grafted chitosan 
nanoparticles displayed an increased selective intratumoral delivery, effective targeted 
silencing of multiple growth-promoting genes (POSTN, FAK, and PLXDC1) and significant 
inhibition of tumor growth [Han et al., 2010]. 
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Table 2. Non-exhaustive examples of developed RGD-targeted nanocarriers loaded with an anticancer-drug for 
pre-clinical studies. 
Formulation Targeting 
motif 
Drug Tumor model Results References 
PEGylated 
Nanoparticles 
cRGD DOX R40P murine 
pancreatic/renal 
carcinoma cells 
15-fold increase in drug 
efficacy compared to free-
DOX treated mice 
[Murphy et 
al., 2008] 
PLGA-PEG 
nanoparticles 
GRGDS and 
peptido-
mimetics 
PTX 
DOX 
HUVEC, TLT 
cells, A431, CT-
26 
High cellular uptake in vitro, 
improved anticancer efficacy 
and higher survival rate 
[Danhier et 
al., 2012c] 
Liposomes cRGD PTX A549 lung 
adenocarcinoma 
Lower tumor microvessel 
density than for taxol-treated 
group 
[Meng et 
al., 2011] 
Liposomes Fatty alcohol 
modified-
RGD 
DTX S-180 sarcoma Better anti-tumor activity than 
the non-modified liposomal 
form 
[Li et al., 
2014] 
polycation 
liposomes 
cRGD siRNA B16F10-luc2 High knockdown efficiency [Yonenaga 
et al., 
2012] 
CH 
nanoparticles 
cRGDfk siRNA SKOV3ip1, 
HeyA8, A2780 
(ovarian 
carcinomas) 
Increased selective 
intratumoral delivery, targeted 
silencing of multiple growth-
promoting genes, significant 
inhibition of tumor growth 
[Han et al., 
2010] 
Abbreviations: CH = chitosan, DOX = doxorubicin, DTX = docetaxel, PTX = paclitaxel 
 
Figure 5. Fluorescent microscopy of TLTs growing in NMRI mice 4 h after injection of non-targeted or RGD-
grafted nanoparticles (RGD-NP) containing fluorescent-PLGA (green). Sections were stained with DAPI for 
nucleus detection (blue) (adapted from [Danhier et al., 2012c]). 
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RGD-based strategies have also been used for imaging of tumors and angiogenesis. Indeed, 
since antiangiogenic drugs have been successfully used in cancer patients, molecular imaging 
for non-invasive assessment of angiogenesis represents potential interest for clinicians 
[Danhier et al., 2012b]. Such a tool can be used for either detection of angiogenesis and tumor 
metastasis or monitoring of anti-angiogenic treatment response [Temming et al., 2005]. As for 
therapeutic purpose, both small RGD-based peptide and RGD-grafted nanocarriers have been 
developed. For imaging purpose, RGD-targeted nanocarriers also present some advantages. 
Beyond their advantages concerning passive accumulation via EPR effect and non-renal 
filtration, two main benefits can be added: (i) numerous imaging labels can be attached to a 
single nanoparticle leading to an increased signal intensity and (ii) different imaging labels 
can be used to create functionalized nanoparticles as multimodality imaging systems [Danhier 
et al., 2012b]. Table 3 gives some examples of the pre-clinical studies in the field of RGD-
based strategies for cancer imaging available in the literature. In this case, RGD-peptides or 
RGD-grafted nanocarriers are coupled with imaging agents. Among those imaging agents, 
radiotracers and SPIO are the most studied allowing positron emission tomography (PET), 
single photon emission computed tomography (SPECT) and magnetic resonance imaging 
(MRI).  
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Table 3. Examples of the pre-clinical studies of RGD-based strategies for cancer imaging 
Formulation Targeting 
motif 
Imaging 
agent 
Tumor model Results References 
Galacto-RGD 
peptides 
conjugates 
cRGDfK 18F Human M21 
melanoma cells 
Suitable metabolic 
stability and low 
estimated radiation dose 
[Haubner et 
al., 2004] 
SPIO-RGD 
peptides 
conjugates 
cRGDyE SPIO HaCaT-ras-A-
5RT3 and A341 
squamous 
carcinoma cells 
Non-invasively 
differentiation of tumor 
with high and lower 
area fraction of αvβ3–
positive tumor vessels 
[Zhang et 
al., 2007] 
SPIO-RGD 
peptides 
conjugates 
RGD-Cys  SPIO A549 non small 
cell lung cancer 
cells 
Efficient active 
targeting and labelling 
of αvβ3–expressing 
tumors 
[Xu et al., 
2011] 
Nanocarriers      
PEGylated 
Nanoparticles 
c(RGDyK) SPIO U87MG (brain 
tumor) 
Non-invasive 
monitoring of the tumor 
response to VEGF(121)/ 
rGel therapy at early 
stages of treatment  
[Zhang et 
al., 2012] 
PLG-PEG 
micelles 
cRGDfC 64Cu 
 
U87MG In vivo monitoring of 
tumor accumulation by 
PET  
[Xiao et al., 
2012] 
PEG-PLA 
micelles 
cRGDfK SPIO A549 non small 
cell lung cancer 
cells 
High efficiency in 
tumor neovasculature 
detection 
[Khemtong 
et al., 2009] 
 
More recently, optical imaging has emerged as a powerful modality for studying molecular 
recognitions and molecular imaging in a noninvasive, sensitive, and real-time way. This 
method presents undeniable advantages including cost-effectiveness, convenience, and non-
ionization safety. Moreover, optical imaging and the abovementioned other imaging 
modalities (MRI, PET, SPECT) have been shown to complete each other [Ye et al., 2011]. 
Hence, many efforts have been made to develop new RGD-targeted carriers with optical 
imaging abilities. These novel kinds of nanoparticles include quantum dots (QDs), carbon 
nanotubes, or gold nanoparticles [Danhier et al., 2012b].  
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I.4.2.3. Folate receptor targeting 
Folate receptors, also known as folate-binding proteins (FBP), are N-glycosylated proteins 
with high binding affinity to vitamin folic acid. Interestingly, folate receptor is not required 
for cellular survival and its expression is highly restricted or absent in normal tissues while 
frequently overexpressed by cancer cells as a consequence of enhanced folate requirements 
for DNA synthesis [Arias, 2011; Zhao et al., 2008]. Moreover, a correlation between its level 
of expression and tumor grade and response to chemotherapy has been highlighted [Toffoli et 
al., 1997]. Therefore, this receptor constitutes an interesting target for cancer therapy. Folate 
receptors include at least four isoforms, α, β, γ/γ′ and δ. Among these isoforms, the alpha and 
beta isoform are the most studied [Yu et al., 2010; Zhao et al., 2008]. The alpha isoform 
folate receptor-α is consistently expressed in several carcinomas, especially in non-mucinous 
ovarian carcinomas, uterine carcinomas, testicular choriocarcinomas, ependymomas, and 
pleural mesotheliomas, and less frequently in breast, colon, and renal cell carcinomas [Clifton 
et al., 2011] whereas the beta isoform was shown to be amplified in activated monocytes, 
macrophages and overexpressed in chronic myelogenous leukemia (CML) and in 70% of 
acute myelogenous leukemias (AML). Linking folic acid to nanocarriers has been shown to 
facilitate tumour-specific delivery of anticancer drugs via receptor-mediated endocytosis [Yu 
et al., 2010; Zhao et al., 2008].  
To date, despite a large number of publications on in vitro and in vivo studies [Lv et al., 2014; 
Ye et al., 2011], relatively few agents have been translated into the clinic. The recent entry of 
fartetuzumab, a fully humanized antibody derived from the murine antibody LK26, and 
vitafolitide, the first folate-drug conjugate to enter into clinical trials as a therapeutic agent, 
into Phase III trial suggests that Folate receptor targeting is finally reaching a critical point 
[Teng et al., 2012]. 
I.4.2.4. Transferrin receptor targeting  
Transferrin, a 78 kDa-monomeric glycoprotein, is the main protein involved in the regulation 
and distribution of circulating iron through the blood and into cells. Cell internalization is 
governed by receptor-mediated endocytosis after binding to transferrin receptor. Since iron is 
required for various biological processes including DNA synthesis, cellular metabolism and 
proliferation, the expression of transferrin receptors have been shown to be upregulated in 
most active prolifering cell type including cancer cells [Tortorella et al., 2014]. Moreover, 
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correlation between increased transferrin receptor expression and the level of malignancy has 
also been determined in a range of cancer type, including bladder transitional cell carcinoma, 
breast cancer, glioma, lung adenocarcinoma, chronic lymphocytic leukaemia and non-
Hodgkin’s lymphoma [Singh et al., 2011]. For all these reasons, transferrin receptors have 
become a high attractive target for cancer therapy. Nanocarriers surface functionalization with 
the transferrin peptide itself or anti-transferrin receptor antibody has proved to be promising . 
To date, four transferrin-conjugated nanocarrier-based drug delivery systems for the 
encapsulation of anticancer therapeutic compounds have progressed into human clinical trials 
(see Table 4). All are currently in early stage (Phase I and/or II) trials for the treatment of 
solid malignancies [van der Meel et al., 2013]. 
Table 4. Overview of transferrin-targeted nanomedicines undergoing clinical evaluation. Clinical data are 
extracted from http://www.clinicaltrials.gov (June 2014) 
Name Drug Formulation Indication Clinical phase 
MBP-426 oxaliplatin Tf coupled-liposome  gastro-esophageal (GE) 
adenocarcinoma 
Phase I/II 
SGT-53 p53-plasmid 
DNA 
scFv anti-Tf receptor 
coupled-liposome 
Solid tumors Phase Ib 
SGT-94 RB94 plasmid 
DNA 
scFv anti-Tf receptor 
coupled-liposome 
Solid tumors Phase I 
CALAA-01 RRM2 siRNA Tf coupled nanoparticles Solid tumors Phase I 
Abbreviations: Tf: transferrin, scFv: single-chain antibody fragment 
I.4.2.5. Human/Epidermal epidermal growth factor receptor 2 targeting 
The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor, member of the 
ErbB family. Ligand binding triggers a signaling cascade promoting cell survival, 
proliferation, adhesion, migration, differentiation and tissue invasion, while inhibiting 
apoptosis [Harari, 2004; Trivedi et al., 2014]. Those receptors are important in tumor 
development via their effect on cell proliferation, migration, angiogenesis and anti-apoptosis. 
Hence, EGFR is frequently overexpressed in numerous cancer types including breast, uterus, 
head and neck as well as ovarian, bladder, colon, prostate, kidney, pancreatic and non-small-
cell lung cancer associated with poor prognostics [Harari, 2004; Li et al., 2013a]. EGFR are 
composed of four receptor known as HER-1, HER-2, HER-3 and HER-4, where HER-2 is the 
most extensively studied. It has become evident that 20-25% of breast cancers are (HER2)-
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positive [Li et al., 2013a]. During the past decades, HER-2 has been demonstrated as a 
validated therapeutic target with dramatically improved survival for patients treated with 
specific HER-2 targeted therapeutics. Those treatments include monoclonal antibodies and 
tyrosine kinase  inhibitors (TKIs). Table 5 summarizes the different currently available 
EGFR-targeted therapeutics for clinical use. 
Table 5. Exemples of currently available EGFR-targeted therapeutics. Clinical data are extracted from 
http://www.clinicaltrials.gov (June 2014). 
* Approved in countries outside USA and Europe. ** Single-chain antibody fragment 
 
Product name Other name Formulation Target Indications Clinical 
phase 
Monoclonal antibody 
trastuzumab Herceptin® Humanized murine IgG HER-2 Breast cancer Approved 
pertuzumab Omnitarg® Fully humanized IgG HER-1, HER-2, 
HER-3, HER-4 
Metastatic breast 
cancer 
Approved 
Trastuzumab-
DM1 
T-DM1 Antibody-drug conjugate 
trastuzumab-DM1 (anti-
microtubule agent) 
HER-2 Breast cancer  Phase III 
zalutumumab HuMax-EGFr Fully humanized IgG EGFR Second-line treatment 
of recurrent SCCHN 
Phase III 
nimotuzumab Theraloc Fully humanized IgG EGFR SCCHN Phase I* 
Tyrosine-kinase inhibitors 
lapatinib Tykerb® Small molecule HER-1, HER-2 Breast cancer 
resistant to 
trastuzumab 
Phase III 
neratinib HKI-272 Small molecule HER-1, HER-2, 
HER-4 
Metastatic breast 
cancer 
Phase II 
afatinib BIBW-2992 Small molecule HER-1, HER-2, 
HER-3, HER-4 
Breast cancer 
resistant to 
trastuzumab 
Phase II 
Nanomedicine      
MM-302  Dox-loaded PEG-ylated 
liposome with scFv** 
antibody fragments 
HER-2 Breast cancer  Phase I 
Anti-EGFR Ils-
DOX 
 Dox-loaded 
immunoliposome coupled 
with Fab fragments of 
cetuximab 
EGFR Advanced solid 
tumor 
Phase I 
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I.4.3. Triggered targeting 
Triggered drug delivery is a common term to refer to systems designed to release their 
contents or react upon exposure to internal or external stimuli. Such environmental-sensitive 
carriers are essentially polymeric wisely engineered materials able to react rapidly to small 
modifications in the environment by experiencing rapid changes either in their structure or in 
their physical properties. Stimuli can be either internal (change in pH or temperature in some 
tissues or disease stage) or external (magnetic, electric fields, light, ultrasound, etc.) [Arias, 
2011; Egusquiaguirre et al., 2012].  
Acid-triggered release 
As aforementioned, tumor cells initiate several changes in the stroma to supports their growth 
and progression including slightly acidic pH. Indeed, tumor extracellular pH is generally 
more acidic (pH 6.5 compared to 7.3 in physiological conditions), due to the increased 
glycolysis and plasma membrane proton-pump activity of tumor cells. Such differences can 
be exploited to induce a tumor specific activation of nanocarriers [Abouelmagd et al., 2014; 
Gullotti et al., 2009]. 
Particularly, many efforts have been made to develop acidic-sensitive nanocarriers. In 
designing these nanocarriers, acidic pH changes the ionization status of the polymer used or 
induces a cleavage of acid-labile linkers resulting in degradation of the carrier, hence 
releasing the entrapped drug [Arias, 2011].  
For instance, Lee et al. developed a pH-responsive micelle system using a poly(lactic acid)-b-
PEG-b-poly(L-histidine) (PLA-b-PEG-b-polyHis) triblock copolymer with a pKa of 7.0 [Lee 
et al., 2007]. Below pH 7, the polyHis part is protonated on the nitrogen of the imidazole ring 
of histidine, allowing the core to release the drug. Hence, this system allows the nanocarrier to 
remain stable until its entrance in tumor interstitium where drug can be released after micelle 
destabilization. Similarly, Kim et al., developed pH-sensitive immunoliposomes using small 
unilamellar vesicles of dioleylphosphatidylethanolamine and cholesteryl hemisuccinate. 
Those immunoliposomes showed good anti-tumor efficacy in vivo [Kim et al., 2009]. Griset 
et al. synthesized cross-linked NPs using acrylate-based hydrophobic polymers with hydroxyl 
groups that were masked by pH-labile protecting groups (e.g., 2,4,6-
trimethoxybenzaldehyde). The NPs were stable at neutral pH, but the protecting group was 
cleaved and the hydroxyl groups were exposed at mildly acidic pH (pH ≈ 5). This 
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hydrophobic-to-hydrophilic transformation caused the swelling of NPs and subsequent drug 
release [Griset et al., 2009].  
This pH-triggered release has also been exploited to deliver the encapsulated drug when 
internalized into late endosomal vesicles to ensure controlled drug release [Griset et al., 2009; 
Yang et al., 2014b]. An interesting study was conducted by Cajot et al. [Cajot et al., 2012]. 
They developed smart nanocarriers combining acid-triggered drug delivery and active 
targeting approach. This systems consists of self-assembled hybrid micelles based on 90% 
wt.% pH-sensitive non-targeted poly(ethylene oxide) – poly(2-vinyl-pyridine) – poly(ε-
caprolactone) ((PEO)129(P2VP)43(PCL)17) ABC star copolymer, which was co-micellized with 
10 wt.% of a biotinylated (P2VP)10(PEO)155(PCL)17 ABC linear copolymer. In these micelles, 
biotin functions, attached to the P2VP polymer part, are protected from blood components 
during circulation (neutral environment) by a PEO corona. Under acidic conditions (such as 
tumor environment), the P2VP block is protonated and stretches out of the PEO shell and then 
exposes biotin at the periphery of micelles (Figure 6). 
 
 
Figure 6. Composition and architecture of the copolymers used for the preparation of the biotinylated hybrid 
micelles, micelles composition and sketch of the shell evolution depending on the pH, illustrating the principle 
of ligand camouflage and exposure thanks to pH (adapted from [Cajot et al., 2012]). 
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Magnetic field 
External magnetic field is used in combination with magnetically responsive nanoparticles, 
so-called “magnetic nanoparticles” (MNP), (i) to accumulate these nanocarriers at the target 
site, keeping them in place for a given period of time to allow drug release and/or (ii) 
triggering drug release (See Figure 7). For the first purpose, referred as “magnetic targeting”, 
a static magnetic field is used to guide MNP at the target site (Figure 7A). Indeed, when a 
permanent magnet is applied externally near the tumor region, the magnetic gradient 
produced exerts attractive forces on MNP delivered via the circulation. However, this 
magnetic gradient decreases as the distance with the source (permanent magnet) increases. 
This constitutes the major limiting factor of this approach to clinical translation [Abouelmagd 
et al., 2014; Arias, 2011; Cole et al., 2011; Laurent et al., 2011; Reddy et al., 2012]. 
Nevertheless, constant efforts are made to overcome magnetic barriers. Researchers are 
currently studying potential solution including improvements in the quality of the source (e.g. 
using a MRI system magnet as a source [Riegler et al., 2010]), deeply focused targeting 
[Huang et al., 2010] and magnetic implants [Polyak et al., 2008].  
Triggering drug release using magnetic field is referred as “magnetic hyperthermia”. This 
strategy consists in the application of an alternating magnetic field on the target as release 
trigger after MNP have reached tumor (Figure 7B). This energy is then absorbed by the MNP 
and converted into heat by the relaxation of rotating magnetic moments induced by the 
alternating magnetic field. This generated heat can, thereafter, be used to either trigger drug 
release from a thermo-responsive nano-carrier or act directly by itself on more sensitive tumor 
cells (discussed in the hyperthermia section) [Cole et al., 2011; Laurent et al., 2011]. The 
amount of heat generated depends on the nature of magnetic material and of magnetic field 
parameters [Gupta et al., 2005]. Chen et al. and Jordan et al., were the first to study this 
hyperthermia effect of MNP in 1993 [Chen et al., 2010; Jordan et al., 1993]. 
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Figure 7. Schematic representation of magnetic triggered drug release. (A) Under application of a static 
magnetic field placed on the surface of the tumor, the so-formed magnetic gradient attracts magnetic 
nanoparticles (MNP) through the leaky vasculature into the tumor tissue. (B) After MNP reach tumor tissue, an 
applied alternative magnetic field induces localized heating by relaxation of rotating MNP (adapted from [Cole 
et al., 2011]). 
 
Light 
Ultraviolet (UV), visible and near-infrared (NIR) lights are widely studied as external stimuli 
to trigger drug release by inducing structural changes of nanocarriers. This approach is 
particularly interesting as it provides a non-invasive technique easy to control in terms of 
intensity and duration of the stimulus. On one hand, UV and short visible lights (< 410 nm) 
are mostly used as energy source to activate nanocarriers compounds and destabilize their 
structure to trigger drug release. However, this technique is limited to the close skin surface 
target as these wave penetration deeps are limited to a few micrometers. This issue limits their 
application into clinic [Abouelmagd et al., 2014]. On the other hand, long visible and NIR 
lights can be used to generate reactive oxygen species (ROS) after activation of a compound 
presented by the drug carrier or the drug itself. Once this photosensitizer-containing drug is 
delivered to the tumor cell, light radiation activates it and, hence, generates “killer” ROS 
inducing apoptosis and enhancing drug release. This technique is called photodynamic 
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therapy (PDT, see Figure 8) [Kelkar et al., 2011; Moses et al., 2013]. PDT is currently an 
FDA-approved first-line treatment for superficial skin cancers (actinic keratosis and basal cell 
carcinomas), age-related macular degeneration and is routinely used for obstructive 
esophageal cancer and some forms of lung cancer [Issa et al., 2010; Kelkar et al., 2011]. 
Porphyrin derivatives are the most commonly used photosensitizers in PDT. When irradiated 
with the proper wavelength, the porphyrin produces cytotoxic ROS by reaction between its 
excited-state and nearby moleculer oxygen [Kelkar et al., 2011]. For instance, Savellano et al. 
conjugated a clinically approved benzoporphyrin derivative (verteporfin) to the anti-EGFR 
MAb cetuximab, and showed that the conjugate effectively targeted and photodynamically 
killed EGFR-overexpressing A431 (epidermal carcinoma) and Ovcar5 (ovarian cancer) 
human cancer cells [Savellano et al., 2005]. Konan et al. studied meso-tetra (p- 
hydroxyphenyl) porphyrin (p-THPP)-loaded nanoparticles and tested their phototoxicities 
against EMT-6 murine mammary tumor cells [Konan et al., 2003]. The incorporation of the 
photosensitizer into nanoparticles has been shown to reduce cutaneous photosensitivity post-
treatment [Kelkar et al., 2011]. 
 
 
Figure 8. Schematic representation of NIR light triggered delivery. Once the photosensitizer-containing 
nanocarrier is delivered to the tumor cell, NIR light radiation activates it and, hence, generates “killer” ROS 
inducing apoptosis and enhancing drug release. This technique is called photodynamic therapy (PDT) (adapted 
from [Moses et al., 2013]). 
 
Ultrasound 
Ultrasound (US) refers to acoustic sound with high frequencies (> 20kHz) above those of 
audible sound. Those waves have the potency to penetrate deeper in inner organ compared to 
light waves. Ultrasound generates two kind of effects: (i) thermal (heat generation) and (ii) 
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non-thermal effects (acoustic cavitation and radiation forces). Both stimuli can be exploited 
for diagnosis, physical therapy and controlled drug delivery. Non-thermal effects of US 
induce a variety of biological responses resulting in increased drug or carrier extravasation, 
BBB disruption and membrane permeabilisation to otherwise cell-impermeable compounds, 
while thermal effects are mostly used to trigger thermoresponsive drug delivery and tumor 
tissue thermal ablation [Abouelmagd et al., 2014; Yudina et al., 2012]. Focused US (FUS) is 
currently used in the clinic for non-invasive treatment of uterine fibroids and prostate tumors. 
This strategy relies on the application of continuous ultrasound pulses of the order of seconds 
to reach temperatures around 60–70°C in the ultrasound focal volume inducing coagulative 
necrosis resulting, hence, in thermal ablation of the diseased tissue [Yudina et al., 2012]. 
Moreover, efforts have been made in combining high-intensity focused ultrasound (HIFU) 
exposures, as a source of hyperthermia, with thermosensitive nanocarriers. Li et al. 
demonstrated the feasibility of this approach using Gold nanocages covered with thermally-
responsive polymers. They demonstrated experimentally that controlled release could be 
achieved by the application of HIFU at depths up to 30 mm [Li et al., 2011].  
 
Cavitation, defined as formation and/or activity of gas-filled bubbles in a medium exposed to 
US, is thought to be responsible for enhancing (i) the permeability of blood vessels, by the 
generation of local streaming and consequent shear that can open up gaps between endothelial 
cells [Cool et al., 2013; Hancock et al., 2009] and (ii) the permeability of individual cells 
through the formation of the transient pores in the plasma membrane, a phenomenon called 
sonoporation (see Figure 9) [Frenkel, 2008; Geers et al., 2012]. Researchers can make the 
most of these properties in enhancing drug delivery [Yudina et al., 2012].  Indeed, 
microbubbles, defined as micron sized (1–10 µm) gas bubbles with a shell composed out of 
phospholipids, polymers or proteins, can be loaded with a drug and used in association with 
applied US for drug delivery. Originally, microbubbles were developed as contrast agent in 
ultrasound imaging [Cool et al., 2013]. At higher acoustical pressures, cavitation will induce 
violent microbubble oscillations, eventually resulting in microbubble destruction (the so 
called ‘inertial cavitation’). Inertial cavitation is particularly useful in drug delivery as it can 
trigger both release of drugs from the microbubbles and uptake of the released drugs into the 
temporary permeabilized cells due to sonoporation [Geers et al., 2012]. For instance, 
Lentacker et al. developed DOX-containing microbubbles and demonstrated a two-fold 
increase efficacy of DOX-loaded microbubbles in killing melanoma cells after exposure to 
ultrasound compared to DOX-liposomes [Lentacker et al., 2010]. Finally, another example by 
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Cool et al. gave the in vivo proof that ultrasound triggered drug delivery can be enhanced by 
coupling drug loaded liposomes to microbubbles using indocyanine green-containing 
liposomes (ICG-liposomes) coupled to perfluorobutane (C4F10) gas containing microbubbles 
[Cool et al., 2013]. They also showed that the perforations in the blood vessels allow the 
passage of ICG-liposomes up to 5 h after microbubble and ultrasound treatment. 
 
Figure 9. Schematic representation of cavitation-mediated US triggered drug delivery. Applied FUS induce 
cavitation resulting in (1) opening of the gap between endothelial cells resulting in an enhanced extravasation, 
(2) formation of transient pores in the plasmic membrane of nearby tumor cells resulting in enhanced cell 
permeability and (3) microbubbles implosion resulting in drug realease (due to inertial cavitation) (adapted from 
[Yudina et al., 2012]). 
 
Hyperthermia 
The heating of tissue to temperatures above those found in normal physiological conditions, 
or hyperthermia, has been used in a number of different strategies to treat cancer including 
thermal ablation, which is the destruction of tumor cells under high hyperthermia. At much 
lower temperatures hyperthermia (referred as “mild hyperthermia”) can be used to induce a 
number of effects on tissue e.g., increased blood flow, improved perfusion, enhanced 
oxygenation and increased permeability. Moreover, mild hyperthermia can be used to trigger 
site-specific drug release from thermo-responsive nanocarriers [May et al., 2013]. Thermo-
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sensitive liposomes, micelles and polymeric nanoparticles are the most widely studied 
stimuli-responsive carrier. Those thermo-sensitive nanocarriers are based on the use of wisely 
engineered polymer presenting a phase transition temperature.  For polymeric micelles, 
transition phase can lead to an intra-molecular collapse of the polymer leading to the 
shrinkage of the micelles and subsequent drug release (Figure 10) [Abulateefeh et al., 2011].  
This transition phase temperature is known as the low critical solution temperature (LCST) 
[Arias, 2011]. For instance, Guo et al. recently developed thermoresponsive Pluronic F127-
poly(d,l-lactic acid) (F127-PLA) copolymer micelles decorated with folate (FA) [Guo et al., 
2014]. F-127-PLA micelles had a low critical solution temperature of 39.2 °C close to body 
temperature. At 37 °C, little amount of encapsulated anticancer drug DOX is released from 
micelles, while at a slightly elevated temperature (40 °C), the shrinkage of thermoresponsive 
segments causes a rapid release of DOX and instantly increases the drug concentration 
locally. 
 
Figure 10. Schematic representation of drug delivery from thermosensitive micelles. When temperature exceeds 
the LCST, micelles shrinks resulting in drug delivery (adapted from [Guo et al., 2014]).  
 
Local hyperthermia is a phenomenon that can be (i) naturally present under certain 
pathological conditions (e.g. some carcinomas, inflammation) or (ii) achieved by several 
external stimuli including the abovementioned light, ultrasound and magnetic field 
[Abouelmagd et al., 2014; Ta et al., 2013]. For instance, an interesting application was given 
by Hayashi et al. who used alternative magnetic field (AMF) to generate hyperthermia using 
SPIO-loaded nanoparticles [Hayashi et al., 2014]. They designed the AMF-responsive smart 
nanoparticles by combining DOX and clustered SPIO core within a containing polymer with a 
glass-transition temperature (Tg) of 44°C. During exposure to the AMF, the inner Fe3O4 
nanoparticles cluster produces heat until at least the Tg, leading to the softening of the 
polymer phase, which allows the release of DOX (Figure 11). 
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Figure 11. Schematic representation of smart NPs that produce heat in response to alternative magnetic field and 
sequentially release doxorubicin [Hayashi et al., 2014]. 
Abbreviations: ACMF = alternating current magnetic field, DOX = Doxorubicine, NPs = nanoparticles, Tg = 
glass transition temperature 
 
Concerning thermosensitive liposomes, payload release is achieved by taking advantage of 
the inherent physical properties of liposomal membranes, or more precisely, by tuning the 
transition temperature between the gel and liquid phases (Tm). At the Tm, the membrane 
becomes disordered, increasing the permeability of the lipid bilayer to its aqueous contents 
via passive transfer through the disordered membrane phase boundaries [May et al., 2013]. 
Thermodox® is a novel formulation of thermosensitive PEGylated liposomal doxorubicin. 
This system is activated by the application of localised hyperthermia and releases its payload 
when reaching temperatures between 39 and 42°C [Egusquiaguirre et al., 2012]. Thermodox® 
is currently being tested in a phase III study to evaluate its efficacy in combination with 
radiofrequency ablation (RFA) in patients with hepatocellular carcinoma, compared to those 
receiving RFA alone [www.clinicaltrials.fgov]. 
Finally, it is noteworthy that most cancer tissues have been shown to possess higher heat-
sensitivity over normal tissue. Hence, this property can be used in cancer therapy to destroy 
the pathological cells by hyperthermia [Cole et al., 2011; Laurent et al., 2011]. The 
destructive ability of hyperthermia arises from damage to several cellular components such as 
membranes, the cytoskeleton and cellular process mechanisms such as DNA repair. This 
strategy has been used by Maier-Hauff et al. in a clinical patient trial to treat recurrent 
glioblastoma by magnetic iron-oxide nanoparticles-mediated hyperthermia [Maier-Hauff et 
al., 2011]. 
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II. NANOPARTICLES 
Over the last decades, numerous nanocarrier platforms have been studied for cancer drug 
delivery [Acharya et al., 2011; Sultana et al., 2013]. These nanocarriers platforms include 
liposomes, polymer conjugates, polymeric micelles, nanoparticles and dendrimers 
(summarized in Figure 12) [Danhier et al., 2010]. We will focus on nanoparticles in this 
thesis.  
II.1. DEFINITIONS 
Nanoparticle refers to solid spherical drug carrier system of less than 1µm diameter prepared 
from natural or synthetic polymers. These nanoparticles have become one of the greats in the 
field of drug delivery considering the wide range of drugs that can be delivered using this 
carriers ensuring a sustained drug delivery [Hans et al., 2002; Sultana et al., 2013]. 
 
Figure 12. Various types of nanocarriers currently used in drug delivery (adapted from [Danhier et al., 2010]). 
 
II.2. POLYMERS 
Among the polymer used to formulate nanoparticles, two categories can be distinguished: (i) 
natural polymers (i.e. proteins and polysaccharides) and more importantly, (ii) synthetic 
polymers. Natural polymers for drug delivery and tissue engineering possess good 
compatibility, but lack of suitable physical properties such as solubility, mechanical strength 
or stability limits their application [Dash et al., 2012a]. Synthetic polymers have been more 
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extensively used. Synthetic polymers include Poly(lactic acid) (PLA), poly(glycolic acid) 
(PGA), the co-polymer of both, Poly(d,l-lactide- co-glycolide) (PLGA) and poly(ε-
caprolactone) (PCL). In this thesis, we will focus on PLGA- and PCL-based polymers.  
Indeed, in the studies presented we used a combination of PLGA, PLGA-PEG and PCL-PEG 
(see chemical structure in Figure 13). 
 
Figure 13. Chemical structures of the three polymers used in this thesis. (A) PLGA, (B) PLGA-PEG, (C) PCL-
PEG. 
 
Poly-d,l-lactide- co-glycolide (PLGA) 
Because of its biodegradability, Poly(lactic-co-glycolic acid) (PLGA) is one of the most 
successfully used polymers to formulate nanoparticles. Indeed, its hydrolysis leads to 
metabolite monomers, lactic acid and glycolic acid, which are endogenous and easily 
metabolized by the body via the Krebs cycle (Figure 14). Hence, a minimal systemic toxicity 
is associated with the use of PLGA for drug delivery or biomaterial applications [Danhier et 
al., 2012a; Kumari et al., 2010]. Interestingly, the US FDA and European Medicine Agency 
(EMA) approved PLGA in various drug delivery systems in humans, which make it very 
attractive in a view of a translational approach. Different molecular weights and copolymer 
compositions are commercially available. Depending on the molecular weight and copolymer 
ratio, PLGA degradation time can vary from several months to several years. The forms of 
PLGA are usually identified with regard to the monomers ratio used (e.g., PLGA 75:25 
identifies a copolymer whose composition is 75% lactic acid and 25% glycolic acid) [Acharya 
et al., 2011; Kumari et al., 2010]. 
 
Figure 14. Hydrolysis of PLGA [Kumari et al., 2010] 
	   A	   B	   C	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Many factors are known to influence drug release and efficiency of formulated PLGA-based 
nanomedicines including surface modification of PLGA, drug encapsulation methods, particle 
size, additives added during formulation, molecular weight of drug and ratio of lactide to 
glycolide moieties [Danhier et al., 2012a; Kumari et al., 2010]. PLGA nanoparticles have 
been extensively used for the encapsulation of various anti-cancer drugs and their successful 
delivery in vivo. These drugs include paclitaxel, doxorubicin, 5-fluorouracil, 9-
nitrocamptothecin, cisplatin, triptorelin, dexam- ethasone, xanthone, etc [Danhier et al., 
2012a]. On the other hand, recent studies have shown successful formulation of PLGA-based 
magnetic nanoparticles encapsulating SPIO for imaging applications [Aryal et al., 2013; Lee 
et al., 2010; Ling et al., 2012]. 
 
Poly(ε-caprolactone) (PCL) 
Poly(ε-caprolactone) (PCL) is a semicrystalline hydrophobic polyester. At room tempera- 
ture, PCL is soluble in aromatic solvents and in chlorine solvents (dichloromethane and 
chloroform), partially soluble in polar solvents, such as acetone and acetonitrile, but insoluble 
in alcohols and water [Pohlmann et al., 2013] However, PCL hydrophobic nature does not 
allow easy release of hydrophobic drugs given its long-term degradation (ranging from weeks 
to months). To overcome this limitation, various types of modification have been developed 
for successful application in pharmaceutical formulations. Among these, Poly(ethylene 
glycol) (PEG), a hydrophilic polymer, is frequently used to modify PCL degradation pattern 
and improve its biodegradability via PCL-PEG co-polymers formation [Dash et al., 2012a; 
Dash et al., 2012b; Pohlmann et al., 2013]. PCL nanoparticles have been prepared mostly by 
nanoprecipitation, solvent displacement and solvent evaporation [Danhier et al., 2012a]. PCL 
nanoparticles have shown their efficacy in encapsulating a wide range of drugs such as 
paclitaxel, doxorubicin, tamoxifene, insulin and so on [Dash et al., 2012b; Kumari et al., 
2010]. 
II.3. FORMULATION 
The drug or molecules of interest may either be entrapped into the particle cavity (so-called 
“nano-capsules”) or homogeneously dispersed into a polymer matrix (so-called 
“nanospheres”) [Sultana et al., 2013]. Polyester nanoparticles are usually prepared using an 
emulsion-evaporation technique. This technique is commonly used to encapsulate 
hydrophobic drugs or SPIO and consists in dissolving both polymers and hydrophobic drugs 
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in an organic solvent (mostly dichloromethane) and incorporating this organic phase into a 
hydrophilic phase containing a surfactant (polysorbate 80 or polyvinyl-alcohol, PVA) 
[Danhier et al., 2009a; Garinot et al., 2007; Lee et al., 2010]. Since these two phases are non-
miscible, an external source of energy (sonication) is used to induce the nanosized droplets 
and create this oil-in-water emulsion (O/W). During the last phase of this process, solvent is 
evaporated and the nanoparticles are collected after centrifugation. This method can be 
adapted to incorporate hydrophilic drugs into nanoparticles and is called double emulsion 
W/O/W. 
Beside this emulsion-evaporation method, another frequently and easier method used to 
prepare nanoparticles is the nanoprecipitation method [Danhier et al., 2009b; Hans et al., 
2002; Soppimath et al., 2001]. In this technique, acetone is used as organic solvent to dissolve 
the polymer matrix and the hydrophobic drug. This organic phase is then added dropwise to 
water. Finally, the same final phase of evaporation and centrifugation is used to remove 
solvent and collect the so-formed nanoparticles.  
II.4. SURFACE MODIFICATION 
Surface modification can be done for two purposes: (i) prolong circulation time of the 
particles and (ii) target tumor specifically.  
After intra-venous injection, hydrophobic nanoparticles are recognized by the body as foreign 
and are, thus rapidly cleared from the systemic circulation by the mononuclear phagocytic 
system (MPS) and end in the liver or the spleen. While this property of nanoparticles can be 
an advantage if treating a liver condition, it mostly limits the application of these carriers in 
many drug delivery systems. A particular attention has been paid to overcome this major 
concern in the past decades. Since size and surface hydrophobicity determines the amount of 
adsorbed blood components and proteins (opsonin) and, hence, the opsonization of the 
particles, surface modification provides a key method to overcome rapid clearance. Of these 
methods, the most frequently used is the adsorption or grafting of poly-ethylene glycol (PEG) 
to the surface of nanoparticles. “PEGylation” of nanoparticles surface results in an increase in 
the blood circulation half-life of the particles by several orders of magnitude (which is of 
huge interest for target site accumulation). Indeed, PEG grafting creates a hydrophilic 
protective layer around the nanoparticles, which pushes away opsonin proteins and prevent 
their adsorption via steric repulsion forces [Hans et al., 2002; Kumari et al., 2010; Soppimath 
et al., 2001]. 
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The second reason to use a surface modification strategy is to address the particles to a 
specific receptor present on the target tissue leading in an increased selectivity of the 
treatment. After specific binding of the particle to its target site, receptor-mediated 
endocytosis leads to the internalization of the particle [Arias, 2011; Hans et al., 2002]. Most 
targeting ligands are loaded onto nanoparticle surfaces via a PEG spacer. The rationale for 
this approach lies in the extension of the ligand from the nanoparticle platform, enhancing its 
flexibility and, hence, its easier interaction with receptors. An important parameter that affects 
the targeting moiety is the concentration of surface ligands. Indeed, there could be a rationale 
for higher ligand densities as a method of increasing the probability of nanoparticle 
interactions with cell receptors (multivalency). However, this point is subjected to 
controversy since the presence of increased non-PEG-like material on nanoparticles surface 
can be related to more MPS uptake as such ligands can be recognized as foreign [Wang et al., 
2010]. 
Among the different methods reported for nanoparticles functionalization, Pourcelle and 
colleagues developed a “clip photochemistry” method. "Clip photochemistry" is a polymer 
derivatization methodology based on the photografting of bifunctional photosensitive linkers. 
This linker, once attached to polymer backbones and activated by UV radiation (creating an 
activated ester) can be used to introduce a compound of interest bearing primary amine 
functions on polymer [Danhier et al., 2009a; Pourcelle et al., 2007]. This technique allowed 
the grafting of the pentapeptide GRGDS (Figure 15) [Pourcelle et al., 2007]. 
 
Figure 15. Schematic representation of clip photochemistry. This method covalently links GRGDS peptides 
mainly on the PEG residue of the PCL-PEG (adaplted from [Pourcelle et al., 2007]). 
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II.5. PHYSICO-CHEMICAL CHARACTERIZATION 
Surface charge is an important parameter in nanoparticles characterization since it has 
potential effect on receptor binding, physiological barrier penetration and dispersion stability 
[Lin et al., 2014]. This parameter is commonly assessed by zeta potential measurement. This 
technique relies on the measurement of the velocity of the charged species towards the 
electrode in the presence of an external electric field across the sample solution. The zeta 
potential can be positive, neutral or negative depending on the nature of the polymer used or 
the material used for its surface modification. This technique can also be used to estimate the 
efficiency of surface modification [Soppimath et al., 2001]. 
The average particle size and the polydispersity index can be measured by dynamic light 
scattering (DLS). The principle of DLS is to monitor the temporal fluctuation of light 
dispersion caused by the Brownian motion of the particles at a fixed scattering angle [Lin et 
al., 2014]. 
Another crucial characteristic that need to be assessed is the drug loading. Drugs are either 
incorporated into the nanoparticles core or adsorbed on the surface of nanoparticles after their 
production [Kumari et al., 2010]. Ultracentrifugation is a common method to separate 
nanoparticles from non-encapsulated or non-adsorbed drug. After nanoparticles dissolution 
and drug content measurement by an appropriate technique, it possible to calculate two 
parameters: (i) the encapsulation efficiency and (ii) the drug loading. The encapsulation 
efficiency is defined by the ratio of the encapsulated drug compared to the initial amount of 
drug, whereas the drug loading is defined as the amount of drug (mg) loaded for 100 mg of 
polymer [Danhier et al., 2010].  
II.6. PHARMACO-KINETICS AND BIODISTRIBUTION 
Particles have a long journey from the injection to the tumor site entrance. This journey 
begins right after the injection while circulating through the blood. At this stage, binding to 
blood proteins may occur and lead to rapid clearance of the body via the so-called 
“opsonization” process. This binding phenomenon is dependent on multiple factors including 
particle charge. Indeed, positive and negatively charged particles are known to amplify 
complement activation and opsonin fixation. This fixation leads to an enhanced recognition 
by the MPS (whose 80 to 90% are represented by the non-parenchymal Kupffer cells of the 
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liver) and, hence, to a rapid clearance. Unmodified particles are known to encounter 
extremely rapid clearance from the blood stream within minutes to an hour depending on the 
particle size. Although, even long circulating carriers exhibit relatively rapid clearance 
depending on the surface charge (as abovementioned) and the size. Actually, particles larger 
than 200 nm have been shown to accumulate in the spleen and enhance the uptake by the 
MPS. Besides MPS clearance, particles have been shown accumulate in the liver tissue due to 
its particular vascular structure (sinusoid capillaries presenting fenestrations) [Nichols and 
Bae, 2012; Bertrand and Leroux, 2012]. Finally, there is a threshold below which renal 
filtration occurs passively (70 kDa). Although particles are often large enough to avoid renal 
filtration, a renal accumulation can be observed. This is probably due to the high part of the 
cardiac output delivered to the kidney (22%) [Kwon et al., 2012]. 
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III. SPIO NANOPARTICLES 
III.1. DEFINITION 
Superparamagnetic iron oxides (SPIO) are small synthetic crystalline structure exhibiting a 
core composed of Fe2O3 (also called maghemite) and Fe3O4 (magnetite) [Boutry et al., 2009]. 
Their given name originates from their property to exhibit “superparamagnetism”. This 
property give to SPIO the ability to be magnetized upon the application of an external 
magnetic field while no longer exhibiting any residual magnetic interaction at magnetic field 
removal [Laurent et al., 2008; Laurent et al., 2011; Reddy et al., 2012]. SPIO can also be used 
for drug delivery. To this end, drug can be either directly conjugated to SPIO surface via a 
covalent link or entrapped in the coating shell of SPIO via physical interactions leading to the 
so-called “SPIO conjugates” [Zou et al., 2010]. Another common strategy consists in the 
encapsulation of SPIO along with a drug in nanocarriers. These SPIO-based drug delivery 
systems are summarized in Figure 16. 
 
Figure 16. Schematic representation of SPIO-based drug delivery system. (A) SPIO-drug conjugates are 
represented either by directly conjugated drug to SPIO surface via a covalent link or entrapped in the coating 
shell of SPIO via physical interactions. (B) SPIO can also be loaded along with a drug into nanoparticles. 
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During the past decades, SPIO have gained much interest given their high potential in 
biomedical application. Indeed, such compounds provide simultaneously many advantages 
[Laurent et al., 2011]:  
(i) SPIO can be used as drug carrier platform by direct conjugation to a therapeutic 
agent 
(ii) showing high transverse relaxivity (T2, T2*), SPIO allow strong negative contrast at 
low concentration, making them attractive candidate for magentic resonance imaging 
(MRI) contrast enhancement [Danhier et al., 2012d]  
(iii) SPIO surface is easily fonctionnalized with ligand, making them suitable candidate 
for molecular imaging using active targeting approach [Wahajuddin et al., 2012]  
(iv) SPIO exhibit low toxicity compared to other MR agent since the iron salvage in the 
natural body iron store [Wang et al., 2001]  
(v) Their capacity to induce local heat when subjected to an externally applied 
alternative mgnetic field (such called “hyperthermia”) [Reddy et al., 2012]  
(vi) Finally, SPIO are able to drag a conjugated drug to its target site through the 
application of an external magnetic field (so-called “magnetic targeting”) [Cole et 
al., 2011] 
III.2. METHODS OF FORMULATION 
SPIO are prepared by many different routes including micro-emulsion, thermal 
decomposition and co-precipitation methods [Laurent et al., 2008]. Among these methods, 
classical co-precipitation technique of iron salts is the most commonly used. This method is 
based on the precipitation of ferrous (Fe2+) and ferric (Fe3+) salts mixtures in a basic medium 
to form Fe3O4. 
Fe 2+ + 2 Fe3+ + 8 OH−  Fe3O4 + 4 H2O  
This method is the most convenient and the cheapest one. SPIO produced by chemical co-
precipitation result in nanoparticles presenting a mean diameter as low as 10 nm and high-
purity [Laurent et al., 2008; Laurent et al., 2011; Reddy et al., 2012]. However, the so-
prepared naked SPIO present a large surface-to-volume ratio with highly chemical reactivity. 
Hence, if not covered with a proper surfactant, SPIO tend to aggregate and are easily oxidized 
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in air, resulting in loss of magnetism and dispersibility [Mahdavi et al., 2013]. Moreover, 
these SPIO are generally polydispersed and poorly crystallized. Thermal decomposition of 
iron precursors (generally iron acetylacetonate) under high temperature and in the presence of 
organic surfactants allows overcoming these problems resulting in monodispersed and 
uniform crystalline SPIO. Other formulation methods exist including hydrothermal reactions 
and microemulsion. These methods are currently less explored given their disadvantages 
(long reaction times, large amount of solvent and surfactant, poor yield) [Laurent et al., 2011; 
Santhosh et al., 2013]. 
Size, shape, composition, and surface nature can be controlled by varying the type of the iron 
salt, the Fe2+/ Fe3+ ratio, the reaction temperature, the pH value, and the surfactants [Wang et 
al., 2013]. 
III.3. SURFACE MODIFICATION 
To avoid aggregation and protect their surface from oxidation, which are crucial 
characteristics to improve their clinical efficacy, the synthetized SPIO need to be coated. 
SPIO have been coated with a wide variety of materials. These coating agents can be either 
physically (electro-static interaction, hydrogen-binding) adsorbed or chemically bound on 
SPIO surface. Among the coating agents usually used, the most common are biocompatible 
polymers (dextran and derivatives, siloxane, poly(ethylene glycol), poly(lactic acid), poly(ε-
caprolactone), chitosan), inorganic materials (gold and silica) and monomeric stabilizers 
(carboxylates, phospates) [Laurent et al., 2008; Laurent et al., 2011; Santhosh et al., 2013]. 
Among the latest, oleic acid is commonly used to stabilize SPIO with strong chemical 
interraction between the carboxylate group of oleic acid and the iron atom, and to increase 
lipophilicity in order to facilitate encapsulation in nanoparticles [Mahdavi et al., 2013; Zhang 
et al., 2006]. In this case stabilization involves steric repulsion forces. 
III.4. PHYSICO-CHEMICAL CHARACTERIZATION 
Physico-chemical characteristics are of great importance since they influence blood 
distribution profile, toxicity, circulation time and magnetic properties. Among the physico-
chemical characteristics, size and shape are determinants [Wahajuddin et al., 2012]. A 
common technique to measure the particle core is transmission electron microscopy (TEM). 
This technique allows the determination of the total particle size of the core (crystalline and 
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amorphous part) and provides an interesting tool to assess size distribution and shape. X-ray 
diffraction (XRD) can be used to give complementary information to TEM. Indeed, XRD 
gives informations about the crystalline structure of the particles [Laurent et al., 2008]. 
Dynamic light scattering (DLS) is also commonly used to assess hydro-dynamic size of the 
particles. The principle of DLS is to monitor the temporal fluctuation of light dispersion 
caused by the Brownian motion of the particles at a fixed scattering angle [Lin et al., 2014]. 
However, it is noteworthy that the hydrodynamic size values obtained by DLS are often much 
larger than diameters obtained from transmission electron microscopic (TEM) measurements. 
This effect is particularly relevant for SPIO since there is a great difference between their 
crystal and their hydrodynamic size [Di Marco et al., 2007].  
The coating percentage of SPIO is also crucial to evaluate. Therefore, thermogravimetric 
analysis (TGA) can be used to investigate the formation of strong chemical bonds between 
the substrates and various molecules such as oleic acid. This technique gives an idea of the 
percentage of inorganic matters and, consequently, the percentage of coating [van Ewijk et 
al., 1999]. 
Finally, magnetic relaxation properties can be obtained by the study of its nuclear magnetic 
resonance dispersion (NMRD) profile. This technique provides the evolution of particles 
relaxivity as a function of the external magnetic field, where relaxivity can be defined as the 
relaxation rate enhancement of an aqueous solution induced by 1mmol of iron/L. The fitting 
of the NMRD profiles by a theoretical relaxation model allows the determination of the 
saturation magnetization (MS), which refers to the maximum magnetization possible. This 
saturation magnetization arises when all the magnetic dipoles are aligned in an external 
magnetic field. This parameter allows a good prediction of SPIO susceptibility to an 
externally applied magnetic field. Indeed, nanoparticles with higher saturation magnetization 
provide higher sensitivity and efficiency [Kolhatkar et al., 2013]. 
III.5. PHARMACOKINETICS AND BIODISTRIBUTION 
After injection, numerous opsonin proteins, cells, and salts bind to the surface of 
nanoparticles, known as the opsonization process responsible for easier recognition by the 
mononuclear phagocytic system (MPS (whose 80 to 90% are represented by the non-
parenchymal Kupffer cells of the liver) leading to rapid clearance from the circulation. 
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Nanoparticles are usually taken up by macrophages in the liver (Kupffer cells – 80 – 90 %), 
spleen (5 – 8 %) and bone marrow (1 – 2 %) [Yu et al., 2012].  
After uptake in specialized macrophages, SPIO are degraded into the lysosomes. The core 
material is supplied to the iron storage pool of the body (total body iron approximately 4 – 5 g) 
and deposited in the liver in the form of ferritin and/or hemosiderin. The natural 
decomposition of these iron reserves is only possible via hematopoiesis (Fe 2 + as central atom 
in the hemoglobin) and the exfoliation of epithelial cells of the skin and bowel. [Ittrich et al., 
2013]. Limiting phagocytosis in the liver and spleen decreases the uptake rates for some 
nanoparticles, resulting in longer blood half-lives and facilitating their clinical application as 
T2 agents for the detection of liver lesions. This can be achieved by surface modification 
yielding stealth nanoparticles. The most common strategy consists in using PEG- or dextran-
coated nanoparticles. Moreover, some physicochemical characteristics are important in 
improving pharmacokinetic profiles of nanoparticles including size, surface charge and shape 
[Yu et al., 2012]. Thus, SPIO with a small hydrodynamic diameter and neutral and 
hydrophilic surface are opsonized and phagocytized more slowly than large SPIO with an 
ionic and hydrophobic coating [Ittrich et al., 2013]. Indeed, particles bearing cationic or 
anionic surface charges have been shown to be more attractive to phagocytes than neutral 
particles of the same size [Zahr et al., 2006; Gessner et al., 2002; Dobrovolskaia et al., 2008]. 
Dextran-coated SPIO have been shown to display a blood clearance half-life of about 10 min 
with uptake by hepatic RES Kupffer cells accounting for 80% of the injected dose whereas 
encapsulation in liposomes allowed prolonging the blood clearance half-life to 4 [Ferrucci and 
Stark, 1990]. The coating material of SPIO is eliminated via other decomposition and 
elimination paths, e. g. the coating of ferumoxtran-10 (Sinerem®) is degraded via intracellular 
dextranases and is eliminated primarily by the kidneys (89 % in 8 weeks). Although, even 
long circulating carriers exhibit relatively rapid clearance depending on the surface charge (as 
abovementioned) and the size. Actually, particles larger than 200 nm have been shown to 
endure an enhanced uptake by the MPS resulting in accumulation in the liver and spleen. 
Besides MPS clearance, particles have been shown accumulate in the liver tissue due to its 
particular vascular structure (sinusoid capillaries presenting fenestrations) [Bertrand et al., 
2012; Nichols et al., 2012]. Finally, there is a threshold below which renal filtration occurs 
passively (70 kDa). Although particles are often large enough to avoid renal filtration, a renal 
accumulation can be observed. This is probably due to the high part of the cardiac output 
delivered to the kidney (22%) [Kwon et al., 2012]. It is noteworthy that in most studies, in 
vivo pharmaco-kinetics and biodistribution of SPIO-based nanosystems are not provided. 
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III.6. VISUALIZING AND QUANTIFYING IRON OXIDES  
To date, MRI is the reference method allowing SPIO visualization in vivo. However, SPIO 
quantification, which is crucial to assess the initial iron uptake and adapt formulation as well 
as for optimizing the administration dose for the subsequent MRI studies, can be assessed by 
four main traditionnaly used techniques including (i) spectrophotometric techniques (based on 
Perls’ Prussian blue reaction), (ii) inductively coupled plasma mass spectroscopy (ICP-MS), 
(iii) fluorometry (requiring the presence of a grafted fluorophore), and (iv) relaxometry based 
on the mesurement of the longitudinal relaxation rate (R1) of iron resulting from the 
dissolution of the iron oxyde core [Boutry et al., 2009; Danhier et al., 2012d]. However, 
despite their sensitivity, all these techniques lack of specificity and do not make the difference 
between iron species contained in biological fluids and SPIO. Recently, a new technique has 
been shown to be highly effective in SPIO quantification showing high sensitivity and high 
specificity, namely, Electron Paramagnetic Resonance spectroscopy also called Electron Spin 
Resonance (ESR) [Danhier et al., 2012d]. 
III.6.1. Magnetic Resonance Imaging  
Basic principle 
Magnetic resonance imaging (MRI) is a non-invasive imaging technique providing high-
resolution morphological and functional images. Such a technique is commonly used in 
diagnostic radiology to detect tissue abnormalities corresponding to a pathological state 
[Reddy et al., 2012]. Nuclear magnetic resonance on which MRI is based was discovered in 
the mid-1940s [Bloch, 1946]. More recently, researches in the MRI field have led to its use in 
functional imaging, which aims to detect or measure changes in metabolism and blood flow 
revealing physiological activities within a certain tissue [Krishna et al., 2001].  
MRI is based on the detection of resonance absorption of nuclei with non-zero nuclear spin. 
The most commonly used is the 1H nucleus. Briefly, proton, as charged (positive) spinning 
particles, generates a characteristic magnetic field called “magnetic moment”. Therefore, each 
proton could be considered as a small rotating magnet. In normal condition, magnetic 
moments are randomly oriented resulting in a zero “net magnetization”. However, when an 
external magnetic field is applied, all those vectors will align to this external magnetic field in 
a parallel (low level of energy) or in an anti-parallel way. Since a small excess population is 
present at the lower energy level, a net magnetization of the entire population is observed, 
which can be materialized as a vector having the same orientation as the external magnetic 
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field (Figure 17 A). When a radiofrequency (RF), corresponding to the proton precession 
frequency (also called “Larmor Frequency”), is applied perpendicularly to the magnetic field 
(RF pulse), atomic nuclei absorb this energy and entered in the excitation state or resonance 
which induces the apparition of a transverse magnetization in the x-y plane as seen in Figure 
17 B. After RF is stopped, the system returns from this state of imbalance to equilibrium 
(relaxation) with characteristic time constants, namely T1 and T2 and emitting an 
electromagnetic energy, which is the registered parameter in MRI (Figure 17 C-D). T1, also 
called longitudinal relaxation, corresponds to the process whereby proton returns to their 
equilibrium energy state causing the restoration of initial longitudinal magnetization, while 
transverse relaxation (T2) refers to the process involving the loss of transverse magnetization 
to recover the equilibrium state [Currie et al., 2013; Krishna et al., 2001] 
 
 
Figure 17. Recovery of longitudinal magnetization following a 90° radiofrequency (RF) pulse. (A) Protons 
aligned with B0 produce a sum vector with longitudinal magnetization. (B) When an RF pulse is applied, 
longitudinal magnetization decreases and transverse magnetization propagates. (C) After the 90° RF pulse, 
transverse magnetization decreases and longitudinal magnetization begins to recover. During this process, the 
whole system continues precessing and so the sum vector takes a spiralling motion (D). Recovery of longitudinal 
magnetisation is termed T1 relaxation and loss of transverse magnetisation is called T2 relaxation [Currie et al., 
2013].  
 
Imaging technique based on magnetic resonance spectroscopy such as MRI provides ideal 
non-invasive imaging modalities. Indeed, this technique responds to a series of criteria needed 
for such aim including (i) providing high-resolution morphological images, (ii) offering 
functional information in regard with anatomy, (iii) avoiding the use of ionizing radiation and 
(iv) being relatively easy to perform [Krishna et al., 2001]. 
 
SPIO in MRI 
The major limitation of MRI consists of a relatively low sensitivity. Superparamagnetic iron 
oxides (SPIO) as MRI contrast agent address this limitation. Indeed, SPIO are excellent MRI 
contrast agent that can produce predominant T2 relaxation effect with excellent sensitivity 
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when compared to other MRI agents such as chelates of paramagnetic ion (Gd3+-DTPA), 
resulting in a strong signal reduction on T2-weighted images [Ittrich et al., 2013; Reddy et al., 
2012]. The magnetic field heterogeneity around the particles, through which water molecules 
diffuse, induces the dephasing of the proton magnetic moments. Consequently, a T2 effective 
transverse relaxation is shortened [Ling et al., 2011].  
Currently, SPIO are widely used as MRI contrast agent either free, as a drug carrier platform 
or encapsulated into nanocarriers for biomedical applications. As such, a variety of free SPIO-
based products (generally coated with dextran to stabilize) are already approved or in clinical 
trial (see table 6).  
 
Table 6. examples of SPIO-based products in clinics (adapted from [Ling et al., 2011]). 
Compound Trade name Coating agent Size (nm) Application Status 
Ferumoxil (AMI-121) Lumirem, 
Gastromark 
dextran 300 Gastro-
intestinal tract 
approved 
Ferumoxide (AMI-25, 
SHU555A) 
Endorem, 
Feridex* 
dextran 120-180 
80-150 
Liver tumor 
imaging 
approved 
Ferixan 
(Ferucarbotran, 
SHU555A) 
Resovist*, 
Cliavist 
dextran 60 Focal liver 
lesions 
imaging 
approved 
Ferumoxtran-10 
(AMI-227, BMS-
180549) 
Sinerem* 
(Europe), 
Combidex (USA) 
Dextran 20-40 Lymph node 
imaging, 
atherosclerosis 
Late phase 
clinical 
Ferristene (OMP) Abdoscan Sulfonated 
styrene-
divinylbenzene 
copolymer 
3500 Gastro-
intestinal tract 
approved 
* withdrawn from the european market  
 
III.6.2. Quantifying SPIO using ESR spectroscopy 
Basic principle 
In contrast with other existing techniques available for SPIO quantification 
(spectrophotometric techniques, ICP-MS and relaxometry), Electron Paramagnetic Resonance 
spectroscopy also called Electron Spin Resonance (ESR) offers a rapid highly sensitive (LOD 
≈ nM) non-destructive technique allowing specific dosage of SPIO without taking iron 
species contained in biological fluids into account [Danhier et al., 2012d; Spasojevic, 2011]. 
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ESR spectroscopy is based on the same principle as MRI. Instead of detecting nuclei, ESR 
probes species with a single unpaired electron spin residing in a molecular orbital [Sahu et al., 
2013]. These species include free radicals, transition metal complex and (super)paramagnetic 
molecules (e.g. SPIO). Since the total number of unpaired electrons in the sample is 
proportional to the signal intensity of the ESR spectrum, ESR allows quantification by a 
double integration technique [Spasojevic, 2011]. 
Noteworthy, because the magnetic moment of the electron is 658 times greater than that of the 
proton, ESR exhibits a much higher sensitivity compared to MRI. Moreover, whereas MRI 
requires high magnetic field (4.7 – 11.4 T) and ends up in a low frequency spectral line width 
(Hz to kHz), ESR requires only magnetic field of mT order and shows a high frequency 
spectral line width (≈MHz) [Krishna et al., 2001]. Figure 18 gives a schematic comparison of 
both techniques. 
 
Figure 18. Schematic comparison of `nuclear magnetic resonance (NRM) and ESR spectroscopy principles. The 
magnetic moments of the protons and electrons are represented as rectangular bars. In the absence of an external 
magnetic field, individual magnetic moments are aligned randomly. In the presence of an external magnetic field 
(hatched rectangle), they occupy two energy levels. Irradiation with radiofrequency radiation of appropriate 
frequency causes resonance absorption, which is shown as an absorption spectrum [Krishna et al., 2001]. 
 
Currently, two ESR spectrometers are available depending on the application. For in vitro or 
ex vivo quantification, a X-band spectrometer is used. This spectrometer offers high frequency 
for good sensitivity. However, given its high frequency waves (9 GHz), this spectrometer 
ESR 
NMR 
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does not allow tissue penetration and, hence, in vivo measurements. Therefore, L-band 
spectrometer, working at low frequency (1.2 GHz), provides a wave penetration of 1 cm 
inside tissue allowing real-time assessment of concentration changes in tissue [Radermacher 
et al., 2010]. ESR has been extensively used during the past decades in biomedical 
applications including oxidative stress measurement, oxymetry measurements in the cancer 
field and membrane fluidity assessment [Spasojevic, 2011]. 
SPIO in ESR 
As superparamagnetic agents, SPIO are suitable for ESR spectroscopy measurement. ESR has 
already been used to characterize SPIO physicochemical properties, for ex vivo biodistribution 
studies (using X-band) and for real-time assessment of changes in SPIO concentration in a 
tissue (using L-band) [Danhier et al., 2014; Radermacher et al., 2010]. Moreover, band-X 
ESR was proven to be more sensitive tool to measure iron oxide in cells compared to the 
classically used methods [Danhier et al., 2012d]. More recently, ESR spectroscopy was 
shown to be a promising method for ex vivo measurements after cell tracking experiments 
[Danhier et al., 2014]. However, this technique is not extensively used for these applications 
yet and is more commonly used for oxidative stress and oxymetry measurements to date. 
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IV. IRON OXIDES LOADED NANOTHERANOSTICS: 
MAJOR OBSTACLES TO IN VIVO STUDIES 
N. Schleich, F. Danhier* and V. Préat* 
Adapted from Journal of Controlled Release, 2014, 198C, 35-54 
IV.1. INTRODUCTION 
According to the American Cancer Society, approximately 1,6 millions new cancer cases are 
expected to be diagnosed in 2014 [2014]. Early detection and effective cancer treatments are 
the most important factors for saving lives [Fan et al., 2014]. Anti-cancer drugs suffer from 
poor pharmacokinetics and inappropriate biodistribution properties. Consequently, many 
agents that are shown to be highly effective in vitro become relatively ineffective when 
administered in vivo and produce significant toxicity [Lammers et al., 2010]. Numerous drug 
delivery systems have been designed to address these problems, specifically, nanomedicines, 
which refer to nano-scaled therapeutics that have been extensively studied. In particular, 
liposomes, nanoparticles, micelles and antibodies have been demonstrated to be clinically 
relevant for cancer therapy [Barenholz, 2012; Cecco et al., 2014; Oerlemans et al., 2010]. The 
first rationale for the use of nanomedicines for cancer therapy is the preferential delivery of 
nano-vectorized drugs to solid tumors due to enhanced permeability and retention (EPR) 
effect [Matsumura et al., 1986]. Tumor vessels surrounding the tumors are leaky due to 
abnormal basement membranes and incomplete endothelial linings, allowing nanomedicines 
to reach the tumor passively through the leaky vasculature. Therefore, the EPR effect enables 
higher local drug concentrations at the tumor site when the drug is delivered in a nanovector. 
The efficacy of passive targeting depends primarily on (i) the degree of tumor vascularization 
and angiogenesis, which is reliant on the tumor type and anatomical site and (ii) the high 
interstitial fluid pressure and heterogeneous blood flow, which limit drug uptake and 
homogenous distribution in the tumor [Danhier et al., 2010; Maeda et al., 2000]. Targeting 
can be improved by grafting ligands to the surface of the nanomedicines, allowing active 
targeting by binding to receptors that are overexpressed by cancer cells or angiogenic 
endothelial cells [Danhier et al., 2010; Petros et al., 2010]. One potential advantage of 
targeted delivery may be altered intracellular distribution. Both targeted and non-targeted 
systems arrive at the tumor via the EPR effect. Subsequently, the tumor cell internalization 
mechanism is enhanced by the presence of surface ligands [Prokop et al., 2008; Wang et al., 
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2010]. It has been demonstrated that ligand-grafted nanoparticles enter cells via receptor-
mediated endocytosis [13,14]. Nanomedicines can also enhance drug-circulation times, 
control drug-release kinetics and enable superior dose scheduling [Petros et al., 2010]. 
Nanomedicines avoid formulations that contain toxic excipients, which contribute to side 
effects for many conventional chemotherapeutics. Nanomedicines also may potentially 
overcome the development of tumor resistance to conventional chemotherapeutics [Jain et al., 
2010]. Finally, nanomedicines allow the delivery of more than one therapeutic agent, 
facilitating combination therapies.  
This review aims to provide an overview of the targeted SPIO-based nanotheranostics 
recently used in pre-clinical studies and the major obstacles to in vivo studies and clinical 
translation. In the first section of this review, we discuss personalized therapy as a biomedical 
application of theranostics. Then, we summarize the different imaging agents used for 
theranostic purposes, with a focus on SPIO. In the third section, we detail the recent advances 
in targeted SPIO-based nanotheranostics that have been used in pre-clinical studies. In the 
final sections, we discuss their limitations for in vivo studies, clinical translation and analyze 
the clinical perspectives of SPIO-based nanotheranostics. 
IV.2. THERANOSTIC NANOMEDICINE 
In addition to therapeutic applications, passively and actively targeted nanomedicines are also 
increasingly being used for diagnostic purposes. Antibodies, liposomes, nanoparticles and 
micelles may deliver a contrast agent, such as radionuclides and MR imaging probes, to detect 
cancer as well as visualize the drug delivery process [Lammers et al., 2010]. In addition to 
nanomedicines that are designed for therapeutic or diagnostic purposes, diagnostic (contrast 
agent) and therapeutic (anti-cancer drug) agents can be combined within a single 
multifunctional nanomedicine, known as “theranostic nanomedicine or nanotheranostics” 
(Figure 19 A). Based on the advances in and close collaboration between several different 
scientific disciplines, such as chemistry, biology, pharmacy, nanotechnology, medicine and 
imaging (Figure 19 B), numerous reports have shown that nanomedicine is one the most 
promising methods for theranostics, although theranostic development is still at an early stage 
[Ahmed et al., 2012; Lammers et al., 2010; Xie et al., 2010]. Theranostic design requires 
broad knowledge and a solid understanding of the detection and therapeutic mechanisms. This 
knowledge includes understanding the molecular mechanisms, diagnostic strategies, 
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therapeutic efficiency, toxicity, side-effects of materials and nanomedicine preparation 
techniques for the dual purposes of diagnosis and therapy [Ahmed et al., 2012]. 
 
Figure 19. Theranostics. (A) Schematic representation of a theranostic multifunctional nanomedicine. (B) 
Schematic representation of the interdisciplinary field of theranostics, adapted from [Lammers et al., 2011]. 
 
The ideal theranostic nanoparticle should possess several advantageous properties: (i) the 
ability for selective tumor accumulation, (ii) the capacity to deliver therapeutic doses of anti-
cancer drugs and to detect tumors at their earliest stage and (iii) the nanovector must be 
biocompatible and biodegradable [Fan et al., 2014].  
Nanotheranostics can be used for various applications: (i) non-invasive assessment of 
biodistribution and target site accumulation, (ii) drug release monitoring, (iii) the 
enhancement of therapeutic efficacy via triggered drug release and (iv) prediction of 
therapeutic response [Lammers et al., 2010]. Additionally, nanotheranostics can be used to 
preselect patients, leading to their significant potential for personalized nanomedicine 
(chemo-) therapeutic interventions. Theranostic strategies include situations where patients 
are pre-selected based on data from initial target site accumulation studies.  
It is important to note that theranostics take their place in its broadest sense. Many 
publications claim that theranostics can be used for simultaneous diagnosis and treatment. 
Actually, their suitability for real diagnoses is questionable. The diagnostic purpose of 
theranostics should not refer to the identification, localization and/or staging of tumors, but to 
the pre-selection of patients, prediction of potential therapeutic responses, and/or longitudinal 
monitoring of treatment efficacy [Rizzo et al., 2013]. As exemplified in Figure 20, the first 
step toward personalized nanomedicine treatment is to pre-select patients on the basis of non-
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invasive imaging data examining target site accumulation. If the tumor accumulation is 
sufficient, patients can be treated with the nanotheranostics, whereas other patients will 
receive conventional chemotherapy or another intervention. A second personalization step 
consists of non-invasive monitoring of the response to the first 1 to 3 treatment cycles. During 
this monitoring, the treatment should be adapted or switched to other therapeutic 
interventions, if necessary [Lammers et al., 2012b; Rizzo et al., 2013]. 
 
Figure 20. Schematic representation of the rationale for image-guided and personalized nanomedicine (adapted 
from [Lammers et al., 2012b]). 
IV.3. CONTRAST AGENTS AND SPIO 
IV.3.1. Imaging techniques and contrast agents for theranostics 
The diagnostic aspect of theranostics primarily revolves around imaging mechanisms using 
different contrast agents. The most commonly used imaging techniques are positron emission 
tomography (PET), single photon emission computed tomography (SPECT), magnetic 
resonance imaging (MRI) and different optical imaging techniques (bioluminescence and 
fluorescence) that have high sensitivity [Danhier et al., 2012b]. Among these techniques, MRI 
is the most commonly studied technique and a considerable amount of research has been 
devoted to the use of magnetic particles as contrast agents. Particles of gadolinium, iron 
oxides, gold, silver and other metals are currently being investigated. The imaging aspect of 
theranostics can also be exemplified by manganese oxide, quantum dots, microbubbles, 
radionuclides and silica nanoparticles [Ahmed et al., 2012]. Examples of theranostics using 
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different contrast agents are presented in Table 7. In this review, we only focus on iron oxides 
as contrast agents. 
Table 7. Examples of currently developed theranostics using different contrast agents for anti-cancer 
applications. 
Contrast 
agent 
Anti-cancer 
drug 
Formulation Applications Studies Ref 
Iron oxide DOX Polymeric 
nanoparticles 
MRI, CT, PET, 
therapy 
in vitro, in 
vivo 
[Maeng et al., 
2010; Yang et 
al., 2011] 
Gadolinium DOX Liposomes/Silica 
nanotubes 
MRI in vitro [de Smet et al., 
2010; Hu et 
al., 2010] 
Manganese DNA, DOX Lipid Micelles MRI, therapy in vitro, 
preliminary 
in vivo 
[Howell et al., 
2013] 
Gold PTX Gold nanoparticles Optical imaging in vitro [Heo et al., 
2012] 
Silica siRNA Silica nanoparticles Optical imaging, 
therapy 
in vitro, in 
vivo 
[Shen et al., 
2014] 
QDs DOX Lipid Micelles MRI, optical 
imaging, therapy 
in vitro, in 
vivo 
[Park et al., 
2008b] 
Silver Silver Silver nanoparticles Optical imaging, 
therapy 
in vitro [Mukherjee et 
al., 2014] 
Perfluoro-
pentane  
DOX Microbubbles Ultrasound, therapy in vitro, in 
vivo 
[Gao et al., 
2008] 
CNT Intrinsic 
property 
Carbon nanotubes Optical imaging in vitro, in 
vivo 
[Robinson et 
al., 2010] 
99mTc 90Y Polymer conjugates Scintigraphic 
imaging, therapy 
in vitro, in 
vivo 
[Mitra et al., 
2004] 
Abbreviations: CNT: carbon nanotube; CT: computer tomography; DNA: Deoxyribonucleic acid; DOX: 
doxorubicin; MRI: magnetic resonance imaging; PET: positron emission tomography, PTX: paclitaxel; siRNA: 
short interfering ribonucleic acid; QDs: quantum dots;  
 
IV.3.2. Iron oxides 
Superparamagnetic iron oxide (SPIO) nanoparticles are contrast agents that have a variety of 
applications in molecular and cellular MRI. Superparamagnetic nanoparticles are composed 
of iron oxides, i.e., magnetite (Fe3O4), maghemite (Fe2O3) or other ferrites. Their given name 
originates from their ability to exhibit “superparamagnetism”. This property allows SPIO to 
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be magnetized upon external magnetic field application without exhibiting any residual 
magnetic interactions after magnetic field removal [Corot et al., 2013]. SPIO are prepared 
using several different methods, including micro-emulsion, thermal decomposition and co-
precipitation. Among these methods, the classical iron salt co-precipitation technique is the 
most commonly used procedure. This method is based on the precipitation of ferrous (Fe2+) 
and ferric (Fe3+) salt mixtures in a basic medium to form Fe3O4 [Laurent et al., 2011; Laurent 
et al., 2014; Reddy et al., 2012]. To avoid aggregation and prevent  surface oxidation, which 
are crucial for their clinical use, it is necessary to coat the synthetized SPIOs. SPIO have been 
coated with a wide variety of materials. Among the coating agents usually used, the most 
common are biocompatible polymers (dextran and its derivatives, siloxane, poly(ethylene 
glycol), poly(lactic acid), poly(ε-caprolactone), chitosan), inorganic materials (gold and silica) 
and monomeric stabilizers (carboxylates, phosphates) [Laurent et al., 2011; Laurent et al., 
2014; Santhosh et al., 2013].  
SPIO are primarily used because of their negative enhancement effect on T2 and T2*-
weighted sequences [Corot et al., 2013]. However, their effects on T1 relaxation time are also 
employed. Different classes of superparamagnetic nanoparticles have been investigated and 
are classified by their particle size: SPIO (>50 nm), ultra-small superparamagnetic iron oxide 
(USPIO) (<50 nm) and micron size iron oxide particles (MPIO) (≈ 1000 nm) [Laurent et al., 
2011]. SPIO provide significant advantages over traditional contrast agents: (i) high magnetic 
signal strength, (ii) relatively low cytotoxicity, (iii) longer lasting contrast enhancement, (iv) 
improved tumor margin delineation and (v) low sensitivity to the number of surrounding 
water molecules. Additionally, studies have shown that the released iron from SPIO is 
metabolized by the body, reducing the potential for long-term cytotoxicity [Laurent et al., 
2011; Laurent et al., 2014; Rosen et al., 2012].  
After intravenous injection, nanoparticles are usually taken up by macrophages in the liver 
(Kupffer cells), spleen and bone marrow. Limiting phagocytosis in the liver and spleen 
decreases the uptake rates for some nanoparticles, resulting in longer blood half-lives and 
facilitating their clinical application as T2 agents for the detection of liver lesions. 
Ferumoxides (Endorem®, in Europe or Ferridex® in the United States) and ferucarbotran 
(Resovist®) have been marketed for this application. However, with the exception of 
Resovist® in Japan, these two products have been withdrawn from the market after several 
years of commercialization due to their limited use by radiologists [Corot et al., 2013]. 
Radiologists consider SPIOs to be negative contrast agents and, consequently, they produce 
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image contrasts that are more difficult to interpret compared with a positive contrast agent, 
resulting in hyperintense signals in MRI. 
SPIOs can also be used for drug delivery. A drug can be either directly conjugated to the 
SPIO surface via a covalent link or entrapped in the SPIO coating shell via physical 
interactions, leading to “SPIO conjugates” [Zou et al., 2010]. However, these strategies suffer 
from several disadvantages. The drug coating entrapment strategy results in low entrapment 
efficiency and covalent binding often results in stable linkages that lead to release failures 
[Wahajuddin et al., 2012]. Another common strategy uses SPIO and drug encapsulation in 
nanocarriers [Brooks et al., 1994]. This strategy overcomes low efficiency entrapment and 
offers controlled release of the encapsulated drug. Moreover, SPIO encapsulation in a 
nanocarrier generally provides optimum magnetic responsiveness [Wahajuddin et al., 2012].  
IV.4. PRE-CLINICAL STUDIES OF SPIO-LOADED THERANOSTICS 
To improve the pharmacokinetic profile and limiting toxicities associated with conventional 
treatments, there have been considerable efforts focused on developing targeted drug delivery 
systems. Consequently, various strategies have been extensively studied during the past 
decades. These strategies involve (i) passive targeting via the EPR effect, (ii) active targeting 
involving ligand-mediated targeting and (iii) triggered targeting based on the release of the 
drug carrier contents in response to a stimulus [Arias, 2011; Lammers et al., 2008; Torchilin, 
2004]. These strategies are schematically represented in Figure 21. This review will provide 
an overview of the different targeting strategies that have been used to improve SPIO-based 
theranostic delivery because SPIO-based diagnostic agents have been extensively reviewed in 
the literature [Corot et al., 2013; Peng et al., 2008]. 
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Figure 21. Schematic representation of the different targeting strategies. (i) Passive targeting is based on the 
so-called enhanced permeability and retention effect (EPR effect) in which nanoparticles can passively enter the 
interstitium through the leaky vasculature. (ii) Active targeting relies on molecular recognition of a ligand 
coupled to nanoparticles surface and its receptor at the target cell site. (iii) Triggered drug release refers to the 
use of stimuli-sensitive carrier materials to trigger drug delivery at the target site. Those externally or internally 
applied stimuli cover, e.g. hyperthermia, ultrasound, lights and magnetic field.  
IV.4.1. Passive targeting 
Passive targeting relies on the passive accumulation of the nanovector in the tumor tissue 
through the leaky vasculature of neo-angiogenic vessels, which is referred to as the EPR 
effect [Matsumura et al., 1986]. To date, this is the most extensively used targeting strategy 
for nanotheranostics. Table 8 provides a non-exhaustive list of recent examples of passively 
targeted SPIO-based theranostics in pre-clinical studies. 
Table 8: Examples of passively targeted SPIO-based theranostics in pre-clinical studies. 
Formulation Drug Cell line In vitro/ 
In vivo MRI 
Results Ref 
PLGA NP PTX CT-26  In vitro High tumor regrowth delay, high 
relaxivity 
[Schleich et al., 2013] 
PLGA NP DTXL PC3  In vitro Effective cellular uptake, good 
relaxivity 
[Ling et al., 2011] 
PLGA NP TMZ C6 glioma  In vitro Good antiproliferative activity and 
relaxivity 
[Ling et al., 2012] 
Silica sphere curcu
min 
HL-60  In vitro Time-dependent induction of apoptosis  [Chen et al., 2010] 
Silica sphere DOX MCF-7 In vitro 
In vivo 
In vitro cytotoxicity and in vivo MRI [Kim et al., 2008] 
SPIO-
conjugate 
MTT 9 L 
glioma  
In vitro In vitro cytotoxicity, in vitro T2 
contrast enhancement MRI 
[Kohler et al., 2006] 
Polyplex DNA HeLa  In vitro Monitoring of DNA release with MRI [Park et al., 2008a] 
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Abbreviations: DOX= doxorubicin, DTXL = docetaxel, MTT = methotrexate, NP = nanoparticles, PLGA = 
poly(lactic-co-glycolide), PT = passive targeting, PTX= paclitaxel, TMZ = temozolomide.  
 
For example, Schleich et al. developed dual paclitaxel (PTX)/SPIO loaded PLGA-based 
nanoparticles for cancer therapy and imaging [Schleich et al., 2013]. They demonstrated the 
efficiency of the nanoparticles for cellular uptake and MRI contrast enhancement in vitro and 
in vivo as an anti-cancer treatment in CT-26 bearing mice. Similarly, Ling et al. developed 
dual docetaxel/SPIO-loaded PLGA-based nanoparticles and demonstrated their efficient in 
vitro cellular uptake, drug release and MRI contrast enhancement in a prostate cancer cell line 
[Ling et al., 2011]. The same group developed temozolomide/SPIO-loaded PLGA 
nanoparticles for the imaging and treatment of malignant gliomas and demonstrated their in 
vitro efficacy for cellular uptake, cytotoxicity and MRI contrast enhancement [Ling et al., 
2012]. Another example of passively targeted SPIO-based nanotheranostic is provided by 
Chen et al. [Chen et al., 2010]. They developed inorganic silica spheres loaded with SPIO and 
curcumin as the anti-cancer agent that were further functionalized using gold nanoparticles. 
These curcumin/SPIO-loaded silica spheres produced a significant time-dependent induction 
of apoptosis in HL-60 cells (human leukemia cells) and in vitro MRI contrast enhancement. 
Similarly, Kim et al. developed PEGylated mesoporous silica materials loaded with both 
doxorubicin (DOX) and a single SPIO nanocrystal core. These nanoparticles demonstrated 
DOX-induced toxicity in vitro and in vivo efficacy as an MRI contrast agent [Kim et al., 
2008]. In addition to SPIO-loaded nanotheranostics, Kohler et al. developed a methotrexate-
SPIO conjugate (MTT-SPIO), which demonstrated higher in vitro anti-tumor efficacy 
compared with free MTT and significant in vitro MRI contrast enhancement in 9 L cultured 
glioma cells [Kohler et al., 2006]. Finally, Park et al. developed a gene delivery-based therapy 
using a SPIO polyplex in HeLa human cervical tumor cells [Park et al., 2008a]. This in vitro 
study demonstrated that MRI could be a sensitive tool for assessing gene delivery via DNA 
release from the SPIO-Polyethylene imine (PEI) polyplex, based on the “T2-magnetic 
relaxation switch effect” (Figure 22). When packaged with DNA, the particles had an 
increased T2 relaxation time, whereas a decrease in T2 relaxation time was observed when the 
DNA was released. This phenomenon may be exploited to monitor DNA release using MR 
imaging. 
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Figure 22. (A) Schematic representation of T2 magnetic relaxation switch caused by USPIO-PEI condensation 
with nucleic acids to form a SPIO-polyplex and subsequent unpackaging of the SPIO-polyplex and DNA 
release. (B) in vitro toxicity of USPIO-PEI compared with PEI 10k and PEI 25k. Cell viability was determined 
using the Cell Titer 96 proliferation assay (Promega) 24 h after incubation with polymers. (C) T2 relaxation 
times of uncomplexed USPIO-PEI, SPIO-polyplex and unpackaged SPIO-polyplex. SPIO-polyplex was 
unpackaged by the addition of 1 M NaCl. The USPIO concentration in all samples remained constant (adapted 
from [Park et al., 2008a]). 
 
IV.4.2. Active targeting   
Passive targeting has several disadvantages. Specifically, the accumulation resulting from the 
EPR effect may not be sufficient to induce high intracellular uptake. Therefore, ligand-
mediated drug delivery appears to be a powerful tool for overcoming this problem. Passively 
targeted nanomedicines primarily rely on macropinocytosis for cellular uptake. Conversely, 
the molecular recognition of a ligand coupled to the nanomedicine surface promotes cellular 
entry via receptor mediated endocytosis, resulting in enhanced nanovector cellular uptake 
[Arias, 2011; Cole et al., 2011]. Therefore, the introduction of targeting ligands should 
increase both drug and contrast agent concentrations in the target-site, resulting in improved 
anti-tumor activity, reduced toxicity and increased target-to-background contrast during 
imaging [Kelkar et al., 2011]. In addition to targeting tumor cells directly, nanomedicine can 
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be directed against neoangiogenic endothelial cells, resulting in subsequent tumor cell death 
due to oxygen and nutrient deprivation [Danhier et al., 2012b; Folkman, 1971]. Table 9 
provides an overview of selected recent examples of actively targeted SPIO-based 
theranostics in pre-clinical studies. 
 
Table 9. Non-exhaustive examples of actively targeted SPIO-based theranostics in pre-clinical studies. 
Formulation Drug Functional 
molecules 
Cell line In vitro/ 
In vivo 
MRI 
Results Ref 
PEG-PCL 
micelles 
DOX FA Bel7402  In vitro 
 
2.5x higher intracellular 
accumulation 
[Hong et 
al., 2008] 
Wormlike 
polymer 
vesicles 
DOX FA HeLa In vitro 
 
Higher relaxivities compared 
to Feridex 
[Yang et 
al., 2010] 
Silica sphere PTX/CMPT FA PANC-1 and 
BxPC3 (pancreatic) 
In vitro 
 
Increased cellular uptake, 
high relaxivities in vitro 
[Liong et 
al., 2008] 
SPIO-
conjugate 
MTT FA MCF-7 
HeLa 
_ In vitro anti-cancer efficacy,  
Higher internalization 
compared to the non-targeted 
SPIO 
[Kohler et 
al., 2005] 
Polymeric 
micelles 
DOX cRGD SLK (Kaposi’s 
sarcoma) 
In vitro 
 
Increased cytotoxicity, 
cellular uptake, relaxivity 
[Nasongkla 
et al., 
2006] 
Polymeric NP fumagillin cRGD, 
peptido-
mimetics 
MDA-435 In vitro 
In vivo 
Effective angiogenesis MRI, 
good anti-angiogenic 
efficacy 
[Schmieder 
et al., 
2008] 
Polymeric 
micelles 
DOX LCP H-2009 In vitro 
 
3x increased cellular uptake, 
high relaxivity 
[Guthi et 
al., 2010] 
SPIO 
conjugates 
DOX, 
ADOX 
HuCC49ΔCH2 
(anti-TAG-72 
antibody) 
LS174T  
A375  
In vitro Increased cancer cell 
targeting, decreased T2 
values in in vitro MRI, lower 
IC50 compared to non-
specific targeted SPIO 
[Zou et al., 
2010] 
Abbreviations: ADOX = azido-doxorubicin, AT = active targeting, CMPT = camptothecin, DOX= doxorubicin, 
FA= folate, LCP = lung cancer targeting peptide, MTT = methotrexate, PCL = poly(ε-caprolactone), PEG = 
poly(ethyleneglycol), TAG-72 = tumor-associated glycoprotein-72 
 
A popular targeting ligand for cancer cells is folate (FA). The folate receptor is a high-
affinity, glycosylphosphatidylinositol-anchored protein. Because FA is vital for rapid 
proliferation, the folate receptor is overexpressed in many tumor types and is highly restricted 
in healthy tissues. Therefore, FA-conjugates and FA-grafted nanocarriers have been 
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intensively investigated for both drug delivery and imaging [Shan, 2004]. For example, Hong 
et al. reported the development of SPIO/DOX-loaded PEG-PCL micelles functionalized with 
folate on their surface (attached to the PEG chain) [Hong et al., 2008]. In vitro intracellular 
accumulation studies demonstrated a 2.5 higher concentration of folate-functionalized 
micelles compared with non-functionalized micelles in Bel 7402 cells (human hepatic 
carcinoma cells). Similarly, Yang et al. developed SPIO/DOX-loaded wormlike polymer 
vesicles grafted with FA and tested their magnetic properties in HeLa cells (Figure 23) [Yang 
et al., 2010]. These theranostic particles displayed higher relaxivities compared with the 
commercial form Feridex® and improved antitumor efficacy compared with non-
functionalized vesicles in vitro. However, their theranostic system was not as effective as free 
doxorubicin. Additionally, Liong et al. developed multifunctional inorganic nanoparticles for 
combined imaging and drug delivery comprised of mesoporous silica nanoparticles 
containing SPIO and PTX or camptothecin (CMPT) that were functionalized with FA on their 
surface [Liong et al., 2008]. Finally, Kohler et al. developed MTT-SPIO conjugates as a 
simultaneous MRI contrast agent and anti-cancer therapy [Kohler et al., 2005]. The conjugate 
was comprised of iron oxide nanoparticles covalently bound to MTT, a chemotherapeutic 
drug that can target multiple cancer cells that overexpress folate receptors. The nanoparticles 
were first surface-modified with (3-aminopropyl)trimethoxysilane to form a self-assembled 
monolayer and were subsequently conjugated with MTT via amidation between the 
carboxylic acid end groups on MTT and the amine groups on the particle surface. The authors 
demonstrated the nanocomposite in vitro anti-cancer efficacy using cellular viability studies 
in human breast cancer cells (MCF-7) and human cervical cancer cells (HeLa). However, they 
did not assess the imaging ability of the developed theranostic. 
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Figure 23. (A) Illustration of the tumor-targeting multifunctional wormlike polymer vesicles formed by triblock 
copolymers for targeted cancer chemotherapy and imaging; (B) Cytotoxicity of free DOX, FA-free and FA-
conjugated SPIO/DOX-loaded wormlike polymer vesicles with crosslinked inner hydrophilic PEG layers against 
HeLa cells at different DOX concentrations (incubation time 48 h); (C) T2 relaxation rates (1/ T2, s-1) as a 
function of iron concentration (mM) for Feridex® and FA-conjugated SPIO/DOX-loaded wormlike polymer 
vesicles with cross- linked inner hydrophilic PEG layers (adapted from [Yang et al., 2010]). 
 
Another interesting target in cancer therapy is the well-known αv integrin family. In the 
integrin family, αvβ3 is the most extensively studied because of its strong implication in 
angiogenesis regulation. Interestingly, integrin αvβ3 has been shown to be overexpressed on 
both neoangiogenic endothelial cells and on the surface of many tumor cell types [Brooks et 
al., 1994; Danhier et al., 2012b]. Therefore, targeting αvβ3 with SPIO-based theranostics may 
provide interesting insights into angiogenesis using MRI as well as effective tumor cell killing 
by both indirect (inducing tumor cell death as a consequence of nutrient and oxygen 
deprivation by killing neoangiogenic endothelial cells) and direct killing of tumor cells 
expressing αvβ3. For this purpose, Nasongkla et al. developed multifunctional polymeric 
micelles loaded with DOX and SPIO functionalized with cRGD [Nasongkla et al., 2006]. The 
RGD tripeptide sequence has been shown to efficiently bind to αvβ3 integrin [Danhier et al., 
2012b; Temming et al., 2005]. Similarly, Schmieder et al. demonstrated the ability of RGD 
functionalized fumagillin- (an anti-angiogenic agent) loaded SPIO nanoparticles to improve 
CHAPTER I - INTRODUCTION 
65 
drug delivery and angiogenesis imaging in MDA-435 cells [Schmieder et al., 2008]. Guthi et 
al. reported LCP (lung cancer targeting peptide) functionalized multifunctional micelles for 
targeting αvβ6 [Guthi et al., 2010]. These DOX/SPIO-loaded micelles displayed high T2 
relaxivity, increased cytotoxicity and MRI capacity in vitro. Finally, Zou et al. developed 
antibody- and fluorescence-SPIO conjugates for MRI and fluorescence cancer cell imaging. 
DOX and azido-DOX were entrapped into an oleic acid shell coating [Zou et al., 2010]. These 
conjugates had increased cancer cell targeting, lower IC50 compared with non-specific 
targeted SPIOs and decreased T2 values in in vitro MRI. 
IV.4.3. Triggered drug release 
Triggered drug release is a commonly used term to refer to systems designed to release their 
contents or react upon exposure to internal or external stimuli. The stimuli can either be 
internal (change in pH or temperature in certain tissues or disease stages) or external 
(magnetic, electric fields, light, ultrasound, etc.) [Arias, 2011; Egusquiaguirre et al., 2012]. 
Table 10 presents a non-exhaustive list of triggered-targeted SPIO-based nanotheranostics in 
pre-clinical studies. 
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Table 10. Examples of triggered-targeted SPIO-based nanothernanostics in pre-clinical studies. 
Abbreviations: CHC = carboxymethyl hexanoyl chitosan, CPT = camptothecin, DOX= doxorubicin, EPI = 
epirubicin, GEM = gemcitabin, FA= folate, (F)US = (focused) ultrasound, HT = Hyperthermia, MT = magnetic 
targeting, MTX = mitoxantrone, Ref = references 
Acid triggered drug release 
 
Acid triggered drug release is based upon the particular microenvironment in tumor tissues 
characterized by a slightly more acidic pH compared with physiological pH (pH 5 - 6.5 
compared to 7.3 in physiological conditions) [Gullotti et al., 2009]. Several research groups 
have used this characteristic to develop a labile link between the drug and carrier or labile 
self-assembling micelles to provide tumor specific drug release. For example, Feng et al. 
recently developed polyethylene glycol (PEG), poly (N-(N’, N’-diisopropylaminoethyl) 
aspartamide) (P(Asp-DIP)) and poly (lysine-cholic acid) (P(Lys-Ca)) (PEALCa) micelles 
loaded with SPIO and PTX for cancer therapy [Feng et al., 2014]. In physiological conditions, 
the polymers organize themselves to form micelles with the hydrophobic drug and 
hydrophilic SPIO loaded in the core, whereas at a lower pH, the pH-sensitive P(Asp-DIP) 
interlayer undergoes a hydrophobic-hydrophilic transition leading to micelle destabilization 
and content release. The authors reported that these micelles effectively suppressed human 
Formulation Targeting 
Type 
Drug Targeting
molecules 
Cell line In vitro/ 
In vivo 
MRI 
Results Ref 
PEALCa 
micelles 
pH-
triggered 
PTX _ CRC LoVo  In vitro 
 
Suppression of cell 
growth in vivo and in 
vitro MRI of delivery 
[Feng et 
al., 
2014] 
Polymeric 
micelles 
pH-
triggered 
DOX FA Bel-7402  In vitro 
 
Enhanced specific 
drug delivery and 
MRI diagnosis 
[Li et 
al., 
2013a] 
β-cyclodextrin-
pluronic 
coated SPIO 
NP 
HT curcumin _ A12780CP 
  PC-3  
  MDA-MB-231  
In vitro 
 
Higher hyperthermia 
effects over time, 
improved therapeutic 
effects 
[Yallapu 
et al., 
2011] 
PLGA-PEG 
NP 
HT + AT SPIO Anti-
EGRF 
Mab 
A-431  NA 
 
Decreased tumor size 
after HT with high 
tumor accumulation 
(scintigraphy) 
[Baldi et 
al., 
2014] 
CHC 
microbubbles 
US CPT _ MDA-MB-
231 
 
In vitro 
 In vivo 
More significant 
transcellular delivery 
and cytotoxicity 
[Yang et 
al., 
2014d]  
Squalene 
based 
nanoplatform 
MT GEM _ L1210 In vitro 
 In vivo 
T2-weighted images 
of anti-tumor efficacy 
[Arias et 
al., 
2011] 
SPIO 
conjugates 
MT EPI _ MGH-U1 and 
MGH-U1R  
In vitro 
In vivo 
10x increase in tumor 
accumulation, good 
MRI contrast agents 
[Yang et 
al., 
2012] 
SPIO 
conjugates 
MT MTX _ VX-2  In vitro 
In vivo 
Effective anti-cancer 
activity, MRI to 
assess tumor 
accumulation  
[Alexio
u et al., 
2000] 
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colorectal carcinoma LoVo cell growth in vivo and effective delivered the micelles for MRI in 
vivo. Similarly, Li et al. studied acid-triggered core cross-linked nanomicelles loaded with 
DOX and SPIO for drug delivery and magnetic resonance imaging in liver cancer cells [Li et 
al., 2013a]. These micelles were comprised of folate-poly(ethylene glycol)-b-poly[N-(N',N'-
diisopropylaminoethyl) (DIP) glutamic acid (GA)] (folated-PEG-P[GA-DIP]) amphiphilic 
block copolymers. DIP was grafted to ~50% of the poly(L-glutamic acid) (PGA)’s carboxyl 
groups for nanomicelle stability. Micelle stability is ensured by the ionic interaction between 
the electronegative carboxylic function of non-grafted PGA (COO-) and the positively 
charged, namely N,N-diisopropyl, tertiary amine group. In acidic conditions (e.g., endosome, 
lysosome), the carboxylic groups are protonated, resulting in a weaker interaction between the 
two polymers and drug release (Figure 24 A). The authors demonstrated the micelle efficacy 
as a contrast agent for MRI in vitro and assessed in vitro cellular uptake (Figure 24 B-C).  
 
Figure 24. Acid-triggered self-assembly of folate-PEG-P(GA-DIP) nanomicelles loaded with DOX and SPIO. 
(A) Schematic representation of nanomicelle assembly following medium acidification. (B) In vitro cellular 
uptake. Bel-7402 cells were incubated with different samples. Arrow: clear DOX fluorescence in targeted group. 
(A) PBS control; (B) Targeted group: folate-PEG-P(GA-DIP); (C) Non-targeted group: PEG-P(GA-DIP); (D) 
The competitive inhibition group: folate-PEG-P(GA- DIP) and 1 mM free folic acid. (C) In vitro MRI. T2-
weighted (A), T2-mapping (B), and colored (C) T2-mapping images. (1) Gelatin contrast of cells not incubated 
with micelles; (2) Targeted group: folate-PEG-P(GA-DIP); (3) Non-targeted group: PEG-P(GA-DIP); (4) 
Competitive inhibition group: folate- PEG-P(GA-DIP) micelles with 1 mM free folic acid. Arrow: clear 
decreased signal in targeted group (adapted from[Li et al., 2013a]. 
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Abbreviations: DOX, doxorubicin; DMSO, dimethyl sulfoxide; folate-PEG-P(GA-DIP), folate-poly(ethylene 
glycol)-b-poly[N-(N′,N′-diisopropylaminoethyl) glutamine]; SPIONs, superparamagnetic iron oxide 
nanoparticles; THF, tetrahydrofuran. 
 
 
Hyperthermia 
The majority or cancer tissues have been shown to have higher heat-sensitivity compared with 
normal tissue. Therefore, hyperthermia can be used in cancer therapies to destroy pathological 
cells. Moreover, SPIOs have been shown to react after the application of an alternating 
magnetic field (AMF) by absorbing this energy and converting it into heat. This generated 
heat can subsequently be used to destroy cancer cells [Cole et al., 2011; Laurent et al., 2011]. 
Multiple encouraging preclinical data led to the first clinical trials in 2007, which were 
conducted by two groups, Johansen and colleagues and Maier-Hauff and colleges, using 
aminosilane-coated SPIO in patients with locally recurrent prostate cancer and glioblastoma 
multiform, respectively [Johannsen et al., 2005; Maier-Hauff et al., 2011]. After those clinical 
trials, numerous SPIO-loaded theranostics have been used in hyperthermia-based pre-clinical 
studies.  
This strategy has been successfully applied by Yallapu et al. using β-cyclodextrin-pluronic 
coated SPIO nanoparticles [Yallapu et al., 2011]. Magnetic nanoparticles loaded with 
curcumin had promising results for hyperthermia and MRI in ovarian, breast and prostate 
cancer cells. More recently, an elegant study performed by Baldi et al. demonstrated the 
efficacy of anti-human epidermal growth factor receptor (EGFR)-targeted and 99mTc 
functionalized PLGA-PEG nanoparticles loaded with SPIO (Figure 25 A) for both 
hyperthermia tumor regression (Figure 25 B) and in vivo imaging capacity using PET (Figure 
25 C) [Baldi et al., 2014]. The tumor site was clearly visible in the PET images, indicating 
nanosystem accumulation. However, substantial liver accumulation was observed (Figure 25 
C). A substantial decrease in tumor size was correlated with an increase in nanoparticle 
accumulation resulting from the EGFR-targeting moieties and local temperature. 
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Figure 25. (A) Schematic representation of the synthesis of anti-human epidermal growth factor receptor 
(EGFR)-targeted and 99mTc functionalized PLGA-PEG nanoparticles loaded with SPIO (B) Mouse tumor 
volume on day 12 through day 24, showing a decrease in tumor volume. (C) In vivo scintigraphic image of 
hybrid radiolabeled Fe3O4-1-PNP-hEGFR-99mTc in an A431 tumor-bearing SCID mouse model (adapted from 
[Baldi et al., 2014]). 
Abbreviations: hEGFR = human epidermal growth factor receptor; PNP = polymeric nanoparticles; SCID = 
severe combined immunodeficiency. 
 
 
 
Ultrasound 
Ultrasound (US, acoustic sound with frequencies > 20 kHz) can produce different effects, 
which are classified into thermal and non-thermal effects. Thermal effects are commonly used 
for thermal ablation of diseased tissue as a non-invasive alternative to surgery. Experimental 
clinical trials have shown promising results for various tumor types, including prostate and 
pancreatic cancer [Malietzis et al., 2013]. US non-thermal effects, mainly cavitation, induce a 
variety of biological responses, resulting in increased drug or carrier extravasation, blood–
brain barrier (BBB) disruption and membrane permeabilization to otherwise cell-impermeable 
compounds. Meanwhile, thermal effects are primarily used to trigger thermoresponsive drug 
delivery and tumor tissue thermal ablation [Abouelmagd et al., 2014; Yudina et al., 2012]. For 
example, Yang et al. developed carboxymethyl hexanoyl chitosan (CHC)-based 
microbubbles, encapsulating both SPIO and CPT along with sulfur hexafluoride (SF6) gas, 
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for cancer therapy and imaging (Figure 26) [Yang et al., 2014c]. They used US to combine 
US-triggered release with US-enhanced cellular uptake. The authors demonstrated the 
efficacy of their system for in vivo MRI, US imaging and in vitro cytotoxicity in MDA-MB-
231 human breast cancer cells. However, few studies have researched simple US-triggered 
targeting. The majority of researchers use combined targeting delivery systems for SPIO-
based theranostics, which will be discussed below. 
 
 
Figure 26. (A) Schematic representation of bubble-forming material (CHC) together with SPIO nanoparticles to 
prepare MR image-guided nanobubbles to efficiently encapsulate a hydrophobic drug (CPT) and exert US-
triggered toxicity to enhance membrane drug permeation; (B) Cell viability of breast tumor cells (MDA-MB-
231) cultured under different conditions. (a) Control group (cells without CPT and without sonication) (b) Cells 
sonicated for 20 min. (c) Cells cultured with CHC/SPIO NB suspension (without CPT) with sonication for 20 
min. (d) Cells cultured with CPT-loaded CHC/SPIO NB suspension without sonication for 20 min. (e) Cells 
cultured with CPT-loaded CHC/SPIO NB suspension with sonication for 20 min. (f) Cells cultured with CPT-
containing medium under sonication for 20 min; (C) In vivo MR images of mouse liver acquired before and 
after injection of CHC/SPIO NB suspension (adapted from [Yang et al., 2014c]). 
  
 
Magnetic targeting 
Due to their superparamagnetic properties, an external magnetic field can be used to guide 
SPIO-based theranostics directly to the tumor. When a permanent magnet is applied 
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externally near the tumor region, the magnetic gradient produced exerts attractive forces on 
magnetic nanoparticles delivered via the circulation [Reddy et al., 2012]. Lübbe et al. were 
the pioneers in this field, using an external magnetic field to guide a treatment [Lubbe et al., 
1996]. Subsequently, numerous studies have used this method, employing magnetic field 
strengths ranging from 0.4 to 4 T. For example, Arias et al., reported a magnetically 
responsive squalene-based nanoplatform for theranostic purposes [Arias et al., 2011]. This 
concept was based on the inclusion of SPIO nanocrystals into nanoparticles constructed by 
self-assembling molecules of a squalenoyl gemcitabine (SQgem) bioconjugate. This 
nanoplatform simultaneously allows (i) the targeting of a gemcitabine prodrug to an 
experimental solid tumor under the influence of a magnetic field produced by an external 
permanent magnet placed on the tumor surface and (ii) the imaging of the targeted tumor 
nodule. Yang et al. developed epirubicin (EPI) conjugated SPIO for magnetically targeted 
cancer therapy [Yang et al., 2012]. This EPI-SPIO conjugate increased accumulation 10-fold 
in tumors following intra-arterial injection and magnetic targeting using a 0.4T neodyme 
permanent magnet and displayed in vivo MRI contrast enhancement. Finally, Alexiou et al., 
examined a mitoxantrone (MTX)-SPIO conjugate that accumulated in the tumor tissue of 
VX-2 squamous carcinoma-bearing rabbits using a 1.7 T electromagnet [Alexiou et al., 2000].  
Complete remission of the rabbits was induced after treatment with the magnetically targeted 
MTX-SPIO conjugate and MRI was used for the in vivo visualization of particle accumulation 
(Figure 27). 
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Figure 27. (A) Schematic representation of the mitoxantrone-conjugated SPIO nanoparticles. (B) Effect of i.a. 
injection of MTX-SPIO conjugate after magnetic drug targeting (   ) compared with control group (no treatment   
). (C) MRI of tumor hind limbs of rabbits after i.a. injection and magnetic drug targeting (1h exposure). The “f-
narrow” points out the accumulation of SPIO (adapted from [Alexiou et al., 2000]). 
 
Combined targeting strategies 
Considering the different disadvantages of each simple targeting strategy, many efforts have 
been made to develop multifunctional platforms with combined targeting strategies. Table 11 
gives non-exhaustive examples of combined-targeted multifunctional SPIO-based 
nanothernanostics in pre-clinical studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I - INTRODUCTION 
73 
Table 11. Non-exhaustive examples of combined-targeted multifunctional SPIO-based nanothernanostics in pre-
clinical studies. 
Abbreviations: AT = active targeting, BBB = blood brain barrier, DOX = doxorubicin, FA = folate, FUS = 
focused ultrasound, HT = hyperthermia, MF = magnetic field, MT = magnetic targeting, PAA= 
poly(acrylamide), PDT = Photodynamic therapy, PTT = photothermic therapy 
 
The classical approach for combining targeting strategies consists of combining the active and 
acid-triggered drug release strategies. Yang et al. used this strategy and developed 64Cu 
labeled SPIO-DOX conjugates linked by an acid labile bond that was further functionalized 
with cRGD [Yang et al., 2011]. This system exhibited high in vitro MRI contrast 
enhancement and tumor accumulation using PET. 
Another strategy combines magnetic targeting (MT) with SPIO induced hyperthermia. For 
example, Pradhan et al. combined these two strategies along with active targeting for 
Formulation Targeting 
Type 
Drug Functional 
molecules 
Cell line In vitro/ 
In vivo 
MRI 
Results Ref 
SPIO  
conjugates 
AT + pH 
triggered 
DOX cRGDfC 
64Cu 
U87MG 
cells 
In vitro 
 
In vitro MRI contrast 
enhancement, 
Enhanced tumor 
accumulation (PET) 
[Yang et al., 
2011] 
Liposomes MT + HT 
+ AT 
DOX FA KB and 
HeLa cells 
In vitro 
 
Improved cellular 
uptake and 
cytotoxicity 
[Pradhan et 
al., 2010] 
Phospholipid-
based 
microbubbles 
MT + 
FUS 
DOX _ C6 glioma 
cells 
In vitro 
In vivo 
BBB opening and 
highly effective drug 
delivery 
[Fan et al., 
2013] 
PEG-PLGA-
PCL NP 
MT+AT PTX GRGDS CT-26 cells In vitro 
In vivo 
High tumor 
accumulation, drastic 
tumor growth delay, 
strong contrast 
enhancement 
[Schleich et 
al., 2014] 
PEG-PAA NP PDT + AT _ F3 9L glioma 
cells 
In vitro 
In vivo 
Significant 
improvement in 
survival rate, in vivo 
MRI 
[Reddy et 
al., 2006] 
 PEGylated 
SPIO 
nanoclusters 
PDT + 
MT 
_ _ 4T1 
(mammary 
carcinoma) 
In vitro 
In vivo 
Dramatically delayed 
tumor growth and 
MF-enhanced PDT 
[Li et al., 
2013b] 
 SPIO 
conjugates                  
Gold 
nanoshell 
PTT + AT _ C225 (anti-
EGFR Mab) 
A431 cells 
FaDu, 
OSC19, and 
HN5 
In vitro 
In vivo 
Thermal ablation, in 
vitro MRI contrast 
enhancement 
[Melancon 
et al., 2011]. 
CHAPTER I - INTRODUCTION 
74 
theranostic purposes [Pradhan et al., 2010].  They developed folate functionalized 
SPIO/DOX-loaded liposomes and tested their efficacy for improving cellular uptake and 
cytotoxicity in vitro.  
More recently, Fan et al. developed a US/MRI dual contrast agent using SPIO-labeled 
phospholipid based microbubbles that incorporated DOX (Figure 28 A) [Fan et al., 2013]. 
They combined magnetic targeting (for tumor accumulation) along with focused US to induce 
BBB opening and therapeutic agent delivery in a glioma-bearing rat. This study demonstrated 
enhanced anti-tumor efficacy mediated by the DOX-loaded microbubbles combined with 
focused US in an in vitro cytotoxicity experiment (Figure 28 B) and contrast enhancement 
after focused US and 40 min of magnetic targeting (Figure 28 C).  
 
Figure 28. (A) Schematic illustration of DOX-SPIO-MBs and their controlled release into brain tissue, triggered 
by focused US, and enhanced SPIO deposition using external MT. (B) In vitro cytotoxicity experiment. (C) In 
vivo MRI T2-weighted (T2W) images (to confirm tumor location) and susceptibility weighted images (SWI) (to 
confirm SPIO deposition) obtained before and after focused US sonication with MT for 40 min. Arrow: Location 
of SPIO deposition [Fan et al., 2013]). 
Abbreviations: DSPC = 1,2-distearoyl-sn-glycero-3-phospho-choline, DSPE-PEG2000 = 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(poly(ethyleneglycol))-2000], DSPG = 1,2-dioctadecanoyl-sn-
glycero-3-phospho-(1′-rac-glycerol), DOX-SPIO-MBs = SPIO labeled microbubbles incorporating DOX, FUS 
= Focused ultrasound, MT = Magnetic targeting 
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Our group recently developed another strategy that combined magnetic and active targeting. 
We developed RGD-functionalized PTX/SPIO-loaded PLGA-based nanoparticles and 
separately compared the double active and magnetic targeting strategy to passive, active and 
magnetic targeting. These SPIO-based multifunctional theranostics displayed a high tumor 
accumulation using the combined strategy (RGD+MT, figure 29 B), as demonstrated by the 
ex vivo biodistribution that corresponds to a strong contrast enhancement of the tumor region 
by in vivo MRI. This high tumor accumulation was correlated to drastically enhanced survival 
time and long-term survival in mice (figure 29 C) [Schleich et al., 2014]. 
 
Figure 29. (A) Schematic representation of the SPIO/PTX-loaded PLGA-based multifunctional nanoparticles. 
(B) Kaplan-Meyer survival plot. Mice treated with the combination RGD+MT had significantly longer survival 
times compared with the other targeting strategies. (C) T2-weighted MR images before injection and 4 h after 
injection and subsequent magnetic targeting (adapted from [Schleich et al., 2014]). 
Abbreviations: CTRL = control, MST = mean survival time, MT = magnetic targeting, PT = passive targeting. 
 
Long visible and NIR lights can be used to generate reactive oxygen species (ROS) after the 
activation of a compound presented by the drug carrier or the drug itself. After delivery of a 
photosensitizer-containing drug to the tumor cell, light radiation activates the drug, generating 
“killer” ROS, which induce apoptosis and enhance drug release. This technique is called 
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photodynamic therapy (PDT) [Alexiou et al., 2000; Kelkar et al., 2011; Moses et al., 2013]. 
PDT has been investigated for several decades, but light-associated toxicity limits its clinical 
application. Therefore, the classical strategy combines PDT and active targeting to increase 
specificity and limit potential damage to healthy tissue [Wang et al., 2014]. For example, in a 
study conducted by Reddy et al., vascular targeted PEGylated Photofrin/SPIO-loaded 
poly(acrylamide) nanoparticles were developed for the treatment of glioma [Reddy et al., 
2006]. The vascular targeting capacity was accomplished by the functionalization of the 
particles using the F3-peptide. In vivo MRI was used to assess biodistribution and the efficacy 
of the active targeting prior to PDT. There was a significant improvement in the survival rate 
of 9L glioma-bearing rats treated with this combined targeting therapy compared with the 
group treated with PDT alone (Figure 30).  
 
Figure 30. (A) Schematic representation of the vascular targeted PEGylated Photofrin/SPIO-loaded 
poly(acrylamide) nanoparticles. (B) T2-weighted magnetic resonance images at day 8 after treatment from (C) a 
representative control tumor and tumors treated with (D) laser light only, (E) i.v. administration of Photofrin plus 
laser light, and (F) non-targeted nanoparticles containing Photofrin plus laser light and (G) targeted nanoparticles 
containing Photofrin plus laser light. The image shown in (H) is from the same tumor shown in (G), which was 
treated with the F3-targeted nanoparticle preparation but at day 40 after treatment. (C) Kaplan-Meier survival 
plot for 9L tumor. Survival curves for brain tumor animals: untreated, laser only, i.v. Photofrin + laser treated, 
non-targeted nanoparticles containing Photofrin + laser, and F3-targeted Photofrin-containing nanoparticles + 
laser treated (Adapted from [Reddy et al., 2006]). 
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A recent example of combined PDT-magnetic targeting is provided by Li et al., who 
developed PEGylated iron oxide nanoclusters loaded with chlorin e6, a photosensitizer, for 
targeted, NIR light induced, photodynamic therapy [Li et al., 2013b]. SPIO were used for 
both their MRI contrast agent properties and the magnetic targeting potential. To further 
improve tumor accumulation, an external magnet was placed, allowing magnetic targeting.  
Another light-mediated strategy uses NIR light to induce local heating and, consequently, 
hyperthermia-induced cell death, known as photothermic therapy (PTT) [Alexiou et al., 2000; 
Kelkar et al., 2011; Moses et al., 2013]. Melancon et al. developed a SPIO-coated gold 
nanoshell functionalized with C225, an anti-EGFR monoclonal antibody, for head and neck 
cancer treatment [Melancon et al., 2011]. They used these C225-SPIO@Au nanoshells to 
image guide thermal ablation (using in vivo MRI). They used the PTT thermic effect by 
applying an NIR laser to induce local hyperthermia and destroy the tumor tissue.  
IV.5. DISCUSSION: MAJOR OBSTACLES FOR IN VIVO AND CLINICAL STUDIES 
SPIO have been extensively used during the last decade because of their (i) high surface 
functionalization for forming SPIO-conjugates, (ii) high efficiency as MRI contrast agents, 
(iii) high potential for multi-modal imaging and (iv) high potential for theranostic purposes. 
To further improve functionality, release kinetics (controlled release) and drug protection 
against degradation, nanoparticles encapsulating SPIO have recently received particular 
attention. These nanoparticular systems are interesting candidates that provide multifunctional 
platforms for theranostic applications [Cohen et al., 2013; Laurent et al., 2011].   
The concept of theranostics has received increasing interest in recent years. Nanotheranostics 
can be used for various biomedical applications including (i) non-invasive assessment of 
biodistribution and target site accumulation, (ii) monitoring of drug release, (iii) enhancement 
of therapeutic efficacy via triggered drug release and (iv) prediction of therapeutic response 
[Lammers et al., 2010]. Furthermore, the potential of theranostic platforms to promote 
personalized therapy has become clear. Because of the potential major adverse effects of 
current available anti-cancer therapies and patient inter- and intra-variability, it is important to 
pre-select patients, based on drug biodistribution, that will likely respond to therapies 
[Kumagai et al., 2009]. Patients that have good tumor accumulation and less undesirable 
accumulation in healthy tissues are more likely to be treatment-responsive and have minimal 
adverse effects.  
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Despite these exciting potential biomedical applications and as seen in the tables presented 
above, only a few in vivo MRI studies of nanotheranostics have been successfully conducted 
in pre-clinical models. Furthermore, the majority of nanotheranostics designed for 
personalized therapy have only demonstrated in vitro efficacy. Moreover, if researchers 
describe in vivo data, that data generally only assesses one of the two purposes of 
theranostics, either therapeutic efficacy or imaging efficacy [Mura et al., 2012]. Studies that 
have shown in vitro and in vivo efficacy for therapeutic and imaging purposes are mostly 
represented by studies combining multiple strategies. This observation raises the question: 
what are the obstacles responsible for so few successful in vivo MRI studies? The answer to 
this question is that SPIO-loaded theranostics have some limitations that lead to challenging 
in vivo and clinical translations. 
 
Impaired biodistribution 
As previously discussed, following i.v. injection, a significant proportion of SPIO-based 
nanoparticles are sequestered by the liver and spleen [Kwon et al., 2012; Nichols et al., 2012]. 
This phenomenon can be explained by their capture by the MPS (i.e., Kupffer cells) due to the 
size of the particles (often larger than 100 nm) and their interaction with plasma proteins 
(opsonins). It is noteworthy that only a small proportion of the injected dose actually reaches 
the tumor [Laurent et al., 2014; Reddy et al., 2012]. This phenomenon has led the researchers 
to usually use SPIO-loaded nanoparticles as a contrast agent for liver imaging [Lu et al., 
2009]. Various physico-chemical parameters have been shown to modulate this 
biodistribution, including particle size, surface charge and surface modifications (PEGylation) 
(see Figure 31). Another strategy for improving tumor accumulation is to use an external 
magnetic field to guide the therapy to the tumor site and maintain its position using magnetic 
force, known as magnetic targeting [Laurent et al., 2014; Reddy et al., 2012]. However, even 
if this strategy has shown drastic improvement of nanoparticles accumulation in tumor site, a 
major fraction of the injected dose is still found in the liver [Nichols et al., 2012; Schleich et 
al., 2014].  
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Figure 31. Illustration of the association of SPIO-based nanoparticles physicochemical properties with their 
biodistribution, pharmacokinetics and cellular uptake. 
 
Formulation challenges 
SPIO-based nanotheranostics have formulation challenges that limit their market entry. The 
vast majority of multifunctional nanomedicine systems described in the literature suffer from 
high manufacturing and material costs, as well as complexity or limitations in their 
production processes [Peer et al., 2007]. This particular point will be discussed in more details 
in the discussion section of this thesis. 
 
Limitations for passive targeting 
Since passive targeting is highly dependent on tumor vascularization and given this 
vascularization is highly heterogeneous depending on the tumor type, the patient (inter-
variability) and the disease stage or even on the tumor areas (intra-variability), EPR effect is a 
highly heterogeneous phenomenon [Bae et al., 2011; Maeda, 2012]. This point will be 
discussed in more details in the discussion section of this thesis. 
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Limitations for active targeting 
In its first conception, as imagined by Paul Ehrlich in 1908 as a “magic bullet”, ligand-
mediated targeting was thought to improve both biodistribution of the targeted nanomedicine 
and tumor accumulation, resulting in enhanced efficacy. However, because targeted 
nanomedicines have no means of self-propulsion, reaching the target site and subsequently 
accumulating in the tumor tissue, relies on EPR-mediated extravasation, which has several 
disadvantages as outlined above [Kwon et al., 2012; Lammers et al., 2008]. Therefore, the 
advantage of functionalizing nanoparticles is the higher chance of internalization. The 
mechanisms of tumor internalization for non-targeted nanoparticles mostly involve 
macropinocytosis [Kocbek et al., 2013; Kumari et al., 2011]. Conversely, functionalized 
nanoparticles are internalized via receptor-mediated endocytosis. Consequently, 
functionalized nanoparticle intratumor distribution shifts from the extracellular compartment 
to the tumor cell intracellular compartment, which improves anti-cancer efficacy [Prokop et 
al., 2008]. Targeting neoangiogenic endothelial cells may provide an interesting alternative 
because nanomedicines do not need to enter the interstitium to reach their target; therefore, 
they do not rely on EPR-mediated extravasation to exert their activity. This targeting can be 
easily achieved using RGD ligand-grafted nanomedicines.  
Furthermore, since PEGylation is a common technique improving nanocarriers stealthness to 
avoid capture by the MPS, ligand grafting, by covering PEG corona, can lower the amount of 
available PEG and, thereby, can alter pharmacokinetic and biodistribution profile [van der 
Meel et al., 2013]. Hence, it is of great importance for novel nanomedicines to verify the 
efficacy of targeting strategy in vivo and to document the dose- and time- dependency of 
targeting to guide protocol design in a view of a translational approach [Duncan and Gaspar, 
2011]. To date, many receptors have been explored in tumor targeting. Knowledge of basic 
cell biology, tumor biology, immunology, and cancer biology would be required to develop 
smart nanocarriers and to guide researchers in the choice of the proper ligand to attach. This 
choice should take several knowledge into account including tumor-specific receptors 
allowing endocytosis, tumor-specific biomarkers, tissue-specific and tumor-specific homing 
proteins, and tumor-specific enzymes allowing selective uptake into cells or accumulation in 
tumor microenvironments [Kim, 2007]. 
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Limitations for magnetic targeting 
Magnetic targeting has gained more and more interest in the last decade. Many research 
groups have now demonstrated its potential in increasing tumor accumulation through 
magnetic attraction [Alexiou et al., 2000; Arias et al., 2011; Yang et al., 2012]. However, the 
success of this targeting strategy is limited by the distance between the magnets and the target 
site. Hence, magnetic targeting should be more effective in regions closer to the magnets 
limiting its application to superficial tumors [Alexiou et al., 2000; Laurent et al., 2011]. This 
point will be discussed in more details in the discussion section of this thesis. 
Limitations for other strategies  
Ultrasound therapy also has several limitations. The challenges for ultrasound-enhanced drug 
delivery are the same as for the other targeting strategies, namely formulation challenges. 
There is a crucial need to develop a new generation of delivery vehicles that have sizes 
smaller than 200 nm, which are tailor-made for cavitation-enhanced drug delivery and may 
profit from high extravasation into tumor tissues [Ibsen et al., 2013; Mo et al., 2012]. 
PDT also has limitations in terms of light penetration. The singlet oxygen produced by the 
photochemical reaction between the sensitizer and light can only diffuse 0.02 µm, limiting 
tissue damage to the penetration depth of the light used to activate the photosensitizer [Nyst et 
al., 2009]. Although this strategy allows more selective and irreversible destruction of tumor 
cells than conventional therapies, there are several challenges that need to be addressed for 
better clinical acceptance. First, the efficiency of this strategy is limited by light penetration 
depth, restricting the use of PDT relatively superficial lesions [Chatterjee et al., 2008]. 
Second, using PDT requires specialized equipment and training [Jerjes et al., 2012]. Finally, 
the most important challenge that needs to be addressed is the high concentration of 
photosensitizer (PS) needed at the target site for clinical efficiency. Poor cancer cell uptake 
and inefficient tumor delivery of PS agents are the two main limiting factors for the current 
application of PDT in cancer therapy [Li et al., 2013b].  
 
Combined strategies 
Given the limitations of each targeting strategy taken individually, there is a crucial need for 
merging advanced targeted delivery systems to further improve selectivity of the currently 
available treatment. In this context, there is a rationale to combine different strategies in a 
same nanomedicine to overcome the limitations of each one taken separately, making those 
multi-modal nanotheranostics. 
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IV.6. CLINICAL PERSPECTIVES AND OPINION 
Few clinical trials using nanotheranostics have provided proof-of-principle for personalized 
nanomedicine. PK2, galactosamine-modified pHPMA-GFLA-GFLG-doxorubicin 
convincingly showed efficient target site localization [Seymour et al., 2002]. 111labeled 
PEGylated liposomes accumulated highly efficiently in the primary tumor mass of a Kaposi’s 
sarcoma patient, as well as in a number of secondary metastatic lesions. This observation 
explains why patients suffering from Kaposi’s sarcoma that are characterized by a dense, 
highly leaky, EPR-vascular network generally respond well to Doxil® treatment [Harrington 
et al., 2001; Lammers et al., 2012b]. VEGF-R2-targeted microbubbles are also a clinically 
relevant example of theranostics and are currently used in early-stage trials for prostate cancer 
staging and monitoring by ultrasound imaging [Kiessling et al., 2012].  
To our knowledge, no clinical trial has been performed with SPIO-based theranostics. 
Nevertheless, advances in the development of SPIO-based magnetic nanoparticles (without 
anti-cancer drug) have demonstrated that it is a promising method for cancer treatment by 
hyperthermia. The advantage of these nanoparticles is their ease of tumor targeting and fewer 
side effects than chemotherapy and radiotherapy, as proven by the results of current/ongoing 
clinical trials. These trials have evaluated both tumor accumulation with magnetic targeting 
and anti-cancer efficacy combined with radiotherapy or via hyperthermia [Laurent et al., 
2011; Maier-Hauff et al., 2011]. These trials are encouraging for the development of SPIO-
based nanotheranostics in the future. 
In our opinion, scientists, clinicians and pharmaceutical companies researching 
nanomedicines should investigate the image guidance of their nanomedicines during the 
initial phase of clinical testing. Because of the co-encapsulation possibility of contrast agents 
and anti-cancer drugs, theranostics should be considered a tool for earliest phases of clinical 
trials. This would allow the collection of important information about their nanomedicine: (i) 
the initial biodistribution and target site accumulation of the nanomedicine and (ii) during 
follow-up, the response monitoring of the nanomedicine. These two results could then be 
correlated [Lammers et al., 2012b]. However, an essential question remains unanswered: why 
do so many papers describe nanomedicines while only a few nanomedicines are 
commercialized? This question has been discussed in this review. To summarize, one major 
reason is the EPR effect is undoubtedly larger in animal model tumors than in patients [Jain et 
al., 2010]. Although there appears to be a clear EPR effect in clinical tumors, practical 
information on the extent of the EPR effect in most solid tumors is needed for the 
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development of nanomedicine. In this context, SPIO-based theranostics, via their non-
invasive biodistribution visualization and the importance of the EPR, should address this 
shortcoming. Assuming that there will be a clear correlation between tumor concentration and 
therapeutic efficacy, it will be highly important to properly differentiate between low and high 
levels of target site accumulation. These studies should also guide the specific use of 
nanomedicines in clinical applications.   
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V. ANTI-CANCER DRUGS 
Among all the anti-cancer drugs currently used, paclitaxel and doxorubicin are the most 
widely used for the treatment of various cancers and have been used in this thesis. 
V.1. PACLITAXEL 
Paclitaxel (PTX) is the first of a new class of microtubule stabilizing agents. PTX is a 
diterpenoid pseudoalkaloid (C47H51NO14, MW 853 Da) isolated in 1960s from the bark of 
Pacific Yew (Taxus brevifolia; Taxaceae) (Figure 32). Its anti-tumor activity is due to the 
entire taxane molecule [Wani et al., 1971].  
 
Figure 32: Structure of paclitaxel.  
 
Unlike other microtubule agents, such as Vinca alkaloids, which induce the disassembly of 
microtubules, PTX stabilizes microtubules and inhibits depolarization back to tubulin [Schiff 
et al., 1979; Wall et al., 1995]. Microtubules are cylindrical structure (made up of proteins, 
mainly tubulin) involved in various essential cellular functions including mitosis. They 
represent a fundamental constitutive part of eukaryotic cell’s cytoskeleton [Marchetti et al., 
2002]. PTX acts by disruption of the dynamic equilibrium within the microtubule system 
causing an increase in mass and number of microtubules which are extremely stable.  
Therefore, the elongation and shortening required for cell division or the vital functions in the 
interphase cannot occur [Fan, 1999]. Thus, PTX blocks cells in the late G2 phase and M phase 
of the cell cycle [Singla et al., 2002]. Consequently, the more the cells are undergoing mitosis 
the more they are sensitive to PTX [Marchetti et al., 2002]. 
Currently, the use of PTX is approved for the treatment of breast cancer, non-small cell lung 
cancer, ovarian cancer and Kaposi’s Sarcoma [paclitaxel RCP]. However, PTX was shown to 
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have neoplasic activity against a variety of other cancers such as ovarian carcinoma, colon, 
head, non-small cell lung cancer and AIDS related Kaposi’s sarcoma [Horwitz, 1992].  
PTX presents a low therapeutic index and treatments are always associated with serious side-
effects due to non-specific activity. Indeed, all cells presenting a high turn-over will be more 
sensitive to PTX with consequences for the patient like neutropenia, thrombocytopenia, 
asymptomatic bradycardia, arrhythmias, ischemia, nausea, vomiting, diarrhea, elevation of 
liver function, alopecia, myopathy, fatigue, pulmonary embolism, etc [Panchagnula, 1998; 
Rowinsky et al., 1995]. 
The usually dose is 135-175 mg/m² and is given as 3 and 24 h perfusion in a weekly or a 3-
weekly schedule. Pharmacokinetics of PTX shows wide variability. Terminal half-life was 
found to be in the range of 1.3-8.6 h. PTX undergoes cytochrome P450 (mainly CYP2C8 and 
CYP3A4) mediated hepatic metabolism and is mainly eliminated in feces. The majority of the 
drug (89-98%) binds to plasma proteins [Singla et al., 2002] (paclitaxel RCP). 
Some resistance has been associated with taxanes such as an increased multidrug resistance 
(MDR). Indeed, natural alkaloids enter the cell by passive diffusion, which is related to the 
presence of cellular membrane proteins such as P-glycoprotein, inducing resistance 
[Marchetti et al., 2002]. 
Paclitaxel is poorly soluble in water and thus, until recently, its commercially available 
preparations are using a vehicle composed of non-ionic solvent Cremophor® EL 
(polyethoxylated castor oil) and ethanol (1:1) (Taxol®, 6 mg/ml, Bristol-Meyers Squibb) 
which is diluted with 5-20-fold in 0.9% sodium chloride injection or 5% dextrose injection. 
However, some side-effects associated with paclitaxel, such as hypersensitivity reactions 
requiring premedication with antihistamines or corticosteroids, myelosuppression, and 
peripheral neuropathy, are known to be worsened by Cremophor® EL [Gupta et al., 2014]. 
Cremophor® EL was also shown to cause vasodilatation, labored breathing, lethargy and 
hypotension [Friedland et al., 1993]. Moreover, Cremophor® EL has been shown to influence 
the pharmacokinetic profile of paclitaxel resulting in a non-linear kinetics of total 
concentration, when administrated as Taxol® [Friedland et al., 1993] whereas unbound 
concentrations were been proven to follow linear kinetics [Friedland et al., 1993]. A more 
recent study demonstrated the influence of Cremophor® EL on the pharmacokinetics of 
paclitaxel metabolites showing that total concentrations of 6α-hydroxypaclitaxel and p-3'-
hydroxypaclitaxel, two primary metabolites, were strongly dependent on predicted 
Cremophor EL concentrations [Friedland et al., 1993]. 
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In recent years, a growing interest has emerged in the design of biocompatible Cremophor-
free formulation of PTX. Polymer-based drug carriers represent an attractive issue because of 
the diversity of existing polymers presenting various physico-chemical properties. Polymeric 
micelles, nanoparticles, liposomes, polymer-drug conjugates have been extensively studied 
with varying degree of success [Gaucher et al., 2010; Lammers et al., 2008]. 
In 2005, a cremophor-free formulation has been introduced into the market. Indeed, 130 nm 
albumin-bound paclitaxel nanoparticle (ABRAXANE® ABI-007) is a new generation 
formulation of paclitaxel that allow avoiding the use of Cremophor®, resulting in a safer 
administration without requiring the use of premedications to avoid hypersensitivity. 
Abraxane® gained its initial FDA approval for metastatic breast cancer patients who failed 
combination chemotherapy [Gradishar et al., 2005].  
V.2. DOXORUBICIN 
Doxorubicin (DOX) is an anthracycline drug isolated from Streptomyces peucetius, a soil 
bacterium [Arcamone et al., 1969]. DOX has shown great efficacy in cancer cell killing. It has 
been used for more than 40 years for the treatment of solid tumors arising in the breast, 
endometrial tissue, ovarian tissue, osteosarcomas, multiple myeloma, soft tissue sarcomas and 
non-Hogkin’s lymphoma [Gewirtz, 1999; Yang et al., 2014a] (doxorubicin RCP]). Despite 
the extensive clinical utilization of this drug, the mechanism by which DOX induces cell 
death remains the subject of controversy. Indeed, multiple mechanisms have shown to be 
involved: 
(i) DOX was been shown to induce topoisomerase II poisoning by trapping this 
enzyme at cleavage site resulting in double-strand DNA breaks and, thus, cell 
death [Forrest et al., 2012; Gewirtz, 1999]. Indeed, when the attempt to repair the 
breaks in DNA fails, the apoptosis pathway is triggered and cellular growth is 
inhibited at phases G1 and G2 [Tacar et al., 2013] 
(ii) Due to its planar conformational structure (Figure 33), DOX acts as a DNA 
intercalator. Intercalation takes place at site containing adjacent GC base via 
specific hydrogen-bond formation. The formation of these DNA-adducts has been 
shown to activate DNA damage responses and induce cell death [Forrest et al., 
2012] 
(iii) Recently, DOX has been demonstrated to have a role in blocking cancer cells 
proliferation through stimulation of ceramide synthesis [Denard et al., 2012] 
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(iv) The quinone structure of DOX can be oxidized to a semiquinone radical by 
numerous NAD(P)H-oxidoreductases, leading to oxidative stress via superoxide 
generation and DNA damage [Saltiel et al., 1983; Yang et al., 2014a]  
The degree and type of cell death caused by DOX varies according to the administered 
dose and cell line treated [Tacar et al., 2013]. 
 
Figure 33. Doxorubicin molecular structure with the anthraquinone core (in green) (adapted from [Forrest et al., 
2012]). 
A major adverse effect limits, however, its clinical application as a free-drug. Indeed, DOX 
induces cardiotoxicity. This well-known phenomenon shows an overall prevalence of 1.7 % 
to 6.8% and is highly dependent on the total dose [Saltiel et al., 1983]. The mechanisms of 
DOX toxicity to cardiomyocytes involve ROS generation leading to both apoptosis and cell 
autophagy [Tacar et al., 2013].  
DOX is administered through a drip-drip at doses varying between 15 and 90 mg/m2 during 
30 minutes corresponding to approximately 5 µM of initial plasma concentration. This plasma 
concentration declines rapidly to 25-250 nM within 1 hour [Gewirtz, 1999]. To limit DOX-
induced cardiotoxicity and improve pharmacokinetics parameters, PEGylated liposomal DOX 
is commonly used. Indeed, liposomes have a circulation half-life of approximately 73.9 h, 
whereas free doxorubicin has a half-life of <10 min. Pegylated liposomal encapsulation also 
reduces plasma levels of free DOX and, consequently, reduces drug delivery to normal tissue, 
leading to a decrease in cardiotoxicity risk [O'Brien et al., 2004]. Currently, two commercial 
forms of these liposomes are available: CAELYXTM and Doxil® (U.S.A.). Pegylated 
liposomal doxorubicin has been investigated in a variety of cancer types, including breast 
cancer, gynecologic malignancies, multiple myeloma, non-Hodgkin’s lymphoma, 
gastrointestinal malignancies, and non-small cell lung cancer. Pegylated liposomal 
doxorubicin is approved by the FDA and EMA for the treatment of metastatic ovarian cancer 
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in patients with disease refractory to both paclitaxel- and platinum-based chemotherapy 
regimens, for the treatment of metastatic breast cancer in patients who are at increased cardiac 
risk, in the second-line treatment of multiple myeloma in combination with bortezomib and in 
the treatment of Kaposi’s sarcoma in patient with a CD4 lymphocytes rate lower than 200 
/mm3 (Caelyx and Doxil RCP). 
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AIMS OF THE THESIS 
 
(i) The first aim of the thesis was to develop and characterize PLGA-based 
nanoparticles as multifunctional entities by co-encapsulation of an anti-cancer drug 
(PTX/DOX) and contrast agents (SPIO) for both anti-cancer therapy and magnetic 
resonance imaging;  
 
 
(ii) The second aim of the thesis was to compare four targeting strategies of these 
multifunctional nanoparticles in terms of anti-tumor efficacy, biodistribution and 
magnetic resonance imaging capabilities. The four targeting strategies compared were 
passive targeting (PT), active αvβ3 targeting (RGD), magnetic targeting (MT) and the 
combination of the two latest (RGD+MT).  
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ABSRACT 
 
We developed dual paclitaxel (PTX)/superparamagnetic iron oxide (SPIO)-loaded PLGA-
based nanoparticles for a theranostic purpose. Nanoparticles presented a spherical 
morphology and a size of 240 nm. The PTX and iron loading were 1.84 ± 0.4 and 10.4 ± 1.93 
mg/100 mg respectively. Relaxometry studies and phantom MRI demonstrated their efficacy 
as T2 contrast agent. Significant cellular uptake by CT26 cells of nanoparticles was shown by 
Prussian blue staining and fluorescent microscopy. While SPIO did not show any toxicity in 
CT-26 cells, PTX-loaded nanoparticles had a cytotoxic activity. PTX-loaded nanoparticle (5 
mg/kg) with or without co-encapulated SPIO induced in vivo a regrowth delay of CT26 
tumors. Together these multifunctional nanoparticles may be considered as future 
nanomedicine for simultaneous molecular imaging, drug delivery and real-time monitoring of 
therapeutic response. 
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I. INTRODUCTION 
Theranostics is a newly emerging concept which involves simultaneous execution of 
therapeutic and diagnostic approaches for personalized medicine. Nanoparticles (NP) can be 
designed to encapsulate a wide variety of chemotherapeutic and diagnostic agents for the 
delivery of these agents to tumor cells [Lammers et al., 2010]. Nanoparticles can target 
tumors by a passive process. Passive targeting implies that nanoparticles are smaller than the 
fenestrations of endothelial cells and can therefore enter the interstitium to be finally 
entrapped in the tumor. The combination of leaky vasculature and poor lymphatic drainage 
results in the well-known Enhanced Permeability and Retention (EPR) effect [Maeda et al., 
2000]. 
Paclitaxel (PTX), a major anti-cancer drug has anti-neoplasic activity particularly against 
various types of solid tumors [Singla et al., 2002]. PTX disrupts the dynamic equilibrium 
within the microtubule system and blocks cells in the late G2 phase and M phase of the cell 
cycle, thereby inhibiting cell replication [Schiff et al., 1979]. PTX is poorly soluble in water. 
To enhance its solubility and allow its parenteral administration, PTX is currently formulated 
at 6 mg/ml in a vehicle composed of a mixture of Cremophor® EL and ethanol (1:1) (Taxol®) 
[Weiss et al., 1990].  
Magnetic resonance imaging (MRI) is a non-invasive imaging technique, presenting a high 
spatial resolution which is suitable for cancer detection and therapeutic response assessment 
[Brindle, 2008]. However, its low sensitivity represents a major limitation. 
Superparamagnetic iron oxide (SPIO) as MRI contrast agent addresses this limitation. SPIO 
can produce predominant T2 relaxation effect, resulting in a signal reduction on T2-weighted 
images. The magnetic field heterogeneity around the particles, through which water 
molecules diffuse, induces the dephasing of the proton magnetic moments. Consequently, a 
T2 effective transverse relaxation is shortened [Bjornerud et al., 2004; Ling et al., 2011].  
Recently, numerous publications have reported various polymer-based nanocarriers 
(Poly(lactide-co-glycolide) (PLGA), Poly (L-lactic acid) PLLA, N-(2-
hydroxypropyl)methacrylamide (HPMA), poly(e-caprolactone)) for magnetic-imaging 
[Hamoudeh et al., 2007; Ling et al., 2011; Lu et al., 2009; Talelli et al., 2009]. These 
theranostics successfully allowed the non-invasive assessment of the biodistribution, the 
visualization of drug distribution, the optimization of strategies, the prediction and real-time 
monitoring of therapeutic responses [Lammers et al., 2010]. However, these SPIO-loaded 
nanocarriers are generally limited because of (i) their lack of functional groups on their 
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surface for covalent modification, (ii) their low capacity of drug loading and (iii) the fact that 
most of polymers used are not approved by the FDA, limiting their potential translation to the 
clinic. 
Previously, we developed PTX-loaded PEGylated PLGA-based nanoparticles showing a 
lower IC50 in vitro and improved in vivo anti-tumor efficacy when compared to Taxol®, due to 
the EPR effect [Danhier et al., 2009a]. (PLGA) was chosen for its biodegradability properties, 
its biocompatibility and its approval by the FDA [Danhier et al., 2012]). Poly(ε-caprolactone-
b-ethylene glycol) (PCL-b-PEG), an amphiphilic copolymer, was added to take advantage of 
the repulsive properties of PEG, to provide a higher stability of nanoparticles in biological 
fluids and to allow the grafting of a targeting ligand [Fievez et al., 2009; Garinot et al., 2007; 
Pourcelle et al., 2007]. We also previously developed RGD-grafted PTX-loaded PEGylated 
PLGA-based nanoparticles showing an effective αvβ3 targeting of the tumor endothelium 
[Danhier et al., 2009c].  
In this study, we aimed at developing these previously described PTX-loaded PEGylated 
PLGA-based nanoparticles as an effective nanocarrier for dual encapsulation of anti-cancer 
drug (PTX) and SPIO for a theranostic purpose. Hence, SPIO were prepared by the co-
precipitation technique and were encapsulated in PLGA-based nanoparticles. The physico-
chemical properties of nanoparticles were characterized by different techniques such as 
transmission electron microscopy (TEM), dynamic light scattering (DLS) method, electron 
spin resonance (ESR) spectroscopy or inductively coupled plasma mass spectroscopy (ICP-
MS). Their magnetic properties were evaluated using relaxometry and MRI. Furthermore, we 
investigated the in vitro cellular uptake and cytotoxicity of nanoparticles. Finally, the in vivo 
anti-tumor efficacy was assessed on CT-26 tumor-bearing mice. 
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II. MATERIALS AND METHODS 
II.1. MATERIALS 
Iron(II) chloride, iron(III) chloride, oleic acid, sodium hydroxide,  chlorhydric acid, 4,6-
diamidino-2-phenylindole (DAPI), 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) (MTT), polyvinylalcohol (PVA, MW=30-70kDa), poly(lactic-co-glycolic acid) 
(PLGA, lactide/glycolide molar ratio of 50:50 MW: 7000-17000), paclitaxel (PTX) and 
doxorubicin (DOX) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Perls’ 
Prussian blue kit and commercial SPIO Molday IonTM were purchased from BioPAL 
(Worcester, UK). PLGA-b-PEG (MW=10 040–4600), PCL-b-PEG (MW=13 100-5000) and 
FITC-PLGA were synthesized as previously described [Danhier et al., 2010; Garinot et al., 
2007]. Dulbecco's modified Eagle’s medium (DMEM), fetal bovine serum (FBS), trypsin–
EDTA and penicillin–streptomycin mixtures were from Gibco® BRL (Carlsbad, CA, USA). 
Murine colon carcinoma CT26 cells were kindly given by Goldyne Savad Institute of Gene 
Therapy, Hadassah-Hebrew University Hospital (Jerusalem, Israël). Water used in all 
experiment was prepared by Aqualab purification system. 
II.2. SYNTHESIS OF SUPERPARAMAGNETIC IRON OXIDES (SPIO) COATED WITH 
OLEIC ACID 
Hydrophobic superparamagnetic iron oxides (SPIO) were synthesized using a classical co-
precipitation technique of ferrous and ferric salts in alkaline medium [Massart, 1981]. Briefly, 
10 mmol iron(III) chloride and 5 mmol iron(II) chloride were mixed together in 12 ml of an 
hydrochloride aqueous solution (HCl 1M). This solution was then added dropwise to an 
aqueous solution of NaOH 1M containing 3.1 g of oleic acid with stirring on a magnetic stir 
plate for 20 minutes under a nitrogen-gas atmosphere at 80°C. The black precipitate was 
separated using a magnet, washed three times using absolute ethanol and then dissolved in 50 
ml of dichloromethane (DCM). The solution was then placed in an ultrasonic bath for 10 
minutes and centrifuged (4416 rcf, 10 min) to remove the undispersed residue. 
Hydrophilic SPIO used as SPIO aqueous solution (SPIO sol) were also synthesized. Briefly 1 
ml of DCM dispersion of SPIO coated with oleic acid (40 mg/ml) was added to a suspension 
of tetramethylammonium 11-aminoundecanoate in DCM (40 mg in 2 ml). After 24 h 
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magnetic stirring, the precipitate was washed three times with DCM and dispersed in water 
[Yang et al., 2010]. 
II.3. PREPARATION OF PLGA-BASED NANOPARTICLES LOADED WITH SPIO 
AND PACLITAXEL OR  DOXORUBICIN 
Both nanoparticles loaded with SPIO and DOX (SPIO/DOX-NP) and nanoparticles loaded 
with SPIO and paclitaxel (SPIO/PTX-NP) were prepared by an emulsion-diffusion-
evaporation method [Danhier et al., 2009a; Garinot et al., 2007]. Briefly, PLGA (14 mg/ml), 
PLGA-PEG (3 mg/ml) and PCL-PEG (3 mg/ml) were dissolved in 2ml DCM containing 
SPIO (Fe concentration: 15 mg/ml). Doxorubicin HCl (0,2 mg/ml) was dissolved in 1ml 
DCM containing 0.001 mg/ml triethanolamine beforehand and stirred overnight [Shieh et al., 
2011] whereas paclitaxel (3 mg) was added directly. This organic solution was then added to 
an aqueous solution (4.5 ml) containing 3 % (p/v) PVA and emulsified using a vortex for 2 
min followed by sonication (2 x 30 sec, 50W). The mixture was then added dropwise and 
under magnetic stirring into an aqueous solution containing 1 % PVA and stirred overnight to 
evaporate the organic solvent. To remove the non-encapsulated drug, the suspension was 
filtered (1,2 µm) and washed three times with water using ultracentrifugation (11 000 g, 30 
min, 4°C) and suspended in 2 ml water. FITC covalently labeled PLGA was used to prepare 
fluorescent nanoparticles [Freichels et al., 2011]. PTX-loaded nanoparticles (PTX-NP) and 
SPIO-loaded nanoparticles (SPIO-NP) were also prepared using the same protocol. 
II.4. PHYSICO-CHEMICAL CHARACTERIZATION OF NANOPARTICLES LOADED 
WITH SPIO AND PACLITAXEL OR DOXORUBICIN 
II.4.1. Thermogravimetric analysis of SPIO 
The coating percentage of SPIO with oleic acid was assessed by thermogravimetric analysis 
(TGA) on a TA Instrument Q500 model, under dry nitrogen flow, with a heating rate of 
15°C/min from RT to 600°C, in an open platinum pan. 
II.4.2. Particles size and morphology determination 
The hydrodynamic particle size and size polydispersity of nanoparticles was assessed using a 
dynamic light scattering method (Nano ZS, Malvern instruments, UK). The Zeta (ζ) potential 
of the nanoparticles was measured in KCL 1 mM with a Malvern Nano ZS at 25 °C. The 
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morphology of the particles was achieved using transmission electron microscopy (TEM).  
TEM was carried out with a Philips CM 100 operating at a voltage of 100 kV, equipped with 
a Megaview G2 camera. Samples for TEM experiments were prepared by spin coating a drop 
of nanoparticles in DCM on a carbon-coated TEM grid. 
II.4.3. Determination of SPIO loading content 
The iron content was measured by Electron Spin Resonance (ESR) spectroscopy using a 
Bruker EMX ESR spectrometer operating at 9 GHz (Bruker Biospin GmBh, Germany) 
validated by inductively coupled plasma mass spectroscopy (ICP-MS) measurements (Agilent 
7500ce instrument). This method allow a sensitive quatification with a LOD and a LOQ of, 
respectively, 91 and 304  ng Fe ml−1 [Danhier et al., 2012]. The solution to be tested was 
drawn into a 75  µl glass capillary tubes as such, no transformation needed, and this capillary 
was placed in the spectrometer for measurement at room temperature. Typical parameters 
were selected for ESR measurements: 3 mT modulation amplitude, 10.11 mW power, 325.1 
mT center field, and field 400 mT sweep width. Double integration of the iron oxides ESR 
spectra was used to quantify signal intensity. 
II.4.4. Determination of drug loading content 
The DOX content was assessed by	  determining the absorbance at 480 nm with a UV–Visible 
spectrophotometer (HP8453 from Hewlett Packard). The PTX content was determined using 
high-performance liquid chromatography (HPLC) with UV detection at 227 nm (Agilent 1100 
series, Agilent Technologies, Diegem, BE), as previously described after dissolution of 
particles in acetonitrile (50:50), vortex (5 min) and filtration (0,22 µm) [Danhier et al., 
2009c]. The mobile phase consisted of acetonitrile and water (70:30 v/v, respectively) at a 
rate of 1ml/min. The column used was a CC 125/4 Nucleod UR 100-5 C18. Standard 
solutions of 5 to 100 µg/ml of PTX dissolved in acetonitrile were used for calibration 
(correlation coefficient = 0.99, LOD = 1.6 µg/ml, LOQ = 5 µg/ml, coefficients of variation < 
4.5 %). The drug loading was defined as the amount of drug (mg) loaded for 100 mg of 
polymer whereas the encapsulation efficiency was defined by the ratio of the encapsulated 
drug compared to the initial amount of drug [Danhier et al., 2010]. 
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II.5. MAGNETIC PROPERTIES 
II.5.1. Relaxometry by proton NMRD 
Nuclear Magnetic Relaxation Dispersion (NMRD) profiles were recorded at 37°C on a Fast 
Field Cycling Relaxometer (Stelar, Mede, Italy) over a magnetic field range from 0.01-40 
MHz. Additional longitudinal (R1) and transverse (R2) relaxation rate measurements at 20 and 
60 MHz were respectively obtained on Minispec mq 20 and mq 60 spin analyzers (Bruker, 
Karlsruhe, Germany). The fitting of the NMRD profiles by a theoretical relaxation model 
allows the determination of the crystal radius (r) and the specific magnetization (MS). The 
proton NMRD curves were fitted using data-processing software, including different theorical 
models describing the nuclear relaxation phenomena [Laurent et al., 2010; Roch et al., 2005; 
Roch et al., 1999].  
II.5.2. Phantom MRI 
T2 relaxivity was obtained using a 11,7 T animal Biospec MR system (Bruker Biospec, 
Ettlingen, Germany). Phantom MRI of SPIO-NP was carried out at various iron concentration 
from 0 µg/ml to 30 µg/ml (0, 5, 10, 15, 20, 25 and 30 µg/ml) in 10 % gelatin using a T2-
weighted multi-slice multi-echo (MSME) sequence. The imaging parameters were: repetition 
time (TR) = 2500 msec, echo time (TE) = 30 msec, field of view (FOV) = 3.00 cm, flip angle 
(FA) = 180.0°. 
II.6. IN VITRO CELL LINE EXPERIMENT 
II.6.1. In vitro cellular uptake  
CT26 colon carcinoma cells were seeded at a density of 1x105 cells per well in Lab-tekII® 
chamber slide system in DMEM supplemented with 10 % fetal bovine serum (FBS), 1 % of a 
penicillin/streptomycin mixture and 1 % L-Glutamine. Cells were incubated for 24 h in a 5% 
CO2 incubator (37°C). Then, 100 µl of SPIO/DOX-NP suspension labeled with FITC was 
added to the medium for 1 h, 2 h or 4 h. After incubation, cells were fixed at room 
temperature for 15 min with 4% paraformaldehyde. Following cell fixation, cells were 
incubated with 4,6-diamidino-2-phenylindole (DAPI) at a concentration of 0,2 µg/ml in 
phosphate buffer saline (PBS) for 15 min protected from light, washed twice with PBS and 
once with water to avoid salt crystals formation.  
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The intracellular iron oxides were visualized using a Prussian blue staining. After 2 h of 
incubation with SPIO/DOX-NP suspension at 80 µg/ml of Fe concentration, CT-26 were 
washed three times with PBS, fixed with 4 % paraformaldehyde for 15 min and incubated for 
30 min with 2 ml working solution provided by the Prussian blue kit comprising equal 
volume of 2 % HCl and 2 % potassium ferrocyanide (II) trihydrate (bioPAL). Wells were 
finally washed twice with PBS and once with water.  
The stained plates were observed using either a fluorescent microscope (Axioskop 40, Zeiss)	  
fitted with three excitation filters: 340/380 nm (blue), 470/490 nm (green), 515/560 nm (red) 
or without filter for iron oxide visualization. Photographs were taken with an AxioCam MRc5 
camera (Zeiss). 
II.6.2. In vitro cytotoxicity  
The cytotoxicity of SPIO, SPIO-NP and SPIO/PTX-NP was determined by a MTT cell 
proliferation assay as previously described [Danhier et al., 2009b; Mosmann, 1983]. Briefly, 
CT26 colon carcinoma cells were seeded at a density of 104 cell per well in 96-well plates. 
Next day, cells were incubated with the different formulations: SPIO solution, SPIO-NP, 
PTX-NP at 3 different iron concentrations (20 µg/ml, 10 µg/ml and 2 µg/ml) and SPIO/PTX-
NP. All the concentrations of SPIO used were based on the corresponding PTX 
aforementioned concentrations when SPIO and PTX are co-loaded (Fe concentrations: 106.8 
µg/ml, 53.4 µg/ml and 10.7 µg/ml). After 24h, supernatants were removed. Wells were then 
washed twice with PBS and incubated with DMEM containing MTT (5 mg/ml) for an 
additional 2 h. After MTT solution removal, DMSO was added to dissolve the formazan 
crystals. Absorbance was measured at 570 nm using a BioRad microplate reader. Untreated 
cells were taken as control with 100 % viability, and Triton X-100 1% was used as a positive 
control of cytotoxicity. Cells without addition of MTT were used as blank to calibrate the 
spectrophotometer to zero absorbance.  
II.7. IN VIVO EVALUATION 
II.7.1. Animal and tumor models 
All experiments were performed in compliance with guidelines set by national regulations 
and were approved by the ethical committee for animal care of the health science sector of the 
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Université Catholique de Louvain. CT26 colon carcinoma cells were inoculated 
subcutaneously in the right flank of BALB/c mice (5x104 cells per mouse). 
 
II.7.2. In vivo anti-tumor efficacy  
The effect of SPIO/PTX-NP on tumor growth was assessed by daily measurements of tumor 
volume with an electronic caliper. CT26 cells were injected subcutaneously in the right flank 
of the mice to allow easy and reproducible tumor volume measurements. Mice were randomly 
assigned to a treatment group when tumor reached a volume of 27 ± 5 mm³. Treatment was 
injected trough the tail vein. Five groups were defined (6 mice per group): group1: PBS 
injection, group 2: injection of a SPIO solution (SPIO sol; Fe dose: 13.5 mg/kg), group 3: 
injection of SPIO loaded nanoparticles (SPIO-NP; Fe dose: 13.5 mg/kg), group 4: injection of 
PTX loaded nanoparticles (PTX-NP) at a concentration of 5 mg/kg PTX and group 5: 
injection of SPIO-PTX co-loaded nanoparticles (SPIO/PTX-NP; PTX dose: 5 mg/kg – Fe 
dose: 13.5 mg/kg). The end point of the experiment was determined as the moment when 
tumor reached 600 mm³. At this point, mice were sacrificed. Tumor growing ratio was 
calculated as the volume measured each day (mm³) compared to the volume measured at day 
1 (day of treatment injection). 
II.8. STATISTICAL ANALYSES 
All results are expressed as mean ± standard deviation (SD). Two-way ANOVA, Bonferroni 
post test, Kaplan-Meier survival rate and T-test	  were performed, using the software GraphPad 
Prism 5 for Windows, to demonstrate statistical differences (p<0,05).  
 
 
CHAPTER III - DUAL PACLITAXEL/SUPERPARAMAGNETIC IRON OXIDE-LOADED PLGA-BASED NANOPARTICLES FOR 
CANCER THERAPY AND MRI 
123 
III. RESULTS AND DISCUSSION  
III.1. PHYSICO-CHEMICAL CHARACTERIZATION 
To ensure dispersibility in organic solvent and hydrophobicity of particles, SPIO were coated 
with oleic acid by a simple adsorption process (Figure 1). Coating efficacy was assessed by 
the percent by mass of inorganic matters using TGA. SPIO showed a percentage of 39.5 % 
inorganic matters representing SPIO suggesting a coating of 60.5 %. This coating is needed to 
prevent the formation of large aggregates when exposed to the biological system or DCM for 
nanoparticle preparation [van Ewijk et al., 1999]. 
 
Figure 1. Schematic representation of SPIO/PTX-loaded PLGA-based nanoparticles 
 
SPIO were also characterized in terms of size and morphology using transmission electron 
microscopy (TEM) (Figure 2A). TEM results showed a spherical morphology with relatively 
uniform sizes ranging from 6 to 12 nm. Apparent aggregation was not detected.  
PLGA-based nanoparticles were prepared using an emulsion-diffusion-evaporation method 
[Garinot et al., 2007] (Figure 1). This method was selected comparing the results obtained 
either by the nanoprecipitation or by the emulsion method after several adjusts (data not 
shown).  As shown in Table 1, all the PLGA-based nanoparticles presented neutral ζ 
potentials and similar sizes between 235 nm and 244 nm (p>0.05) except for the PLGA-based 
nanoparticles loaded with both SPIO and doxorubicin (SPIO/DOX-NP), which presented a 
slightly larger size (285 nm). It is well known that the EPR effect is exploited to allow 
nanocarriers the passive targeting of tumors. Thus, the particle size plays an important role. 
Endothelial pores have sizes varying from 10 to 1000 nm. It was further established that the 
optimal particles size is ranging from 20 to 400 nm [Danhier et al., 2010; Maeda et al., 2000]. 
PTX/SPIO-loaded nanoparticles are thus convenient to benefit from the EPR effect.  
CHAPTER III - DUAL PACLITAXEL/SUPERPARAMAGNETIC IRON OXIDE-LOADED PLGA-BASED NANOPARTICLES FOR 
CANCER THERAPY AND MRI 
124 
Table 1. Particle size, ζ potential, drug loading and SPIO loading of PLGA-based nanoparticles loaded with 
either SPIO (SPIO-NP), paclitaxel (PTX-NP), SPIO and paclitaxel (SPIO/PTX-NP) or with SPIO and 
doxorubicin (SPIO/DOX-NP) (n=3). 
 
The size and morphology of SPIO-PTX-loaded nanoparticles were also investigated by TEM. 
Particles were spherical and presented a narrow distribution without aggregation. Particles 
size appeared to be approximately 50 nm. Only iron oxides induced differences in 
transmission and consequently in contrast. The measured size does not probably constitute the 
real size of nanoparticles, in comparison with the hydrodynamic diameter measured by DLS. 
The polymers shape was visible in grey areas surrounding black spots (SPIO). Interestingly, 
size, morphology or distribution of nanoparticles were not affected by the co-encapsulation of 
SPIO and PTX (Figures 2B,C). 
All formulations presented a similar SPIO loading around 10 mg/100 mg of polymer (p>0.05) 
which is similar to those found in the literature [Guthi et al., 2010; Hu et al., 2012; Lee et al., 
2010] The Fe concentration was the same when quantified by ESR spectroscopy or by ICP-
MS. 
PTX loading was not affected by the co-encapsulation of SPIO. The PTX loading was 1.8 
mg/100 mg polymer. Drug loading is crucial for formulations of drug delivery systems 
because it directly affects the therapeutic dose available for the targeted tissue. Interestingly, 
the drug loading of nanoparticles, formulated by an emulsion-diffusion-evaporation method 
using PVA as emulsifier, was 4.5-fold higher than with the same method, described 
previously, using sodium cholate and 2.5-fold higher than with the nanoprecipitation 
technique [Danhier et al., 2009a]. Moreover, the drug loading of nanoparticles was 2.8 to 4.8-
fold higher than those described in previous studies [Hu et al., 2012; Singh et al., 2011]. 
However, other studies using either other contrast agent or other polymers have shown better 
paclitaxel loading (7,5-17 mg/100 mg polymer) [Bao et al., 2014; Yoon et al., 2012]. Due to 
the small amount of doxorubicin used to formulate SPIO/DOX-NP (0.5 mg/100 mg of 
polymer), the encapsulation efficiency reached 100%.  
 SPIO-NP PTX-NP SPIO/PTX-NP SPIO/DOX-NP 
Size (nm) 235 ± 8 238 ± 8 243 ± 9 285 ± 1 
ζ potential (mV) 0 ± 0.04 0 ± 0.01 0 ± 0.01 -2 ± 0.56 
Drug loading 
(mg/100 mg polymer) 
- 1.8 ± 0.3 1.8 ± 0.4 0.5 ± 0.0 
SPIO loading 
(mg/100 mg polymer) 
9 ± 1.5 - 10 ± 1.9 9 ± 0.6 
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Figure 2. TEM micrographs of (A) SPIO, (B) SPIO-NP and (C) SPIO/PTX-NP.  
III.2. MAGNETIC PROPERTIES OF SPIO AND SPIO-NP 
III.2.1. Relaxometry studies 
The relaxivity of SPIO is defined as the efficiency to enhance the relaxation rate of the 
neighboring water protons and is expressed in s-1mM-1. The relaxivities of SPIO are 
summarized in Table 2. Noticeably,	   the	   r2/r1	   ratios	   of	   SPIO	   are	   higher	   than	   those	   of	  Resovist®	   [Allkemper	   et	   al.,	   2002],	   indicating	   that	   SPIO	   could	   be	   considered	   as	   highly	  efficient	  T2	  contrast	  agents. 
The NMRD profiles, which display the evolution of proton longitudinal relaxivity as a 
function of the applied field, illustrates typically superparamagnetic relaxation profiles both 
for SPIO-loaded nanoparticles and SPIO/PTX-loaded nanoparticles (Figure 3). The shape of 
the NMRD profile of superparamagnetic iron oxide nanoparticle suspensions is governed (i) 
by the size, the crystallinity and the magnetization of the magnetic cores, (ii) by the diffusion 
of solvent close to the particle cores, and (iii) by the interaction between superparamagnetic 
cores, as they affect the anisotropy energy [Roch et al., 1999]. Table 3 shows the parameters 
obtained from the theoretical fitting of the NMRD profiles. The specific magnetization (MS), 
the crystal radius (r) and the Néel relaxation time (τN) highlight the superparamagnetism 
properties of SPIO. Interestingly, the presence of PTX into nanoparticles did not change 
significantly the relaxometric properties. 
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Table 2. Longitudinal (r1) and transverse (r2) relaxivities of SPIO-NP, SPIO/PTX-NP and Resovist® at 20 and 
60 MHz in water (37°C). 
NA Not available 
 
Table 3. Parameters obtained from the theoretical fitting of the NMRD profiles. 
 
 
 
 
 
 
Figure 3. 1H NMRD relaxivity profiles of (A) SPIO-loaded nanoparticles and (B) SPIO/PTX-loaded 
nanoparticles.  
 
III.2.2. Phantom MRI 
Various concentrations of SPIO in aqueous solution (SPIO sol) and PLGA-based 
nanoparticles loaded with SPIO (SPIO-NP) ranging from 0 to 30µg/ml (Fe concentrations: 0-
5-10-15-20-25-30µg/ml) were investigated by T2-weighted MRI to assess their T2 enhancing 
capability. Commercial SPIO (BioPAL, Worcester, UK) were used as a reference at the same 
concentrations (Figure 4). This pilot experiment confirmed that the magnetism of the 
	   20	  MHz	  
r1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  r2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  r2/r1	  
(mM-1s-1)      (mM-1s-1)	  
60	  MHz	  
r1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  r2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  r2/r1	  
(mM-1s-1)      (mM-1s-1)	  SPIO-­‐NP	   3.4	   134.4	   39.5	   1.1	   139	   126.4	  SPIO/PTX-­‐	  NP	   3.8	   127	   33.4	   1.3	   137	   105.4	  Resovist®	  [Allkemper	  et	  al.,	  2002]	   25	   119	   4.8	   NA	   NA	   NA	  
 SPIO-NP SPIO/PTX-NP 
Ms (Am2/kg) 14,5 ± 0,1 15,1 ± 0,1 
r (nm) 16,1 ± 0,1 15,9 ± 0,1 
tN (ns) 5,88 ± 0,08 5,78 ± 0,08 
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synthesized SPIO was detectable by MRI either when freely suspended in water (SPIO sol) or 
when encapsulated in PLGA-based nanoparticles (SPIO-NP). For all treatments, the signal 
intensity of MRI decreased as the SPIO concentration increased. It is important to note that 
synthesized SPIO presented similar relaxation rates (R2 = T2-1) profiles than commercialized 
SPIO (BioPAL). Furthermore, as shown on Figure 4A, the transverse relaxation rates (T2-1) of 
all treatments were well fitted by a line within the analyzed range of iron concentration. 
Nevertheless, compared to SPIO sol, SPIO-NP relaxed more slowly indicating that the 
presence of PLGA surrounding SPIO could slightly affect T2 enhancing capability.  
 
Figure 4: (A) T2 relaxation rate of commercial SPIO (BioPAL, Worcester, UK), an aqueous suspension 
hydrophilic SPIO (SPIO sol) and SPIO loaded nanoparticles (SPIO NP) as a function of Fe concentration 
(µg/ml) (B) T2-weighted MR images as a function of Fe concentration (µg/ml, TE=30msec). 
 
III.3. IN VITRO CELLULAR UPTAKE 
To assess the uptake of SPIO/DOX-NP, fluorescent NP were used. Fluorescein isothiocyanate 
(FITC) was grafted covalently on PLGA to label polymer matrix (green fluorescence). 
Doxorubicin was chosen because of its natural fluorescence (red fluorescence) to follow the 
drug into cells. Nuclei of cells were labeled using DAPI staining (blue fluorescence). Figure 5 
A shows that DOX fluorescence increased with the incubation time of the formulation. 
Moreover, the red and blue fluorescence were co-localized indicating that DOX was able to 
reach the nucleus which is its site of action. FITC-fluorescence indicated that polymeric 
nanoparticles have also been internalized by cells allowing a broad distribution of free DOX 
and SPIO in the cytosol. After 4 h, the blue fluorescence (DAPI) was co-localized with DOX, 
indicating that DOX accumulated in nuclei. The cellular uptake was thus time-dependent, as 
reported previously [Danhier et al., 2009a]. 
Figure 5 B shows the entrapment of SPIO stained in intense blue color into the cells. 
Obviously, there was no blue color appearance in cells of the control group. Conversely, cells 
incubated with SPIO/PTX-NP (Fe concentration = 80µg/ml) were stained in intensive blue 
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color. Consistent with previous publications, blue areas or spots could be seen in almost every 
cell [Ling et al., 2012]. SPIO-loaded PLGA nanoparticles were internalized by cells PLGA 
nanoparticles are mostly internalized through fluid phase pinocytosis and also through 
clathrin-mediated endocytosis [Petros et al., 2010]. 
 
Figure 5. Nanoparticles uptake by CT26 cells. (A) Fluorescence microscopy of CT26 cells (1 x 105) after 1, 2 or 
4 h of incubation with SPIO/DOX-NP followed by DAPI staining (magnification = 40x). (B) Prussian blue 
staining images after 4h of incubation with SPIO/PTX-NP at a Fe concentration of 80µg/ml, treated with 
Prussian blue liquid for 30 min. Black lines correspond to 10µm. 
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III.4. IN VITRO CYTOTOXICITY 
The cytotoxicity of multifunctional nanoparticles was evaluated by the MTT test in CT26 
colon carcinoma cells after 24 h incubation (Figure 6). The range of PTX concentrations (2 to 
20 µg/ml) corresponds to plasma levels of the drug achievable in human [Raymond et al., 
1997]. The range of Fe concentrations (106.8 µg/ml, 53.4 µg/ml and 10.7 µg/ml) corresponds 
to the concentrations present in solution of the different tested concentrations of PTX. An 
aqueous solution containing hydrophilic SPIO was used to test the toxicity of free SPIO 
(without entrapment into nanoparticles; SPIO sol). Consistent with other published data [Ling 
et al., 2011], SPIO (in solution or entrapped into NP) did not present any cytotoxic activity. 
The addition of PTX in formulations induced cell death. Compared with SPIO or SPIO-NP, 
the viability of cells treated with PTX-NP and SPIO/PTX-NP was decreased (p<0.01). This 
PTX cytotoxicity was increased in dose-dependent manner. Hence, PTX anti-tumor efficacy 
was maintained while encapsulated in PLGA-based nanoparticles in presence or in absence of 
SPIO. 
 
Figure 6. Viability of CT26 cells incubated with a solution of hydrophilic SPIO (SPIO sol, SPIO concentration 
corresponding to SPIO/PTX-NP formulation: Fe concentration of 106.8 µg/ml, 53.4 µg/ml and 10.7 µg/ml), 
paclitaxel-free nanoparticles (SPIO-NP, same concentrations as above), nanoparticles loaded with paclitaxel  
(PTX-NP, PTX concentrations 2, 10 and 20 µg/ml) and nanoparticles loaded with paclitaxel and SPIO 
(SPIO/PTX-NP). Cell viability was determined by the MTT assay. Untreated cells were taken as a negative 
control and Triton X-100 1% was used as a positive control. The results were expressed as mean values ± 
standard deviation (n=5). **p < 0.01, ***p < 0.001.  
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III.5. IN VIVO ANTI-TUMOR EFFICACY 
The in vivo anti-tumor efficacy of multifunctional nanoparticles was evaluated in CT26-
tumor-bearing mice (Figure 7). In a previous study of our group, paclitaxel-loaded 
nanoparticles were been shown to display a better efficacy compared with Taxol® [Danhier et 
al., 2009a]. Therefore we did not use this control. Consistent with in vitro cytotoxicity data, 
all treatments containing PTX (PTX-NP and SPIO/PTX-NP) induced a higher delay in tumor 
growth than other treatments (Figure 7A). Moreover, SPIO sol and SPIO-NP did not inhibit 
the tumor growth when compared with the PBS control group (Figure 7A). Kaplan-Meier 
survival rate was performed (Figure 7B). PTX-NP and SPIO/PTX-NP exhibited higher 
survival rates than the untreated group (PBS) with median survival rates of 13 and 15 days, 
respectively, compared to 9 days (p<0.05 and p<0.01). No significant difference was 
observed between the two PTX-based treatment (p>0.05). Additionally, SPIO sol and SPIO-
NP presented median survival times of 10.2 and 10 days (p>0.05), which are not statistically 
different than the control PBS group (p>0.05).  
 
 
 
 
Figure 7. (A) Tumor growth curves of CT26-tumor bearing mice treated with free SPIO in aqueous solution 
(SPIO sol), SPIO loaded nanoparticles (SPIO-NP), paclitaxel-loaded nanoparticles (PTX-NP) (PTX dose = 5 
mg/kg), paclitaxel and SPIO co-loaded nanoparticles (SPIO/PTX-NP) (PTX dose = 5 mg/kg) or untreated 
(PBS). The treatment was injected in the tail vein of the mice when tumors reached 27±5mm (n=6/group). 
Results are presented as the average tumor growing ratio ± SEM versus time after treatment injection. (B) 
Survival rates of tumor-bearing mice.  
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IV. CONCLUSIONS 
Based on previous developed PLGA-based nanoparticles for anti-tumor drugs delivery, we 
aimed to extent these nanoparticles as multifunctional entities by co-encapsulation of an anti-
cancer drug (PTX) and contrast agents (SPIO) for both anti-cancer therapy and magnetic 
resonance imaging. We successfully co-encapsulated SPIO and PTX in PLGA-based 
nanoparticles. We demonstrated that these nanoparticles inhibited the growth of CT26 cells. 
PTX/SPIO-loaded nanoparticles could be used as potential tumor-targeting MRI contrast 
agents, thanks to the high uptake of nanoparticles by cells as well as their magnetic 
characteristics. Together these results, these multifunctional nanoparticles may be considered 
as future nanomedicine for simultaneous targeting imaging, drug delivery and real-time 
monitoring of therapeutic response.  
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ABSTRACT 
 
Multifunctional nanoparticles combining therapy and imaging have the potential to improve 
cancer treatment by allowing personalized therapy. Herein, we aimed to compare in vivo 
different strategies in terms of targeting capabilities: (1) passive targeting via the EPR effect, 
(2) active targeting of αvβ3 integrin via RGD grafting, (3) magnetic targeting via a magnet 
placed on the tumor and (4) the combination of the magnetic targeting and the active targeting 
of αvβ3 integrin. For a translational approach, PLGA-based nanoparticles loaded with 
paclitaxel and superparamagnetic iron oxides were used. Electron Spin Resonance 
spectroscopy and Magnetic Resonance Imaging (MRI) were used to both quantify and 
visualize the accumulation of multifunctional nanoparticles into the tumors. We demonstrate 
that compared to untargeted or single targeted nanoparticles, the combination of both active 
strategy and magnetic targeting drastically enhanced (i) nanoparticle accumulation into the 
tumor tissue with a 8–fold increase compared to passive targeting (1.12% and 0.135% of the 
injected dose, respectively), (ii) contrast in MRI (imaging purpose) and (iii) anti-cancer 
efficacy with a median survival time of 22 days compared to 13 for the passive targeting 
(therapeutic purpose). Double targeting of nanoparticles to tumors by different mechanisms 
could be a promising translational approach for the management of therapeutic treatment and 
personalized therapy. 
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I. INTRODUCTION 
Multifunctional nanoparticles combining therapy and imaging have the potential to improve 
cancer treatment by allowing personalized therapy. Based on the advances made in different 
scientific disciplines, such as chemistry, biology, pharmacy, nanotechnology, medicine and 
imaging, many reports have shown that the use of nanotheranostics is one the most promising 
methods, although this is still at an early stage [Ahmed et al., 2012; Lammers et al., 2010; Xie 
et al., 2010].  
Theranostic refers to the combination of a therapeutic and a diagnostic agent in a same unique 
vector. This term is commonly used to describe multifunctional system combining therapeutic 
and imaging abilities [Lammers et al., 2010].	  Such a tool could be helpful in non-invasive 
assessment of the biodistribution, visualization of drug distribution, optimization of strategies, 
prediction and real-time monitoring of therapeutic responses [Janib et al., 2010; Lammers et 
al., 2010].  
Additionally, nanotheranostics can be used for preselecting patients, seeming to hold 
significant potential for personalizing nanomedicine (chemo-) therapeutic interventions. 
Theranostics strategies range from set-ups in which patients are pre-selected on the basis of 
initial target site accumulation studies. It is important to note that theranostics take their place 
in its broadest sense. Many publications claim that theranostics can be used for the 
simultaneous diagnosis and treatment. The diagnosis purpose of theranostics should not refer 
to the identification, the localization and/or the staging of tumors but to the pre-selection of 
patients, to the prediction of potential therapeutic responses, and/or to the longitudinal 
monitoring of treatment efficacy [Rizzo et al., 2013]. The first step toward personalized 
nanomedicine treatment is to pre-select patients on the basis of non-invasive imaging insights 
on target site accumulation. A second personalization step consists in the non-invasive 
monitoring of the response of the first cycles of treatment. During this monitoring, the 
treatment should be adapted, if necessary [Rizzo et al., 2013]. 
 
Different tumoral targeting strategies have been described in the literature. However, in vivo 
quantification of the accumulation of theranostic nanoparticles targeting tumors by different 
strategies has not been yet studied [Danhier et al., 2010; Danhier et al., 2012b]. Hence, we 
evaluated in vivo in parallel three tumoral targeting strategies.  
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Passive targeting is based on the so-called enhanced permeability and retention (EPR) effect 
[Maeda et al., 2000]. This strategy relies on the presence of fenestrations in the endothelium 
of tumor vessels. These fenestrations allow the entry of macromolecules or nanoparticle into 
the tumor tissue (enhanced permeability effect). Moreover, the deficiency of the lymphatic 
system in tumor tissue prevents the recapture of these macromolecules leading to a retention 
effect [Danhier et al., 2010; Maeda et al., 2000; Taurin et al., 2012].  
Active targeting consists in coupling a ligand to the surface of nanoparticles that can interact 
with its receptor at the target cell site [Danhier et al., 2012b; Danhier et al., 2009b]. Although 
angiogenesis is a physiological process by which new blood vessels are formed, it is also at 
the root of tumor growth and metastasis. Since angiogenesis is controlled by the endothelial 
cells, it is of great interest to target tumor endothelial cells. αvβ3 is an adhesion integrin 
overexpressed at the surface of the endothelial cells of neo-angiogenic vessels involved in the 
angiogenic process. Its expression is correlated with the malignancy of tumor. Moreover, αvβ3 
is also overexpressed at the surface of many tumor cells. Therefore, many efforts have been 
made by researchers to specifically target this integrin in order to make the most of this 
“double sword” [Danhier et al., 2009b; Liu et al., 2013]. Numerous studies have shown that 
the tripeptide arginine–glycine–aspartic acid (RGD) was able to bind preferentially to 
particular αvβ3integrin [Danhier et al., 2009b; Garanger et al., 2006; Murphy et al., 2008; Son 
et al., 2013]. 
More recently, magnetic drug targeting has been studied. In this approach, magnetic 
nanoparticles are guided to tumor site using magnetic fields [Arias et al., 2011; Cole et al., 
2011].  
 
Many groups have demonstrated differential levels of tumor growth between tumors treated 
by targeted or untargeted drug-loaded nanoparticles. However, only few have shown in vivo 
efficacy in both therapeutic and diagnostic approach. We hypothesized that the combination 
of both active strategy and magnetic targeting could enhance multifunctional nanoparticles 
concentration into the tumor tissue leading, therefore, to a better anti-cancer efficacy 
(therapeutic purpose) and increased contrast enhancement in MRI (diagnosis purpose). Our 
main objective was to directly evaluate different targeting strategies in vivo using two 
complementary techniques: (1) the Electron Spin Resonance (ESR) spectroscopy, a very 
sensitive quantification tool [Danhier et al., 2012a; Radermacher et al., 2009] and (2) the 11.7 
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T Magnetic Resonance Imaging (MRI), a quantification and an imaging tool [Radermacher et 
al., 2012]. 
The present study relies on previously developed and described nanoparticles [Schleich et al., 
2013]. These dual paclitaxel/superparamagnetic iron oxide-loaded PEGylated PLGA-based 
nanoparticles showed strong magnetic properties, and in vivo anti-tumor efficacy. In a view of 
a translational approach, poly(lactide-co-glycolide)(PLGA) was chosen for its 
biodegradability properties, its biocompatibility and its approval in parenteral products by the 
FDA.  
Hence, different strategies have been compared in terms of targeting capabilities: (1) passive 
targeting via the EPR effect, (2) active targeting of αvβ3 integrin via RGD grafting, (3) 
magnetic targeting via a magnet placed on the tumor and (4) the combination of the magnetic 
targeting and the active targeting of αvβ3 integrin (Figure 1). 
 
Figure 1. Schematic representation of the different tumor targeting strategies compared in the present 
study. (1) passive targeting via the EPR effect (PT), (2) active targeting of αvβ3 integrin via RGD grafting 
(RGD), (3) magnetic targeting via a magnet of 1.1 T placed on the tumor (MT) and (4) the combination of the 
magnetic targeting and the active targeting of αvβ3 integrin (RGD+MT). 
 
We aimed at comparing different targeting strategies for multifunctional nanoparticles in 
terms of anti-cancer efficacy, biodistribution, and MRI contrast agent efficiency. The most 
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effective targeting strategy was obtained by the use of a combination of active strategy using 
RGD-grafted nanoparticles and magnetic targeting.  
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II. MATERIAL AND METHODS 
II.1. NANOPARTICLES FORMULATION 
Superparamagnetic iron oxides (SPIO) coated with oleic acid were synthetized by a co-
precipitation technique of ferrous and ferric salts in alkaline medium as previously described 
[Schleich et al., 2013]. All nanoparticles formulations were prepared by an emulsion-
diffusion-evaporation method [Danhier et al., 2010; Garinot et al., 2007; Schleich et al., 
2013]. Briefly, PLGA (Sigma Aldrich, 28 mg/ml), PLGA-PEG (6 mg/ml) and PCL-PEG (6 
mg/ml), synthesized as previously described [Danhier et al., 2009b; Garinot et al., 2007], 
were dissolved in 2 ml dichloromethane containing SPIO (30 mg/ml) and paclitaxel (PTX) 
(Chemieliva) (1.5 mg/ml) [Schleich et al., 2013]. This organic solution was then added to an 
aqueous solution (4.5 ml) containing 3 % (p/v) PVA and emulsified using a vortex for 2 min 
followed by sonication (2 x 30 s, 50 W). The mixture was then added dropwise and under 
magnetic stirring into an aqueous solution containing 1 % PVA and stirred overnight to 
evaporate the organic solvent. To remove the non-encapsulated drug and oleic acid-coated 
SPIO, the suspension was filtered (1,2 µm) and washed three times with water using 
ultracentrifugation (11 000 g, 30 min, 4°C) and suspended in 2 ml water. Two different types 
of nanoparticles were prepared:  
(1) SPIO/PTX-loaded nanoparticles (SPIO/PTX-NP) 
(2) SPIO/PTX-loaded nanoparticles grafted with the RGD peptide on their surface 
(SPIO/PTX-NP RGD) 
For the latest formulation, we used exactly the same method while PCL-PEG was replaced by 
PCL-PEG-RGD that was synthetized by photografting as previously described [Pourcelle et 
al., 2009]. 
II.2. PHYSICO-CHEMICAL CHARACTERIZATION 
The hydrodynamic particle size and size polydispersity of nanoparticles was assessed using a 
dynamic light scattering method (Nano ZS, Malvern instruments, UK).  
The Zeta (ζ) potential of the nanoparticles was measured in KCl 1 mM with a Malvern Nano 
ZS at 25 °C. 
Iron content was measured by Electron Spin Resonance (ESR) using a Bruker EMX ESR 
spectrometer operating at 9 GHz (BrukerBiospinGmBh) validated by inductively coupled 
plasma mass spectroscopy (ICP-MS) measurements (Agilent 7500ce instrument) [Danhier et 
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al., 2009a]. Typical parameters were selected for ESR measurements: 3 mT modulation 
amplitude, 10.11mW power, 325.1 mT center field, and 400 mT sweep width field. Double 
integration of the iron oxides ESR spectra was used to quantify signal intensity.  
PTX content was determined using high-performance liquid chromatography (HPLC) with 
UV detection at 227 nm (Agilent 1100 series, Agilent Technologies), as previously described 
after dissolution of the particles by acetonitrile [Danhier et al., 2009a]. The mobile phase 
consisted of acetonitrile and water (70:30 v/v, respectively) at a rate of 1ml/min. The column 
used was a CC 125/4 Nucleod UR 100-5 C18.The drug loading was defined as the amount of 
drug (mg) loaded for 100 mg of polymer whereas the encapsulation efficiency was defined by 
the ratio of the encapsulated drug compared to the initial amount of drug [Danhier et al., 
2010; Schleich et al., 2013]. 
Saturation magnetisation values were obtained from the fitting by a theoretical relaxation 
model of Nuclear Magnetic Relaxation Dispersion (NMRD) profiles recorded at 37°C on a 
Fast Field Cycling Relaxometer (Stelar, Mede, Italy) over a magnetic field range from 0.01-
40 MHz. The proton NMRD curves were fitted using data-processing software, including 
different theorical models describing the nuclear relaxation phenomena [Danhier et al., 2010; 
Schleich et al., 2013]. 
II.3. ANIMAL MODELS 
All experiments were performed in compliance with guidelines set by national regulations 
and were approved by the ethical committee for animal care of the medical sector of the 
Université catholique de Louvain. CT26 colon carcinoma was chosen because of its 
sensitivity to PTX [Yang et al., 2012] and of its angiogenic properties [Lyons et al., 2007]. 
CT26 colon carcinoma cells were inoculated subcutaneously in the right flank or in the right 
leg (to avoid respiratory artifacts in MRI studies) of BALB/c mice (5x104 cells per mouse) 
depending on the experiment. For all the experiments, mice were divided into 5 groups:   
Group 1: control group (injected with PBS for in vivo anti-tumor efficacy study and 
histological study and SPIO-loaded nanoparticles for ex vivo biodistribution and MRI, 
Group 2: mice treated by SPIO/PTX-NP (passive targeting, PT),  
Group 3: mice treated by SPIO/PTX-NP grafted with RGD peptide (active targeting or 
RGD), Group 4: mice treated with SPIO/PTX-NP magnetic guided by placing a 1.1 T 
neodyme-iron-bore external magnet (Webcraft GmbH) on the surface of the tumor during 1 or 
4 h (magnetic targeting or MT), 
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Group 5: mice treated with SPIO/PTX-NP using both magnetic and active targeting 
(RGD+MT).  
For magnetic targeting, the magnet was placed directly in contact of the tumor surface and 
fixed by a bandage. The bandage was fixed as the space between the magnet and the skin 
would not be exceeding 0.3 cm. The exposure time varies from 1h (ESR spectroscopy) to 4h 
(in vivo anti-tumor efficacy, ESR spectroscopy and MRI experiments as well as histological 
studies).  
PTX and Fe doses were 5 mg/kg and 27.1 mg/kg, respectively, for in vivo anti-tumor efficacy 
experiment and 2.5 mg/kg and 13.5 mg/kg for other experiments. For tumor inoculation, mice 
were anesthetized by intra-peritoneal injections of a mixed ketamine (100 mg/kg) and 
xylazine (10 mg/kg). For in vivo MRI experiments, mice were maintained under anesthesia 
during the entire experiment using 1-2 % isoflurane (Abbott) inhalation in air. 
II.4. IN VIVO ANTI-TUMOR EFFICACY 
The effect of SPIO/PTX-NP on tumor growth was assessed by daily measurements of tumor 
volume with an electronic caliper. CT26 cells were injected subcutaneously in the right flank 
of the mice to allow easy and reproducible tumor volume measurements. Mice were randomly 
assigned to a treatment group when tumor reached a volume of 27 ± 5 mm³. Treatments were 
injected trough the tail vein. Five groups were defined as aforementioned (n=6):  PBS, PT, 
RGD, MT and RGD+MT. In this experiment, the magnet was placed on the surface of the 
tumor during 4 h. The end point of the experiment was determined as the moment when 
tumor reached 600 mm³. At this point, mice were sacrificed.  
II.5. EX VIVO BIODISTRIBUTION STUDY BY ESR SPECTROSCOPY 
The biodistribution of the different treatments was assessed using ESR spectroscopy (X-
band). CT26 cells were subcutaneously inoculated in the right flank of the mice. When tumor 
reached 50-100 mm3 in volume, mice were randomly dispersed into 5 groups as 
aforementioned (n=6):  CTRL, PT, RGD, MT and RGD+MT. The control group was a group 
injected with SPIO-loaded nanoparticles. For mice treated with magnetic targeting, the 
external magnet was maintained on the tumor until sacrifice. Treatments were injected in the 
tail vein of the mouse. 1 or 4 h post-treatment, mice were first taken a retro-orbital blood 
sample and were then sacrificed for dissection in order to remove liver, lungs and tumor. 
Thereafter, samples were frozen in liquid nitrogen, dehydrated for 24 h in a freeze-dryer 
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(Labconco), crushed into a fine powder, weighed and analyzed by ESR spectroscopy to 
determine iron concentration in each tissue. 
II.6. IN VIVO MR IMAGING 
For these experiments, CT26 cells were injected subcutaneously in the right leg of the mice to 
avoid respiratory artifacts. Mice were enrolled in the study when tumor reached 50-100 mm3 
in diameter. The same amount of SPIO/PTX-NP or SPIO/PTX-NP-RGD were injected, and 
the same groups were defined (n=5): PT, RGD, MT and RGD + MT. Each mouse was imaged 
before and 1 h after treatment injection in the tail vein in order to use each mouse as its own 
control.  
MR experiments were performed using a 11.7 T Bruker Biospec horizontal MR System 
(Bruker Biospin). RF transmission and reception were achieved with a quadrature volume 
resonator (inner diameter 40 mm). At first, mice were anesthetized by isoflurane inhalation 3 
% in air and they were placed in an MRI compatible cradle. The breathing rate was assessed 
via a breathing pillow, placed under the thorax, and kept at 70 breaths/minute by adjusting the 
isoflurane concentration. The body temperature was maintained at 37°C by a warm waterbed 
and monitored using a rectal probe. Vital functions were monitored during the whole 
anesthesia period using SamPC Monitor (version 6.17, Small Animal Instruments Inc). 
Anatomical images of the mice were provided by T2-weighted axial images acquired with a 
Rapid Acquisition with Relaxation Enhancement sequence (RARE; TR/TE: 2500/30 ms, 
RARE factor: 6, 10 slices non-contiguous with a gap of 0.08 mm, resolution: 125 x 125 x 800 
µm³). T2 maps were acquired with the same geometry than the anatomical images using a 
Multi Slice Multi Echo sequence (MSME; TR/TE: 2500/10 ms; 16 echoes). Quantitative T2 
maps were calculated from the MSME multi-echo trains and assuming mono-exponential 
decays, using ImageJ (ImageJ version, 1.48 NIH). The volume of interest (VOI) 
corresponding to the tumor volume were manually delineated on a slice by slice basis on the 
anatomical images acquired before and after treatment injection, for each animal. These VOIs 
were applied on corresponding maps to determine the T2 values. Relative standard deviations 
(RSD) were calculated as RSD = SD/mean T2, where SD is the standard deviation of the mean 
T2 value [Oakes et al., 2014]. 
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II.7. HISTOLOGICAL STUDY OF TUMOR TISSUES 
The accumulation of multifunctional nanoparticles in tumor tissue was visualized by 
histological analysis of tumor tissue after Prussian’s blue staining. After MR imaging, mice 
were sacrificed and tumor tissues were surgically removed and fixed in 4% paraformaldehyde 
and imbedded in paraffin. Representative 5 µm tumor cross-sections were cut and mounted on 
glass slides. Thereafter sections were placed in a bath containing 5% Potassium 
hexacyanoferrate (II) trihydrate (Sigma Aldrich) and 5% HCl in distilled water for 30 min at 
room temperature and protected from light. Tumor sections were counterstained with a 0.1% 
nuclear fast red aqueous solution (Sigma Aldrich) containing 5% aluminum sulfate for 5 min.  
II.8. STATISTICAL ANALYSIS 
All results arising from in vivo antitumor efficacy and ex vivo biodistribution are expressed as 
mean ± SEM. Two-way ANOVA, Bonferroni post-test, Kaplan-Meier survival rate and t-test 
were performed using the software GraphPad Prism 5 for Windows, to demonstrate statistical 
differences (p<0,05). MRI results were expressed as mean RSD ± SD. One-way ANOVA and  
Bonferroni post-test were performed using the software GraphPad Prism 5 for Windows, to 
demonstrate statistical differences (p<0,05). 
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III. RESULTS 
III.1. PHYSICO-CHEMICAL CHARACTERIZATION 
Physico-chemical features of the nanoparticles are summarized in Table 1. Nanoparticles co-
loaded with SPIO and PTX presented a similar size of about 240 nm when grafted with RGD 
or not. They all presented a neutral ζ potential and drug encapsulation efficiency 
approximately 25%. This corresponds to a paclitaxel-loading of around 1.8 mg/100 mg of 
polymer. SPIO-loading was about 10 mg/100 mg of polymer. Moreover, they all presented a 
saturation magnetization around 15 Am2/kg.  In a previous study, we evaluated the drug 
release from nanoparticles [Danhier et al., 2009b]. Briefly, after the initial burst release for 
about 4 h (50%), the release rate of PTX slowed down and became an almost zero-order rate 
of release (75% released in 11 days) 
 
Table 1: Physico-chemical properties of nanoparticles. Size, ζ potential, drug encapsulation efficiency, drug 
loading, SPIO loading and saturation magnetization (Msat) of SPIO-loaded nanoparticles (SPIO-NP), paclitaxel-
loaded nanoparticles (PTX-NP), co-loaded SPIO/paclitaxel nanoparticles (SPIO/PTX-NP) and co-loaded 
SPIO/paclitaxel nanoparticles grafted with RGD (n=5).  
 
 
III.2. IN VIVO ANTI-TUMOR EFFICACY 
The in vivo anti-tumor efficacy of the different targeting strategies was evaluated in CT26-
tumor-bearing mice (Figure 2). All PTX-loaded nanoparticles induced a higher delay in tumor 
growth than the control group (PBS) (Figure 2A). Moreover, all the groups treated with an 
active targeting (RGD, MT and RGD + MT) induced a higher delay compared with PT 
(Figure 2A). Kaplan-Meier survival rate was performed (Figure 2B). PT exhibited higher 
survival rate than the untreated group (PBS) with median survival rate of 13 compared to 10 
 SPIO-NP SPIO/PTX-NP SPIO/PTX-NP 
RGD 
Size (nm) 235.8 ± 8.9 243 ± 9.9 245 ± 1.2 
Ζeta ζ  potential (mV) -0.16 ± 0.04 -0.02 ± 0.01 -0.42 ± 0.6 
Drug encapsulation efficiency 
(%) 
/ 24.8 ± 4.9 25.2 ± 2.8 
PTX loading  
(mg/100 mg of polymer) 
/ 1.84 ± 0.4 1.85 ± 0.2 
SPIO-loading  
(mg/100mg of polymer) 
9.0 ± 1.5 10.4 ± 1.9 10.1 ± 0.6 
Msat (Am2/kg or emu/g) 14,5 ± 0,1 15,1 ± 0,1 14,1 ± 0,1 
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days (p<0.01). No significant difference was observed between RGD and MT with median 
survival times of 14.7 and 15 days (p>0.05), which are statistically different from the PBS 
group (p<0.01) and from the PT group (p<0.01). Moreover, one long-term survival mouse was 
found in the RGD group. Finally, mice treated with the combination of active and magnetic 
targeting (RGD + MT) exhibited the highest survival rate with a median survival time of 21.5 
days (p<0.05). In this group, there were two long-term survival mice. The benefits of the 
combination of RGD+MT are illustrated in Figure 2C. The time to reach a tumor-growing 
ratio of 13 (endpoint of the PBS group) was prolonged by both RGD and MT treatments 
compared to the control group (11.7, 12.1, respectively compared to 8.6; p<0.001 and 
p<0.0001, respectively). Mice treated with RGD-grafted nanoparticles and magnetically 
targeted nanoparticles (MT) showed an equivalent time to reach a tumor-growing ratio of 13 
(p>0.05). The time to reach a tumor-growing ratio of 13 was enhanced when mice were 
treated with RGD-grafted nanoparticles combined with the magnetic targeting (RGD+MT) 
when compared to MT or RGD alone (14.8 days versus 12.1 and 11.7 days, respectively; 
p<0.01and p<0.05).  
 
Figure 2. Tumoral growing ratio and survival rates of CT26-tumor bearing mice. (A) Tumor growth curves 
of CT26-tumor bearing mice treated with co-loaded SPIO/PTX nanoparticles (PT) (PTX dose = 5 mg/kg), 
SPIO/PTX-NP grafted with RGD-peptide (RGD), SPIO/PTX-NP followed by 4 hours of magnetic targeting 
(MT) and SPIO/PTX-NP RGD followed by 4 hours of magnetic targeting (RGD + MT) or untreated (PBS). The 
treatment was injected in the tail vein of the mice when tumors reached 27±5 mm (n=6). Results are presented as 
the average tumor growing ratio ± SEM versus time after treatment injection.  
(B) Survival rates of tumor-bearing. Mean survival times (MST) in days were calculated for each group. (C) 
Comparison of time for tumor to reach a growing ratio of 13 (in days). 
* p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
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III.3. BIODISTRIBUTION USING ESR SPECTROSCOPY 
Biodistribution studies of SPIO/PTX-loaded NP are illustrated in Figure 3. Iron accumulation 
in blood, tumor tissue, liver and lungs was measured using ESR spectroscopy. Blood samples 
did not show any statistical differences in terms of iron concentration with a mean 
concentration around 2 ng/mg of blood for all groups (data not shown). Concerning the iron 
accumulation in tumor tissues (Figure 3A), no significant difference was observed between 1 
h and 4 h after injection even when using magnetic targeting. Mice treated with RGD showed 
a 2.5-fold accumulation increase in tumor tissue compared to the group treated with PT with 
0.35 % of the injected dose and 0.135 %, respectively (p<0.05). This accumulation rose to 5-
fold in MT (0.737%, p<0.001). The highest iron concentration was obtained in mice treated 
with the combination of RGD+MT with a 8–fold increase in iron accumulation (1.12 % of the 
injected dose). The iron uptake by the liver (Figure 3B) was dominant for all treatment groups 
with iron concentration rising up to 35 % of the injected dose. However, after 4 h of MT, this 
iron uptake was drastically reduced to 11.29 % of the injected dose (p<0.001). Interestingly, 
RGD-, MT- and RGD+MT-treated group showed a highly significant decrease of the iron 
accumulation in lungs compared to control and PT-treated groups with 0.52 %, 0.43 % and 
0.47 % of the injected dose for RGD-, MT- and RGD+MT-treated group, respectively 
compared to 1.31 % and 1.21 % of the injected dose for control and PT-treated group after 1h 
(p<0.001, Figure 3C). 
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Figure 3. Biodistribution of multifunctional nanoparticles. Biodistribution of multifunctional nanoparticles 
using ESR spectroscopy, 1 or 4 hours after injection of the treatment. 5 groups were defined: SPIO-loaded 
nanoparticles (CTRL), PT, RGD, MT and RGD + MT. (A) Iron accumulation in tumor tissue in ng/mg of tissue 
(n=5). (B) Iron accumulation in liver (n=5). (C) Iron accumulation in lungs (n=5). 
*p<0.05, ***p<0.001, NS: Not Significant  
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III.4. HISTOLOGICAL ANALYSIS  
Figure 4 shows representative histological sections of tumor tissues stained with Prussian’s 
blue to label the SPIO nanoparticles. Blue spots indicating the presence of SPIO are pointed 
out by white arrows. As seen in Figure 4A, no blue coloration was observed in untreated 
tumor tissue. Only a few blue spots were observed in tumor treated with PT (Figure 4B). 
There were more blue spots in tissues of mice treated by RGD (Figure 4C). These blue spots 
were even more numerous in tumor tissue when using MT (Figure 4D). Nevertheless, the 
most colored sections were obtained for mice of the RGD+MT group (Figure 4E). 
 
 
Figure 4. Histological study of tumor tissue using Prussian’s blue staining. A: CTRL, B: SPIO/PTX-NP 
treated mouse, C: SPIO/PTX-NP RGD treated mouse, D: SPIO/PTX-NP treated group with magnetic targeting. 
E: SPIO/PTX-NP RGD treated group with magnetic targeting. 
III.5. IN VIVO MRI  
To detect the contrast enhancement provided by the injection of the different treatments, MR 
imaging of mice were performed before and 4 h after injection. T2-weighted images, obtained 
with different TE from MSME sequence, showed very low signal intensity in the areas 
characterized by the presence of SPIO (Figure 5, red arrows). For this reason, the T2 value 
corresponding to these areas could not be determined. To estimate the local disturbance 
induced by SPIO in MRI, RSD of T2 is commonly used [Oakes et al., 2014]. Injection of the 
passive targeted nanoparticles (PT) induced no visible darkening of the tumor region (Figure 
5A). No significant change in RSD was observed (p>0.05) (Figure 6). Mice treated with 
actively targeted nanoparticles (RGD) showed a slight darkening of the tumor region with a 
few darker spots located into the tumor tissue pointed out by narrow-head (Figure 5B). This 
effect was reflected by a 3-times increase tendency in RSD after injection (p>0.05) (Figure 6). 
As for mice treated with magnetic targeted treatment (MT), many dark spots were clearly 
found in the tumor region (Figure 5C) inducing a 30–fold increase in RSD after injection 
(p<0.001) (Figure 6). The combination of magnetic targeting and active targeting induced 
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also a high darkening contrast (Figure 5D) translated into a 40–fold increase in RSD after 
injection (p<0.001) (Figure 6). The difference between MT and RGD+MT was not significant 
(p>0.05) but a tendency of a larger increase in RSD was observed for RGD+MT (3.4 ± 0.42 
vs 4.4 ± 0.67, for MT and RGD+MT, respectively). 
 
 
Figure 5. MRI imaging. T2-weighted images, obtained from MSME sequence (TE = 10 ms) of CT26-tumor 
bearing mice pre-injection and 4 h after injection. The position of dark region in tumor was pointed by red head-
narrows (n=5). A: PT, B: RGD, C: MT, D: RGD+MT. 
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Figure 6. MRI quantification. Mean RSD (Relative Standard Deviation) calculation of the tumor region pre- 
and 4 h after injection of PT, RGD, MT and RGD+MT (results expressed as mean ± SD, n=5). 
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IV. DISCUSSION 
A major challenge to address in cancer therapy lies in improving the amount of drug reaching 
the tumor to have an efficient treatment while limiting the damages to healthy tissues. 
Therefore, different targeting strategies have been developed [Danhier et al., 2010; Kwon et 
al., 2012]. In this study, we compared four targeting strategies of multifunctional 
nanoparticles loaded with an anti-cancer drug and a imaging agent in terms of anti-tumor 
efficacy, biodistribution and magnetic resonance imaging capabilities: passive targeting (PT), 
active αvβ3 targeting (RGD), magnetic targeting (MT) and the combination of the two latest 
(RGD+MT). The current multifunctional nanoparticles incorporated SPIO for their diagnostic 
and superparamagnetic properties and PTX for its therapeutic properties. 
All experiments (PTX anti-cancer efficacy, biodistribution, MRI and histological studies) 
were consistent with each other indicating that active targeting (RGD) was more effective 
than passive targeting (PT). Magnetic targeting (MT) showed a better efficacy compared to 
active targeting (RGD) in biodistribution, MRI and histological studies. PTX anti-cancer 
efficacy, biodistribution and histological studies confirmed that the most effective targeting 
was obtained using a double targeting (RGD+MT).  
 
Magnetic resonance imaging (MRI) is a clinical widely used non-invasive imaging technique, 
presenting a high spatial resolution, which is suitable for cancer detection and therapeutic 
response assessment [Brindle, 2008; Liu et al., 2013]. However, its major limitation consists 
of a relatively low sensitivity. Superparamagnetic iron oxides (SPIO) as MRI contrast agent 
address this limitation. SPIO can produce predominant T2 relaxation effect, resulting in a 
signal reduction on T2-weighted images. The magnetic field heterogeneity around the 
particles, through which water molecules diffuse, induces the dephasing of the proton 
magnetic moments. Consequently, a T2 effective transverse relaxation is shortened. Moreover, 
with their high magnetic properties, SPIO are among the most suitable candidate to achieve 
magnetic targeting abilities by using an external magnet [Laurent et al., 2011]. However, 
when SPIO concentration is very high, a fitting deficiency can occur and lead to difficulties in 
measuring T2 values. Indeed, high concentration of SPIO in the tumor produced a too fast 
decrease of the T2 value resulting in a non-exponential relationship. Thus, it was impossible 
to measure a proper T2 value at these sites. Therefore, we measured a relative standard 
deviation of these T2 values in the ROI. RSD is a measure of tumor heterogeneity after the 
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SPIO injection. This method is commonly used in MRI when T2 signal is too heterogeneous 
[Mitra et al., 2004].	  	  
 
Recently, numerous publications have reported various polymer-based nanocarriers (PLGA, 
PLLA, HPMA, PCL, etc.) for magnetic-imaging [Hamoudeh et al., 2007; Lin et al., 2012; 
Ling et al., 2011; Talelli et al., 2009]. These SPIO-loaded nanocarriers are generally limited 
because of (i) their lack of functional groups on their surface for covalent modification, (ii) 
their low capacity of drug loading and (iii) the fact that the use of most of polymers used are 
not approved by the FDA/EMA, limiting their potential translation to the clinic [Schleich et 
al., 2013]. So far, many researchers have shown the interest of an active targeting [Danhier et 
al., 2009b; Lin et al., 2012; Zhang et al., 2012] or of the magnetic targeting [Arias et al., 
2011; Yang et al., 2012]. However, only few have shown in vivo efficacy in both therapeutic 
and imaging approach. 
 
In vivo anti-tumor efficacy study showed a significant longer regrowth delay with a longer 
survival time for mice treated with actively-targeted nanoparticles (RGD) compared to the 
passively-targeted nanoparticles. This result is consistent with our previous study [Danhier et 
al., 2009b]. The potential advantage of targeted delivery may result from an altered 
intracellular distribution. Both targeted and non-targeted systems arrive at the tumor site via 
the EPR effect, after which the mechanism of tumor cell internalization is enhanced by the 
presence of surface ligands via a receptor-mediated endocytosis [Prokop et al., 2008; Wang et 
al., 2010]. On the contrary, non-targeted nanoparticles mainly enter into the cells via 
pinocytosis [Melancon et al., 2012; Petros et al., 2010; Stromhaug et al., 1997]. Furthermore, 
this better anti-tumor efficacy can be easily explained by the increased accumulation in tumor 
tissue. Indeed, ex-vivo biodistribution, histological studies and MRI confirmed the iron 
concentration increase in tumor tissue suggesting a better accumulation of nanoparticles. 
However, despite this better accumulation in tumor tissue, a major issue that remains to be 
solved is the massive uptake by the liver. This phenomenon is well known and described in 
the literature [Bertrand et al., 2012]. Zhang et al. reported an accumulation of RGD-grafted 
magnetite PLGA-based nanoclusters of 35% of the injected dose in the liver [Zhang et al., 
2012]. For this reason, SPIO-loaded nanoparticles are usually used as contrast agent for liver 
imaging [Lu et al., 2009].  
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Magnetic targeting showed a better nanoparticles accumulation in tumor compared to active 
targeting in ex-vivo biodistribution, histological study and MRI. As expected, this better 
accumulation was correlated with a longer survival time and a longer regrowth delay 
compared to the passively-targeted group. Lübbe et al. were the pioneers in using an external 
magnetic field to guide a treatment [Lubbe et al., 1996]. Later, numerous studies used this 
method with magnetic field strength ranging from 0.4 to 4 T [Alexiou et al., 2000; Arias et 
al., 2011; Chertok et al., 2008; Kim et al., 2009]. The success of magnetic targeting is limited 
by inadequate magnetic gradients, thus, by the distance between the magnets and the target 
site. The magnetic targeting would be more effective in regions closer to the magnets. In this 
experiment, a 1.1 T neodyme permanent magnet was used to create an external magnetic field 
to accumulate the treatment in the tumor. For superficial tumors, this strategy can be easily 
done by placing the permanent magnet outside of the body at the surface of the tumor 
[Alexiou et al., 2000; Arias et al., 2011; Lubbe et al., 1996].  
The most impressive results were undoubtedly obtained with the combination of both active 
and magnetic strategies. Indeed, the double targeting-treated group of mice showed the most 
important regrowth delay compared to all the other groups. Moreover, two mice were long-
time survivor in the RGD+MT-treated group. Unsurprisingly, this better anti-cancer efficacy 
was correlated with a higher nanoparticles accumulation in tumor (shown by both ESR 
spectroscopy and histological studies). The lack of difference in the T2 RSD of MT and RGD 
+ MT could be due to the very fast decrease in the T2 value obtained in both groups leading to 
the fitting deficiency as aforementioned. Moreover, MRI is less sensitive compared to ESR 
spectroscopy [Danhier et al., 2014] Furthermore, using such a combination could be useful to 
potentialize the effect of the active targeting. Indeed, since active targeting is a saturable 
process [Kranenborg et al., 1998] and sometimes lacks of selectivity, it becomes more and 
more interesting to combine several targeting strategies [Al-Jamal, 2013].  
 
These results confirmed our hypothesis. Indeed, there was a rationale to think that two 
targeting strategies would show better results compared to a simple strategy. Many groups 
have studied a double targeting strategy for a delivery purpose. Recently, Fang et al., used a 
combination of MT and lactoferrin [Fang et al., 2014]. Yang et al., have studied a double 
RGD and NGR targeting [Yang et al., 2014]. However, to our knowledge, this is the first 
study having investigated the combination of both αvβ3 integrin-targeting and magnetic 
targeting for a theranostic purpose. RGD targeting is a very promising strategy since it can 
target both neoangiogenic endothelial cells and tumors cells. Moreover, αvβ3 plays an 
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important role in angiogenesis [Desgrosellier et al., 2010]. Finally, in our previous study, we 
demonstrated the efficacy of targeting to tumor endothelium of RGD-grafted nanoparticles 
and their better anti-tumor efficacy [Danhier et al., 2012b]. 
 
Solid tumors are known to be highly heterogeneous either depending on the cancer type, 
patient or even on the disease stage (inter-tumor heterogeneity). Moreover, different cell types 
can be found inside a solid tumor (intra-tumor heterogeneity). Furthermore, in response to any 
given therapy, solid tumors inevitably evolve, leading to strong difficulties in managing 
cancer therapy. Therefore, there is a critical need in developing personalized therapy [Blanco 
et al., 2009; Guthi et al., 2010]. The combination of imaging and therapeutic capabilities in a 
same vector could provide a useful tool in addressing this challenge. Indeed, such theranostic 
platforms allow the molecular diagnosis by imaging to verify the expression of cancer 
biomarker to guide target-specific therapy. Furthermore, it enables to assess the efficacy of 
the treatment at different stages of the therapy then using those results to intelligently modify 
the strategy for cancer treatment (real-time monitoring) [Guthi et al., 2010; Lammers et al., 
2010]. The multifunctional αvβ3-targeted nanoparticles developed in this study showed 
promising results in terms of anti-tumor efficiency and imaging abilities when combined to 
magnetic targeting. Finally, their imaging abilities could be useful to monitor the 
biodistribution of these multifunctional nanoparticles after injection to the patient in a first 
step. Thereafter, on the basis of this non-invasive imaging insight on target site, and possibly 
undesirable liver accumulation it would be possible to evaluate a benefice/risk ratio and, if 
favorable, select the patient for the treatment. This particular application could be of great 
interest to limit the treatment of non-responding patients and patients at high risk of 
undesirable toxicity. 
 
This study also proves that MRI could be predictive of the anti-cancer treatment efficacy. 
This finding could be interesting from the perspective of a translational approach in the 
management of therapeutic treatment and personalized therapy, using these multifunctional 
nanoparticles as theranostics. 
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V. CONCLUSION 
This study is the first to compare in vivo four targeting strategies for multifunctional 
nanoparticles in terms of anti-cancer efficacy, ex-vivo biodistribution, and MRI contrast agent 
efficiency. The most effective targeting strategy for imaging and therapeutic purposes was 
obtained by the use of a combination of active strategy using RGD-grafted nanoparticles and 
magnetic targeting.  
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I. PRINCIPAL FINDINGS OF THE STUDIES 
The main objectives of this thesis were (i) to develop PLGA-based nanoparticles as 
multifunctional entities by co-encapsulation of an anti-cancer drug (PTX) and a contrast agent 
(SPIO) for both anti-cancer therapy and magnetic resonance imaging; (ii) to compare four 
targeting strategies of these multifunctional nanoparticles in terms of anti-tumor efficacy, 
biodistribution and MRI contrast enhancement. The four targeting strategies were passive 
targeting (PT), active αvβ3 integrin targeting by grafting RGD (RGD), magnetic targeting 
(MT) and the combination of the two latest (RGD+MT).  
 
In this thesis we prepared and characterized multifunctionnal PLGA-based nanoparticles 
loaded with SPIO along with an anti-cancer drug (PTX or DOX).  One part of these particles 
was grafted with RGD to allow active targeting. Table 1 summarizes the major physico-
chemical characteristics of the developed nanoparticles as well as the efficacy of the targeting 
strategy used in terms of tumor accumulation, in vivo anticancer efficacy and local 
disturbance induced by SPIO in MRI (measured by T2 RSD of the tumor region).  
 
Nanoparticles presented a spherical morphology and a size of 240 nm. Relaxometry studies 
and phantom MRI demonstrated their efficacy as T2 contrast agent. Significant cellular uptake 
by CT26 cells of nanoparticles was shown by Prussian blue staining and fluorescent 
microscopy for non-grafted nanoparticles. While SPIO did not show any toxicity in CT-26 
cells, PTX-loaded nanoparticles had a cytotoxic activity. PTX-loaded nanoparticle (5 mg/kg) 
with or without co-encapulated SPIO induced in vivo a regrowth delay of CT26 tumors. This 
regrowth delay was even better for RGD grafted and magnetic targeted nanoparticles. The 
best in vivo regrowth delay was obtained for RGD+MT-treated mice. Electron Spin 
Resonance spectroscopy and Magnetic Resonance Imaging (MRI) were used to both quantify 
and visualize the accumulation of theranostic nanoparticles into the tumors. We demonstrated 
that, compared to untargeted or single targeted nanoparticles, the combination of both active 
strategy and magnetic guidance drastically enhanced (i) nanoparticle accumulation into the 
tumor tissue (ii) contrast in MRI (diagnosis purpose). Double targeting of nanoparticles to 
tumors by different mechanisms could be a promising translational approach for the 
management of therapeutic treatment and personalized therapy. 
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Table 1. Major physico-chemical characteristics of the developed nanoparticles and efficacy of each targeting 
strategy in terms of tumor accumulation, in vivo anticancer efficacy and local disturbance induced by SPIO in 
MRI (measured by T2 RSD of the tumor region). 
 
 
Abbreviations: i.d. = injected dose, Msat = saturation magnetization, MST = mean survival time, RSD = 
relative standard deviation, T2W = T2-weigthed  
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II. OPEN QUESTIONS AND PERSPECTIVES 
Considering all the results presented in this thesis, there are still remaining numerous 
questions to be answered and point to be discussed. Some points and questions are discussed 
below based on the literature, on the results obtained and on my personal opinion. An opening 
on potential perspectives is discussed based on these questions. 
II.1. WAS THE CT-26 TUMOR MODEL APPROPRIATE? 
All experiments of the thesis were performed on CT26-bearing BALB/c mice. CT-26 cell line 
is a syngenic murine colon adenocarcinoma cell line induced in BALB/c mice by N-nitroso-
N-methylurethane [Chen et al., 2002]. This tumor model was chosen because of its sensibility 
to paclitaxel [Yang et al., 2013] and its vasculature appropriate for the EPR effect [Lyons et 
al., 2007]. Moreover, the tumor growing rate of this cell line was relatively reproducible. The 
main advantages of this model in the studies conducted in this thesis were: (i) the easy-to-
manipulate characteristic of this sub-cutaneous tumor allowing simple tumor volume 
measurements and (ii) the superficial location of the tumor allowed an effective and easy 
magnetic targeting as well as an easy localization in MR images. Although this ectopic animal 
model was convenient for these proof-of-concept studies, this tumor model presents some 
limitations. Data obtained from such a model may not necessarily represent the actual 
orthotopic tissue microenvironments, which is critical for proper development [Chen et al., 
2002]. Indeed, tumor vasculature has been shown to develop to a lesser extent in 
subcutaneous tumor model than in orthotopic model showing more vessels in the periphery of 
the tissue [Borgstrom et al., 2013]. 
 
In a view of a translational approach and to further investigate the relevance of our findings, 
an orthotopic model should be used. For instance, the murine melanoma B16-F10 could be 
appropriate [Thomas et al., 2014]. Given its superficial localization, it should be a good 
choice for magnetic targeting application. Moreover, this tumor model has been shown to 
express αvβ3 [Boles et al., 2010]. Testing our formulations in this model to confirm our results 
could be a first step.  
In a second step, another interesting application of an orthotopic model could be studying the 
efficacy of magnetic targeting in tracting nanoparticles to a more deeply situated tumor. For 
instance, we could test our formulations in an orthotopically implanted U87MG glioma 
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model. Indeed, this model has been shown to be well vascularized and to express αvβ3 
[Wegscheid et al., 2014]. Moreover, the location of the tumor although more deeply situated 
than in the skin is still not too deep and could be potentially suitable for magnetic targeting. 
Furthermore, since effectiveness of the currently available treatment is very limited due to the 
development of resistance mechanisms by tumor cells [Fan et al., 2013; St-Coeur et al., 
2013], personalized therapy could be of great interest in this cancer type to allow early 
identification of treatment-resistant patients. Finally, since glioblastoma is infiltrative, 
complete resection is virtually impossible and relapse almost inevitable [Brandes et al., 2008]. 
Therefore, using RGD-grafted multifunctional nanoparticles could be interesting to visualize 
and preferentially entered the remaining unremoved tumor cells. However, in order to 
overcome the BBB penetration issue, intracranial administration based on the convection 
enhanced delivery method should be used to administer the treatment directly into the 
peritumoral brain tissue [St-Coeur et al., 2013]. 
II.2. IS SPIO A GOOD CONTRAST AGENT FOR MRI? 
Magnetic resonance imaging (MRI) is a clinical widely used non-invasive imaging technique, 
presenting a high spatial resolution, which is suitable for cancer detection and therapeutic 
response assessment [Brindle, 2008; Liu et al., 2013]. Imaging technique based on magnetic 
resonance spectroscopy such as MRI provides ideal imaging modalities. Indeed, this 
technique responds to a series of criteria needed for such aim including (i) providing high-
resolution morphological images, (ii) offering functional information in regard with anatomy, 
(iii) avoiding the use of ionizing radiation and (iv) being relatively easy to perform [Krishna 
et al., 2001]. However, its major limitation consists of a relatively low sensitivity. 
Superparamagnetic iron oxides (SPIO) as excellent MRI contrast agent address this 
limitation. Indeed, SPIO can produce predominant T2 relaxation effect with excellent 
sensitivity and biocompatibility when compared to other MRI agents such as chelates of 
paramagnetic ion (Gd3+-DTPA). This results in a strong signal reduction on T2-weighted 
images [Ittrich et al., 2013; Reddy et al., 2012]. Hence, SPIO are considered as negative 
contrast agents. Moreover, given their reactivity to an externally applied magnetic field, SPIO 
are among the most suitable candidate to achieve magnetic targeting abilities by using an 
external magnet [Laurent et al., 2011].  
However, when SPIO concentration is very high, the T2 decreases so fast that the software 
failed to give a proper T2 curve fitting resulting in a non-exponential relationship and thus, an 
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incorrect T2 value. This phenomenon was observed in the results obtained for magnetic 
targeting and the combination of magnetic and active targeting in the in vivo MRI experiment 
in this thesis. Therefore, we measured a relative standard deviation of these T2 values in the 
region of interest. RSD is a measure of tumor heterogeneity after the SPIO injection. This 
method is commonly used in MRI when T2 signal is too heterogeneous [Oakes et al., 2014]. 
Nevertheless, in this thesis, SPIO injected dose was determined considering those found in the 
literature and the minimal concentration detected by MRI (using the in vitro MRI phantom 
study). Thus, further studies should investigate the proper SPIO dose to be injected in order to 
optimize (i) the decrease in T2 relaxation of the tumor tissue and (ii) the maximum 
concentration threshold above which MRI is not discriminative anymore. This could be 
assessed by in vitro MRI phantom studies by increasing SPIO concentration in the phantom 
samples. 
Furthermore, a major concern in using SPIO is their relatively unpopularity among the 
radiologists. Although SPIOs and USPIOs have been approved by the FDA and EMEA for 
use in the past, various commercial form including ferumoxides (Endorem®/Feridex®) have 
been withdrawn from the market after several years of commercialization due to their limited 
use by radiologists [Corot et al., 2013]. Indeed, radiologists blame the SPIO to be negative 
contrast agents and, consequently, to produce image contrasts more difficult to interprete than 
a positive contrast agent resulting in hyperintense signal in MRI. This pitfall contradicts SPIO 
as a good choice for tumor diagnosis.  
However, in my opinion, since this developed theranostic system does not intend to diagnose 
the presence of a nascent tumor but visualize nanoparticle accumulation in tumor when its 
location is already precisely known, such SPIO utilization could be accountable. Indeed, since 
many tumors are visualized hyperintense using MRI, a negative contrast agent could be 
indicated to characterize tumor accumulation. Nevertheless, effective elimination of SPIO 
should be investigated to ensure proper diagnosis if MRI is required for another further 
medical examination (given the tendency of SPIO to accumulate in various tissues). 
Pharmacokinetic studies should be performed to determine the half-life of our multifunctional 
nanoparticles as well as the time needed for complete clearance from the body. Those 
informations could be relevant since a compromise between long circulation time to reach 
sufficient tumor accumulation and efficient elimination of SPIO to avoid signal perturbations 
if another MRI is required. Therefore, blood samples following administration of a finite dose 
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of multifunctional nanoparticles should be taken over time and SPIO concentration should be 
measured. 
II.3. WHAT ABOUT THE SPIO ACCUMULATION-MEDIATED TOXICITY? 
SPIO-based multifunctional nanoparticles have been shown to be massively taken up in the 
liver (30 – 35 % of the injected dose). This phenomenon is well known and extensively 
described in the literature [Bertrand et al., 2012]. Zhang et al. reported an accumulation of 
RGD-grafted magnetite PLGA-based nanoclusters of 35% of the injected dose in the liver 
[Zhang et al., 2012]. Incidentally, SPIO-loaded nanoparticles are usually used as contrast 
agent for liver imaging [Lu et al., 2009]. This particular point raises the question of the 
toxicity of such accumulation. Analysis of the literature shows conflicting results on the 
toxicity of SPIO. Some studies have shown that SPIO could generate a production of ROS in 
liver cells that could lead to toxicity [Bae et al., 2011]. However, this toxicity seems to 
depend on the particle shape, size, charge and dose. Moreover, in normal circumstances, the 
injected iron is expected to be sequestered by Kupffer cells, metabolized and regulated by 
normal physiological iron homeostatic mechanisms [Laurent et al., 2014]. This SPIO 
sequestration seems to protect liver cells from apoptosis since only free iron oxides proved to 
be toxic. Indeed, Jain et al. showed that the intra-venous administration of oleic acid coated 
SPIO (10 mg Fe/kg) did not result in any notable alteration of the liver functionality [Jain et 
al., 2008]. Nevertheless, repeated dosing of SPIO in short intervals would not be a desirable 
option in imaging and drug delivery since it could lead to a surpassed transferrin iron-binding 
capacity and, therefore, to high free iron concentration [Laurent et al., 2014; Reddy et al., 
2012]. Hence, in a view of a translational approach, further toxicity assessment should be 
performed. In a cellular point of view, at high concentration (>600µg Fe/ml) the ferric ions 
released from SPIO into the acidic endolysosomal compartments have been shown to have a 
negative influence on cell homeostasis with consequences like affected actin cytosqueleton, 
diminished cell proliferation and ROS production. However, it is yet unclear what the precise 
effect of these factors is on cell viability as all cells have defence mechanisms, which allows 
them to deal with certain levels of oxidative stress [Soenen et al., 2011]. This point highlights 
again the importance of toxicity assessments in evaluating nanoparticle efficiency as at non-
toxic concentrations of IONPs. 
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In a first step, in vitro toxicity should be assessed on hepatocytes to investigate the type of 
cell death mediated by SPIO and the influence of PLGA encapsulation. Apoptosis, necrosis, 
autophagy as well as ROS production should be assessed using adequate assays.  
In a second step, in vivo test should be performed. Apoptosis in liver after injection of SPIO-
loaded nanoparticles should be investigated by a TUNEL assay on histological sections. 
However, in vivo evaluation of the toxicity should be performed as well to investigate ROS 
production. For instance, evaluation of the lipid hydroperoxide level in serum samples 24h 
after injection should provide interesting data over the oxidative stress [Jain et al., 2008].  
II.4. IS THERE A REAL INTEREST TO COMBINE ACTIVE AND MAGNETIC 
TARGETING? 
Active targeting presents an important issue constituting the most limitations: since targeted 
nanomedicines have no mean of self-propulsion, reaching the target site and thereby, 
accumulating in the tumor tissue only relies on EPR-mediated extravasation and all the 
pitfalls related to it [Kwon et al., 2012; Lammers et al., 2008]. In this context, the only 
advantage in functionalizing nanoparticles relies in the higher chance of internalization. 
Another important point that needs to be considered is the fact that despite the rather easy in 
vitro demonstration of receptor-mediated targeting, in vivo efficacy is more difficult to show. 
Moreover, even if a better internalization is demonstrated in vivo, the entire amount of drug 
localized in the tumor is often still lower than 0.01% of the injected dose [Jain and 
Stylianopoulos, 2010]. Indeed, before reaching their specific receptor expressed on tumor 
cells, targeted-nanomedicine face different challenges including escaping target receptor 
present on normal tissue, heterogeneity in receptor expression by tumor cells or according to 
the disease stage and a possible receptor saturation limiting targeting efficiency [Duncan and 
Gaspar, 2011].  
Both targeted and non-targeted systems arrive at the tumor via the EPR effect. Magnetic 
targeting promotes the accumulation of nanoparticles near the magnet and, thus, near tumor 
cells. However, to date, studies showed that this strategy did not promote nanoparticles 
entrance into the cells [Bae et al., 2011; Kocbek et al., 2013]. Mechanisms of tumor 
internalization for both non-targeted and magnetically-targeted nanoparticles mostly involve 
macropinocytosis [Kocbek et al., 2013; Kumari et al., 2011]. On the contrary, RGD-targeted 
nanoparticles are internalized by both tumor cells and endothelial cells (which are expressing 
αvβ3integrin) via receptor-mediated endocytosis, as abovementioned.  
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Consequently, nanoparticles intratumoral distribution could shift from the extracellular 
compartment to the tumor cell intracellular compartment [Prokop et al., 2008]. Therefore, 
combining active targeting (RGD) and magnetic targeting (MT) could enhance anti-tumor 
efficacy by both an enhanced accumulation (by MT) and an enhanced entrance (via αvβ3 
receptor-mediated endocytosis by RGD targeting). 
Moreover, for non-grafted nanoparticles only the EPR effect can explain the accumulation of 
drug-loaded nanocarriers into the tumor. By contrast, RGD-targeted nanoparticles exert a 
double active targeting of both endothelial and cancer cells. Indeed, αvβ3integrin is expressed 
on endothelial cells of neoangiogenic vessels, allowing the binding of circulating RGD-
nanoparticles resulting in subsequently tumor cells death by lack of oxygen and nutrients, and 
on tumor cells [Danhier et al., 2010; Folkman, 1971]. This putative anti-angiogenic effect of 
the active targeting of drug-loaded RGD-nanoparticles may constitute an advantage to the 
RGD-nanoparticles treatment since this effect does not rely on the penetration of 
nanoparticles into tumor interstitium which is complicated by the high interstitial fluid 
pressure [Bouzin et al., 2007; Jain, 1987]. Figure 2 represents the putative complementarity 
between these two targeting strategies. 
 
Finally, analysis of the literature shows that most studies having demonstrated in vivo efficacy 
of their theranostics in both the therapeutic and the imaging approach use combined targeting 
strategies. Indeed, researchers usually face the issue of poor tumor accumulation leading to 
difficulties in terms of in vivo anti-tumor efficacy or in vivo imaging efficacy. Indeed, 
percentage of the injected dose reaching the tumor is rarely above 1 %. Moreover, 
accumulation in healthy tissue such as liver and spleen is often larger than 35 %. In this 
context, there is a rationale to combine different strategies in a same nanomedicine to 
overcome the limitations of each one taken separately, making those multi-modal 
nanotheranostics. This strategy has gained much interest among the scientist during the past 
few years. Promising results have been reported. In this thesis, we demonstrated using ESR 
spectroscopy a 3- and 2-fold increase in tumor accumulation using a combination of magnetic 
and active targeting compared to active targeting and magnetic targeting, respectively, when 
used separately [Schleich et al., 2014]. Interesting results were also obtained for the 
combination of PDT and active targeting [Reddy et al., 2006]. This combination allowed to 
drastically improve the survival rate of 9L glioma-bearing rats when compared to PDT when 
used separately. Similarly, the interest of combined strategies was also confirmed in a study 
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conducted by Fan et al. in which focused US and magnetic targeting displayed drastic 
contrast enhancement in susceptibility weighted images compared to focused ultrasound as a 
unique targeting strategy [Fan et al., 2013].  
 
In my opinion and considering the results obtained in this thesis and the literature, there is a 
real interest in combining magnetic targeting (mostly useful to accumulate nanotheranostics 
into tumor tissue) and RGD-mediated targeting strategy for enhancing cell internalization and 
anti-angiogenic effect. However, further studies could be interesting to perform in order to 
investigate this complementary relationship between both strategies. 
 
To investigate the complementarity of active and magnetic targeting, immunohistochemistry 
should be performed on frozen tumor sections. Endothelium could be labeled using a CD-31 
monoclonal antibody and a secondary Alexa-fluor 488-labeled antibody. FITC-grafted PLGA 
could be used to label nanoparticles [Danhier et al., 2012]. Finally, nuclear labeling should be 
performed using DAPI. Sections could be, thereafter analyzed by a fluorescent microscope to 
assess if the combining strategy allows improving cellular internalization when compared to 
magnetic targeting alone. 
Another interesting study should investigate whether the combination of both targeting 
strategies could overcome the absence of EPR effect. Therefore, it could be interesting to 
assess their efficacy in a tumor model known to exhibit practically no EPR effect such as 
metastatic liver, pancreatic and prostate cancer [Maeda, 2012]. For instance an orthotopic 
model of DU 145 MN1 prostate cancer cell line could be used [Korbel et al., 2014]. 
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Figure 2. Schematic representation of the complementarity between magnetic and active targeting. Normally, 
RGD-grafted nanoparticles only accumulate in tumor interstitium via EPR effect. Magnetic targeting has the 
potential to improve nanoparticles accumulation by magnetic force attraction. Once RGD sequence is recognized 
by either tumor or endothelial cells, internalization occurs leading to an anti-tumor effect mediated by both a 
direct and an indirect effect, respectively. 
 
 
 
 
 
II.5. ARE THESE MULTIFUNCTIONAL NANOPARTICLES COMBINING MAGNETIC 
AND ACTIVE TARGETING SUITABLE FOR CLINICAL TRANSLATION? 
Magnetic targeting into clinic 
Lübbe et al. were the pioneers in using an external magnetic field to guide a treatment in 
patients [Lubbe et al., 1996]. Later, numerous studies used this method with magnetic field 
strength ranging from 0.4 to 4 T [Alexiou et al., 2000; Arias et al., 2011; Chertok et al., 2008; 
Kim et al., 2009]. For superficial tumors, this strategy can be easily transposable into clinic by 
placing the permanent magnet outside of the body at the surface of the tumor. However, the 
success of this targeting strategy is limited by inadequate magnetic gradients, thus, by the 
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distance between the magnets and the target site. Indeed, to allow magnetic targeting, 
magnetic forces should exceed the linear blood flow rates in arteries (10 cm s−1) or 
capillaries (0.05 cm s−1). Since magnetic gradient decreases as a function of the distance with 
the magnetic source, magnetic targeting should be more effective in regions closer to the 
magnets limiting its application to superficial tumors [Alexiou et al., 2000; Laurent et al., 
2011]. Nevertheless, many strategies to overcome this problem are under investigation. In 
most cases, the magnetic field gradient is generated by a strong permanent magnet, such as 
Nd–Fe–B. This type of magnet is known to enhance the depth of magnetic field by up to 10 - 
15 cm [Laurent et al., 2014]. However, such a distance could not allow magnetic targeting of 
tumor localized deeper in the body. For such tumor, it seems that the particles could be 
focused to the tumor region by using rotating magnetic fields [Alexiou et al., 2000; Huang et 
al., 2010]. Another proposed strategy is to improve the quality of the source (e.g. using a MRI 
system magnet as a source [Riegler et al., 2010]). Finally, another solution could involve 
magnetic implants near the tumor region [Polyak et al., 2008]. 
Since the magnetism is size-dependent, particles size can also influence the attraction by the 
magnet. Indeed, small particles are less susceptible to be attracted than large particles 
[Alexiou et al., 2000]. Magnetic targeting efficacy is also dependent on the saturation 
magnetization, which refers to the maximum magnetization possible. Generally, nanoparticles 
with higher saturation magnetization are preferred because they provide higher sensitivity and 
efficiency [Colombo et al., 2012]. Our particles showed a relatively low saturation 
magnetization (Ms) compared to free SPIO described in the literature [Larumbe et al., 2012; 
Shamim et al., 2007]. Indeed, while the use of a polymer coating around SPIO has been 
shown to increase relaxivities (R2) or reduce transverse relaxation times (T2) making, thus, 
more effective contrast agent, at the same time, it is associated with a change in the anisotropy 
constant leading to a further reduction in magnetization [Kolhatkar et al., 2013]. This 
phenomenon constitutes another limitation to magnetic targeting. This limitation could be 
reduced by further investigating the modulation of nanoparticles physical parameters (size, 
shape, composition, and shell-core architecture) to optimize the properties of these magnetic 
nanoparticles for improved magnetic targeting applications.  
EPR effect into clinic 
Most of the currently developed nanoparticular systems rely on this passive targeting via the 
EPR effect. Nevertheless, this strategy has recently known disenchantment. Since passive 
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targeting is highly dependent on tumor vascularization and given this vascularization is highly 
heterogeneous depending on the patient (inter-variability) and depending on the disease stage 
or even on the tumor areas (intra-variability), EPR effect is a highly heterogeneous 
phenomenon. Moreover, EPR effect has shown to be much more important in animal models 
compared to human. This is due to the much faster growth of animal tumors compared to 
patients. This speed increase results in more leaky vasculature and consequently in larger EPR 
effect [Lammers et al., 2012]. Secondly, due to the high interstitial pressure and dense 
extracellular matrix, penetration of the carrier is quite limited [Nichols et al., 2014]. 
Interestingly, some pharmacological treatment interfering with extracellular matrix (matrix 
degrading enzymes, inhibitors of fibrosis) or enhancing extravasation (inflammatory 
mediators such as TNF-α) have been shown to promote tumor penetration when co-
administered [Kumagai et al., 2009; McKee et al., 2006]. 
Formulation challenges 
The vast majority of multifunctional nanomedicine systems described in literature is suffering 
from high cost of manufacture and material as well as complexity or limitations of production 
process and analytical characterization [Peer et al., 2007]. Indeed, these kinds of nanoplatform 
combining different components are difficult to synthesize and scale-up by the 
pharmaceutical industry since their production involves many different synthetic and 
purification steps decreasing their commercial attractiveness [Lammers et al., 2012]. For 
nanocarrier-based theranostics, only few excipients evaluated as matrix materials or 
stabilizing agents in the literature, have a solid track record of preclinical and clinical 
experience to overcome the regulatory obstacles that assure quality and safety of new 
nanomedicines. In this thesis, keeping regulatory sciences in mind, we have used PLGA, a 
FDA approved polymer for parenteral drug delivery and SPIO for their FDA approval as MRI 
contrast agents in a view of a translational approach.  
Moreover, since pharmacokinetics and toxicology of nanocarriers are strongly dependent on 
the physico-chemical properties, minor changes in manufacture may have a major impact on 
their behavior in vivo. As a consequence, nanocarriers-manufacturing process requires precise 
control to limit batch-to-batch variability [Wacker, 2013].  
Furthermore, a major challenge with theranostic therapies arises from the opposing time line 
and concentrations of imaging and therapeutic agents. Indeed, although the main goal in 
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imaging is to deliver the smallest amount of imaging agent for a short time to ensure a strong 
signal-to-noise ratio, the amount of drug desired to induce a strong anti-cancer effect must be 
the highest as possible (maximum tolerated dose) [Svenson, 2013]. Consequently, there is a 
formulation challenge to address in order to ensure a maximum drug delivery and a minimum 
imaging agent. This challenge could be more easily addressed by nanocarrier-based 
theranostic compared to SPIO-conjugate due to the encapsulation of various amount of drug 
and imaging agent that nanocarriers offer. Moreover, this issue could be easily solved by 
maintaining the original two-step process in which the same nanocarrier is used to 
encapsulate at first the imaging agent in order to visualize biodistribution and tumor 
accumulation and, thereafter, the anti-cancer drug to treat the patient [Svenson, 2013]. 
Finally, another important limitation to clinical translation is the toxicological concern of 
using organic solvent such as dichloromethane (DCM) in the formulation process. DCM is 
part of the Class 2 solvents in the FDA guidance for industry classification on residual 
solvents. In this guidance, solvents in Class 2 (Table 2) should be limited in pharmaceutical 
products because of their inherent toxicity [http://www.fda.gov]. Indeed, concerns relating to 
the carcinogenic potential of dichloromethane arose in the 1980s and since, have been 
subjected to many toxicology studies. This carcinogenicity has been attributed to the 
glutathione-S transferase-theta 1 (GST-T1)-catalyzed metabolic pathway of DCM resulting in 
the production of two highly reactive intermediates, formaldehyde and S-
(chloromethyl)glutathione, and carbon dioxide [Cooper et al., 2011; Graves et al., 1994]. 
FDA’s regulatory guidance gives for DCM a maximal residual concentration of 600 ppm 
[http://www.fda.gov]. Alternatives like using Class 3 solvents, which are considered as less 
toxic and of lower risk to human health could be used in the future perspectives. These 
include ethyl acetate, a solvent in which oleic acid-coated SPIO, paclitaxel, and our polymers 
are predicted to be solved based on chemical models 
(http://showme.physics.drexel.edu/onsc/models/multisolvent.php). However, this should be 
tested experimentally. Litterature shows examples where ethyl acetate has been used to 
formulate Poly(D,L-lactic acid)  and PLGA nanoparticles using a similar emulsion/diffusion 
technique as used in this thesis [Sahana et al., 2008; Trimaille et al., 2003]. Further studies 
should investigate the use of this solvent to replace DCM in order to meet regulatory criteria. 
All these limitations show the long way multifunctional nanoparticles combining active and 
magnetic targeting need to travel before reaching the market.  
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II.6. WHAT IS THE REAL INTEREST OF NANOTHERANOSTICS IN ANTI-CANCER 
THERAPIES? 
Many publications claim that theranostics can be used for the simultaneous diagnosis and 
treatment. Actually, their suitability for real diagnosis is questionable. The diagnosis purpose 
of theranostics should not refer to the identification, the localization and/or the staging of 
tumors but to the pre-selection of patients, to the prediction of potential therapeutic responses, 
and/or to the longitudinal monitoring of treatment efficacy [Rizzo et al., 2013].  
 
Solid tumors are known to be highly heterogeneous either depending on the cancer type, 
patient or even on the disease stage (inter-tumor heterogeneity). Moreover, different cell types 
can be found inside a solid tumor (intra-tumor heterogeneity). Furthermore, in response to any 
given therapy, solid tumors inevitably evolve, leading to strong difficulties in managing 
cancer therapy. Therefore, there is a critical need in developing personalized therapy [Blanco 
et al., 2009; Guthi et al., 2010].  
 
At first, personalized therapy has been widely studied in the terms of genetic and genomic. 
The principle of this personalized medicine is based on ex vivo tumor molecular profiling or 
whole-genome profiling. Briefly, it relies on the evaluation of genetic sequences to confirm 
the expression of a biomarker. Thereafter, patients are selected for the treatment regarding 
this level of expression [Kalia, 2013; Tessari et al., 2013]. This method has been proved to be 
effective in assuring optimal efficacy and hence, is currently being used clinically in various 
cancer therapy [Lammers et al., 2012]. However, as the amount of information generated by 
an individual patient's tumor genomic profiling increases, it become more and more difficult 
for the clinicians to analyze, interpret, and act on this information [Van Allen et al., 2013]. In 
this context, nanotheranostics have emerged as high potential tools to make the personalized 
therapy easier. Indeed, visualizing and quantifying the overall level of target site 
accumulation is far easier than genome analysis.  
 
A successful clinical application of this personalized therapy concept is the clinically 
approved Zevalin® (a radioimmunotherapeutic directed against CD-20) for the treatment of 
Rituximab-failed non-Hodgkins lymphoma. The therapeutic schedule involves the injection 
on day one of 111Indium ibritumomab tiuxetan followed by whole-body planar gamma 
imaging (SPECT) obtained 48–72 h later in order to assess biodistribution. If the patients 
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present an appropriate biodistribution, they receive the active agent, 90yttrium ibritumomab 
tiuxetan, on day 8 [Beaven et al., 2012]. However, to date, all the theranostics involved in 
clinical studies rely on the use of PET or SPECT agents and, hence on ionizing radiations. 
 
In my point of view, this particular challenge of personalized therapy is the real interest of 
nanotheranostics. Indeed, such theranostic platforms allow the molecular diagnosis by 
imaging to assess the expression of cancer biomarker to guide target-specific therapy. 
Moreover, administration of such theranostic platform allows a non-invasive visualization of 
nanocarriers biodistribution and, consequently, evaluation of tumor accumulation and 
unintended accumulation in healthy tissue. Furthermore, it enables to assess the efficacy of 
the treatment at different stages of the therapy then using those results to intelligently modify 
the strategy for cancer treatment (real-time monitoring) [Guthi et al., 2010; Lammers et al., 
2010]. The multifunctional αvβ3-targeted nanoparticles developed in this thesis showed 
promising results in terms of anti-tumor efficiency and imaging abilities when combined to 
magnetic targeting. In clinical management of cancer therapy, their imaging abilities could be 
useful to monitor the biodistribution of these multifunctional nanoparticles after injection to 
the patient in a first step. Thereafter, on the basis of this non-invasive imaging insight on 
target site, and possibly undesirable liver accumulation, it would be possible to evaluate a 
benefice/risk ratio and, if favorable, select the patient for the treatment. This particular 
application could be of great interest to limit the treatment of non-responding patients and 
patients at high risk of undesirable toxicity. 
 
In this thesis, we have observed that there was a link between treatment response and tumor 
accumulation of the multifunctional nanoparticles assessed using MRI. This observation led 
to the hypothesis that MRI could be predictive of the treatment response. To confirm this 
hypothesis, we should image mice before treatment and measure tumor volume using T2-
weighted MRI (more precise compared to the caliper). Thereafter, treatment should be 
injected and re-imaged. This operation should be repeated every two days and tumor volume 
should be measured to monitor treatment response.  This experiment could confirm our 
hypothesis and explore another application of theranostic (real-time monitoring of the 
treatment response). Moreover, determining the link between tumor vessel maturation and the 
preferential accumulation of targeted and untargeted nanoparticles could be interesting to 
design a time schedule of administration to both treat and image tumors. Therefore, we could 
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correlate the T2 contrast due to the accumulation of SPIO-loaded RGD-nanoparticles imaged 
by MRI with the T1 contrast obtained by DCE-MRI (at 11.7 T) after the injection of 
monogadolinium macrocyclic compound (Gd-DOTA) [Baudelet et al., 2006; Boles et al., 
2010; Schmieder et al., 2008]. This technique has emerged as a non-invasive imaging 
technique of the tumor vasculature. By analyzing the kinetics of contrast-media uptake and 
wash-out, DCE-MRI provides information on perfusion and permeability and, consequently, 
vessel maturation [Baudelet et al., 2006].   
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